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Abstract 
For bladder tissue-engineering, there is a need for a surrogate epithelial cell source for 
patients whose own bladder epithelial cells (urothelial cells) are compromised by 
disease or cancer. Current work in the field has focused on attempting to differentiate 
various types of stem cells into urothelial cells using conditioned medium, co-culture or 
specific factors. These approaches have lacked clear focus, making it obvious that a 
better understanding of the transcription factors underlying urothelial lineage, 
development, and cell differentiation is necessary. The aim of the work presented in this 
thesis was to acquire specific knowledge regarding transcription factors involved in 
urothelial cell differentiation, which could be applied to an in vitro transdifferentiation 
approach of cell reprogramming. Since buccal mucosa is readily available, and already 
used as a grafted tissue for urology surgical applications, buccal epithelial cells were 
identified as a potential starting cell type. 
 
An in vitro comparison of human buccal epithelial cells to urothelial cells revealed that 
buccal epithelial cells had weak transcript and protein expression of four transcription 
factors that play key roles in urothelial cell differentiation: ELF3, FOXA1, GATA3 and 
PPARγ. Since ELF3 and FOXA1 have been previously shown to act downstream of 
PPARγ in urothelial cells, PPARγ and GATA3 were chosen as key upstream 
transcription factors to overexpress in buccal epithelial cells. Investigation into PPARγ 
expression in human urothelial cells revealed that of the two main PPARγ protein 
isoforms, PPARγ1 was most critical for urothelial cell differentiation. Knockdown of 
GATA3 expression in urothelial cells using specific siRNA revealed an important role 
for GATA3 in maintaining the differentiated state of urothelium. Individual 
overexpression of GATA3 and PPARγ1 in human buccal epithelial cells was unable to 
cause complete transdifferentiation to urothelial cells, but each resulted in the 
upregulation of downstream genes that play critical roles in urothelial cell 
differentiation and barrier formation. 
 
This work revealed key differences in transcription factor expression between buccal 
epithelial cells and urothelial cells, allowing for a better understanding of transcription 
factors involved in urothelial cell differentiation. The work provides a starting point for 
future urothelial-type cell reprogramming efforts which will likely require combined 
overexpression of several of these identified transcription factors to achieve complete 
transdifferentiation. 
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1 Introduction 
 Peroxisome Proliferator-Activated Receptor Gamma 
(PPARγ) 
PPARγ is a nuclear receptor, which when bound to retinoid X receptor α (RXRα), and 
activated by a specific ligand, is able to act as a transcription factor to regulate gene 
expression. PPARγ is best known as a key transcription factor involved in adipocyte 
differentiation (reviewed in Lefterova et al., 2014), but it has also been shown to have 
important roles in other cell types including macrophages, and both prostate and bladder 
epithelia (Ricote et al., 1998; Varley et al., 2006; Strand et al., 2013). PPARγ is one of a 
family of receptors which also includes PPARα and PPARβ/δ. 
 
1.1.1 PPARγ Transcript Variants 
The most recent description of human PPARG transcript variants defines four main 
splice variants (PPARG1, PPARG2, PPARG3 and PPARG4), which produce two 
unique proteins, PPARγ1 and PPARγ2 (Aprile et al., 2014) (Figure 1.1). The PPARG1, 
PPARG3 and PPARG4 transcript variants differ in their 5’ untranslated regions (UTRs) 
and promoter usage, but all produce the same protein product, PPARγ1 (Aprile et al., 
2014). The PPARγ2 protein is produced from the PPARG2 transcript variant, which is 
generated though alternate promoter usage (Tontonoz et al., 1994). The human PPARγ2 
protein contains the same protein sequence as PPARγ1, but has an additional 28 amino 
acids at its N-terminus; the human PPARγ1 protein is 477 amino acids, while the human 
PPARγ2 protein is 505 amino acids (Fajas et al., 1997). 
 
In addition to the transcript variants mentioned above, several other PPARγ splice 
variants have been identified in humans (Chen et al., 2006). Various truncated isoforms 
have also been identified, which lack the exons necessary to produce the ligand binding 
domain; these transcript variants have been described to act in a dominant negative 
fashion, inhibiting full length PPARγ expression (Kim et al., 2006; Aprile et al., 2014). 
Chapter 1 
 
27 
 
Figure 1.1 Human PPARγ Transcript Variants 
A) The most recent description of the human PPARG gene structure defines ten exons: 
A1.1, A1.2, A2, B and 1-6 (Aprile et al., 2014). Alternative splicing of these exons 
results in the production of four main protein coding transcript variants, which are 
used to produce the PPARγ1 and PPARγ2 proteins. Several other protein coding and 
non-protein coding splice variants have also been described in humans (Chen et al., 
2006). 
 
B) Three PPARγ transcript variants produce PPARγ1 protein: PPARG1, PPARG3, 
PPARG4; these variants all differ in their 5’ UTR (Aprile et al., 2014). Translation of 
the PPARG2 variant produces the PPARγ2 protein. 
 
C) The PPARγ1 protein is produced from the translation of exons 1-6. The PPARγ2 
protein is produced from the translation of a portion of exon B plus exons 1-6, which 
results in the human PPARγ2 protein having the same amino acid sequence as 
PPARγ1, with an additional 28 amino acids at the N-terminus (Fajas et al., 1997). 
This figure is adapted from (Aprile et al., 2014). 
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1.1.2 PPARγ Structure, Ligand Binding and Modifications 
The PPARγ proteins, like other nuclear receptors, contain four distinct regions: an 
N-terminal ligand-independent activation function (AF1), a DNA binding domain, a 
hinge domain, and a C-terminal ligand binding domain, which contains a ligand-
dependent activation function (AF2) (reviewed in Jin and Li, 2010) (Figure 1.2). The 
AF-1 and AF-2 domains act as docking sites for coactivators and corepressors (Nolte et 
al., 1998; Bugge et al., 2009). 
 
The PPARγ-RXRα heterodimer binds to a specific site in promoter regions called the 
PPAR response element (PPRE) (Chandra et al., 2008). It consists of two repeated 
sequences with a single base pair in the middle: ‘AGGTCAxAGGTCA’. The DNA 
binding domain of PPARγ binds to the first (5’) sequence, and the DNA binding domain 
of RXRα binds to the second sequence (Jpenberg et al., 1997) (Figure 1.3). 
 
The majority of PPARγ-mediated transcriptional activity requires the binding of a 
ligand to the ligand binding domain, which causes a conformational change in the 
PPARγ protein structure in order to elicit gene activation (Chandra et al., 2008). There 
have been several natural ligands described for PPARγ, including some unsaturated and 
oxidized fatty acids, and prostaglandins, but they are all known to have weak binding 
affinities (Kliewer et al., 1995; Kliewer et al., 1997). Potent synthetic ligands have been 
identified which bind to and activate PPARγ at high affinity; one group of ligands, 
termed thiazolidinediones, includes troglitazone, pioglitazone and rosiglitazone 
(Lehmann et al., 1995). RXRα is also ligand mediated, with its natural ligand being 
9-cis-retinoic acid (Heyman et al., 1992). 
 
Several forms of PPARγ modification occur which can affect its ability to modulate 
gene expression; these include sumoylation, phosphorylation and ubiquitination. PPARγ 
has been shown to be regulated by small ubiquitin-related modifier 1 (SUMO-1) 
modification (Ohshima et al., 2004). Ohshima et al. demonstrated that the conjugation 
of SUMO-1 to PPARγ resulted in a repression of PPARγ-dependent transcription. It 
was later shown, by another group, that the sumoylation of PPARγ prevented the 
removal of corepressor proteins from PPARγ-dependent promoters, and thus inhibited 
gene activity (Pascual et al., 2005). Phosphorylation of PPARγ has also been shown to 
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reduce PPARγ activity, and several groups have demonstrated that the phosphorylation 
of PPARγ is mediated by mitogen activated protein (MAP) kinases (Hu et al., 1996; 
Zhang et al., 1996; Camp and Tafuri, 1997). Another form of modification shown to 
regulate PPARγ is ubiquitination, which has been shown to occur prior to PPARγ 
degradation by the proteasome (Hauser et al., 2000). 
 
 
 
 
 
 
Figure 1.2 Human PPARγ1 Linear Protein Structure 
The PPARγ protein structure, like other nuclear receptors, contains four main protein 
domains: 
AF-1 Domain - Acts as a ligand independent transactivation domain and interacts 
with both coactivators and corepressors (Bugge et al., 2009). It is also a site where 
posttranslational modifications occur (Adams et al., 1997). 
DNA Binding Domain - Interacts directly with PPRE sequences in promoter regions 
(Chandra et al., 2008).  
Hinge Domain - A flexible portion of the protein between the DNA and ligand 
binding domains. 
Ligand Binding Domain – Location where PPARγ agonist binds to allow for 
transcriptional activation (Chandra et al., 2008). The AF-2 domain is located at the 
C-terminus, and its function is dependent on ligand binding (Nolte et al., 1998). 
This figure is adapted from (review by Rosen and Spiegelman, 2001; review by Jin and 
Li, 2010). 
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1.1.3 PPARγ Knockout Mice 
PPARγ knockout mice die before embryonic day 10 (E10.0) due to a defective placenta 
(Barak et al., 1999). In the study, the authors showed that PPARγ1 is highly expressed 
in the placenta from at least E8.5. To determine the effect of PPARγ beyond this early 
stage, a mouse was produced which was PPARγ-null, but could generate a wild-type 
placenta during development, allowing the embryo to be viable. The mouse was 
sacrificed at postnatal day 6.5 where it was shown that it had failed to develop all types 
of adipose tissue. 
 
 
Figure 1.3 PPARγ-RXRα Binding at a PPRE 
Simplified diagram showing PPARγ heterodimerisation with RXRα, and ligand binding, 
at a PPRE. The binding of an agonist to PPARγ causes a conformational change in the 
ligand binding domain, which allows for transcriptional activation to occur (Chandra et 
al., 2008). Common synthetic ligands used to activate PPARγ include troglitazone, 
pioglitazone and rosiglitazone (Lehmann et al., 1995). The common natural ligand for 
RXRα is 9-cis-retinoic acid (Heyman et al., 1992). 
This figure is adapted from (review by Ahmadian et al., 2013). 
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To determine the role of the different PPARγ isoforms in mouse development, 
PPARγ2-null mice were generated by two groups and showed some similar and 
differing results (Zhang et al., 2004; Medina-Gomez et al., 2005). Overall, both studies 
found that PPARγ2 knockout mice survived to term and displayed normal development. 
PPARγ2-null mice generated by Zhang et al. had reduced amounts of white adipose 
tissue, and histological analysis of the white adipose tissue present showed a marked 
difference in appearance in comparison to control mice. By contrast, Medina-Gomez et 
al. saw no difference in the amount or appearance of white adipose tissue between the 
PPARγ2-null and control mice. Both groups did demonstrate that the expression of 
several genes (LPL, aP2, Leptin, Resistin) known to play important roles in adipocytes 
were significantly downregulated in PPARγ2-null white adipose tissue. They also both 
demonstrated that when preadipocyte cells were taken from PPARγ2-null mice and 
induced to differentiate in vitro, their differentiation capacity was greatly impaired. 
These results whilst indicating a potential role for PPARγ2 in white adipose tissue 
development in vivo, suggested its involvement was not essential, since adipose tissue 
was still generated in both instances. 
 
 
1.1.4 PPARγ in Adipogenesis 
Adipogenesis is the process of generating mature adipocytes. Much of the work done to 
investigate adipocyte differentiation has been completed in vitro using a mouse 
embryonic fibroblast cell line, called NIH 3T3-L1, which is predisposed to adipocyte 
differentiation. Using this model system, among others, PPARγ was identified as an 
important regulator of both adipogenesis and maintenance of the adipocyte phenotype; 
PPARγ-null fibroblasts were incapable of undergoing adipocyte differentiation (Rosen 
et al., 2002), and mature NIH 3T3-L1 adipocytes, which were transduced to overexpress 
a dominant negative form of PPARγ, displayed impairment of the adipocyte phenotype 
(Tamori et al., 2002). 
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Adipogenesis is thought to occur through a two-stage transcription factor activation 
cascade (Lefterova et al., 2014). During the first part of adipogenesis, following 
initiation by blocking proliferation and cyclin D1 expression (Fu et al., 2005), two key 
transcription factors are upregulated, C/EBPβ and C/EBPδ (Wu et al., 1995b; Tanaka et 
al., 1997). The upregulation of these transcription factors causes the second stage of 
adipogenesis, where upregulation of PPARγ and C/EBPα expression occurs (Rosen et 
al., 2002). The expression of C/EBPα is thought to play a role in the maintenance of 
PPARγ expression; C/EBPα has been shown to directly bind to, and activate expression 
of PPARγ2 in adipocytes (Rosen et al., 2002). 
 
Using in vitro models, both PPARγ1 and PPARγ2 have been shown to play important 
roles during adipogenesis. Mueller et al. used a PPARγ-null murine fibroblast cell line 
to demonstrate that the independent overexpression of PPARγ1 or PPARγ2 was able to 
induce adipocyte differentiation when the appropriate ligands were present. In low 
ligand concentrations, PPARγ2 overexpression was found to be better at inducing 
adipocyte differentiation than PPARγ1 overexpression (Mueller et al., 2002). 
 
 GATA Binding Protein 3 (GATA3) 
GATA3 is a member of the GATA family of transcription factors. All six GATA 
transcription factors (GATA1-6) contain two zinc finger domains (C-terminal and 
N-terminal) which can bind directly to the DNA of target genes. Binding of the 
C-terminal zinc finger to ‘(A/T)GATA(A/G)’ sequences of promoter regions is able to 
either activate or repress gene expression (Ko and Engel, 1993; Bates et al., 2008). The 
binding of the N-terminal zinc finger in GATA-2 and -3 to ‘GATC’ is also able to elicit 
gene activity (Pedone et al., 1997). GATA transcription factors are considered to be 
‘pioneer factors’, with the ability to bind to areas of condensed chromatin, allowing 
access to silenced genes (reviewed in Zaret and Carroll, 2011). 
 
Knockout of GATA3 in mice is embryonically lethal, with death occurring at 
embryonic day 11 or 12. This occurs as a result of several factors which include internal 
bleeding, growth retardation, malformations of the brain and spinal cord, and abnormal 
liver haematopoiesis. GATA3 is best studied for its important regulatory role in T cell 
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commitment and differentiation (reviewed in Wan, 2014). Depending on the T cell type, 
GATA3 binds to and regulates a wide range of target genes (Wei et al., 2011). In T 
helper 2 cells, GATA3 was shown to both bind to and positively regulate PPARγ gene 
expression in mice (Wei et al., 2011). 
 
GATA3 has a well-documented role in breast epithelial cell differentiation and cancer 
progression. In normal mammary epithelium, GATA3 is expressed in the luminal 
epithelial cells, but not in the basal epithelial cells (Kouros-Mehr et al., 2006). 
Mammary epithelium-specific knockout of GATA3 in mice resulted in reduced 
mammary gland branching and bud formation (Kouros-Mehr et al., 2006). The 
mammary epithelium was also affected, and formed areas of multi-layered epithelium, 
which was caused by the expansion of undifferentiated luminal cells. 
 
The expression of GATA3 is also strongly associated with breast cancer, where low 
GATA3 expression is indicative of poor prognosis (Mehra et al., 2005). GATA3 
expression varies among metastatic and non-metastatic breast cancers, with metastatic 
breast cancers having low GATA3 expression. In contrast, the non-metastatic breast 
carcinoma-derived cell line, MCF-7, has high GATA3 expression (Kouros-Mehr et al., 
2008). GATA3 has been shown to act upstream of, and directly regulate the expression 
of another key transcription factor involved in breast cancer development, forkhead box 
protein A1 (FOXA1) (Kouros-Mehr et al., 2006; Theodorou et al., 2013). 
 
In human epidermis, GATA3 is expressed in both the basal and suprabasal layers 
(Chikh et al., 2007). It has been suggested that GATA3 may be regulated in part by p63 
in the skin, and it has been shown that both the Tap63 and ∆Np63 isoforms are able to 
bind to the GATA3 promoter to activate gene expression (Candi et al., 2006; Chikh et 
al., 2007). Epidermal-specific deletion of GATA3 in mice resulted in death shortly after 
birth due to a defective skin barrier (de Guzman Strong et al., 2006). Mice had 
desiccated skin at birth, and the rate of water loss across the epidermis was significant 
in comparison to control mice. The authors identified that the cause of the barrier 
impairment was as a result of abnormal lipid synthesis, with tight junctions and the 
cornified cell envelope appearing normal. 
  
Chapter 1 
 
34 
 Urothelium 
The renal pelvis, ureters, bladder and upper portion of the urethra are lined on their 
luminal surfaces by a specialised epithelium called urothelium. The primary role of the 
urothelium is to act as a permeability barrier to the toxins present in urine, preventing 
them from re-entering the body. Urothelium is classified as a transitional type of 
epithelium. It is derived from the embryonic endoderm layer in the bladder and urethra, 
and the embryonic mesoderm layer in the renal pelvis and ureters (review by Staack et 
al., 2005). It consists of three main epithelial cell zones: basal, intermediate and 
superficial (Figure 1.4), and in general averages approximately 4-5 cell layers thick 
(Jost et al., 1989). 
 
 
Figure 1.4 Human Urothelium 
Haematoxylin stained human bladder epithelium section. The three epithelial zones of the 
transitional epithelium are shown: the basal layer, intermediate layer and superficial layer. 
The dashed line represents the basement membrane, which separates the epithelium from 
the underlying connective tissue. 
 
Urothelium is a largely quiescent tissue, with a very low cell turnover rate (Limas, 
1993); when urothelium sections are analysed for Ki67 expression, a marker of 
proliferating cells, the expression is either absent or limited to a few cells (Varley et al., 
2005). In response to insult or injury, the quiescent nature of urothelium changes to a 
highly regenerative phenotype, which allows for rapid repair of the epithelium (Pust et 
al., 1976). Like other multi-layered epithelia, urothelium has a hierarchical structure; the 
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least differentiated cells make up the basal cell layer and the most specialised cells 
reside at the luminal/superficial side of the epithelium. 
 
Various stem cell populations have been described in urothelium in animal and human 
models, but no consensus has been reached as to the exact identity of the cells. Several 
groups have described the bladder urothelium as having different clonogenic cell 
populations, and these have been observed in rat, porcine and human systems (Nguyen 
et al., 2007; Thangappan and Kurzrock, 2009; Larsson et al., 2014). Several lineage 
tracing experiments have also been performed using mouse and rat models, but they 
have had differing results; two groups found that BrdU or EdU labelled cells could be 
observed in all layers of the urothelium (Zhang et al., 2012; Sun et al., 2014),  while a 
third group demonstrated label retaining cells were restricted to the basal cells of the 
urothelium (Kurzrock et al., 2008). Several specific stem cell populations have also 
been described in the bladder urothelium, these include CK5-expressing basal cells 
(Shin et al., 2011), p63-expressing cells (Pignon et al., 2013), specific intermediate cells 
(Gandhi et al., 2013) and combinations of CK5-expressing basal cells and specific 
intermediate cells (Colopy et al., 2014). None of these specific stem cell populations 
have been described in the human system. This area of research remains controversial. 
Much more work is needed to determine whether a specific stem cell population does 
exist in the urothelium, and if it does, then what are the true characteristics that define 
the cells. 
 
As with all epithelia, the urothelium can be classified by its specific expression of 
epithelial cell–specific intermediate filament forming proteins called cytokeratins (CK), 
which act to support the epithelial cell cytoskeletal structure. Urothelium is 
characterised as being CK5, CK7, CK8, CK13, CK18, CK19, and CK20 positive 
(reviewed in Southgate et al., 1999). CK20 expression is restricted to the superficial 
cells of the urothelium, and as a result is a useful marker of urothelial cell 
differentiation. 
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1.3.1 Urothelial Barrier Function 
Urothelium is one of the tightest barrier epithelia in the body, with skin being the only 
other epithelium type of comparable barrier function (reviewed in Powell, 1981). The 
tight barrier of the urothelium is attributed to two groups of proteins: the uroplakin 
proteins and tight junction-associated proteins (reviewed in Khandelwal et al., 2009). 
The uroplakin proteins play a role in inhibiting transcellular function (movement of ions 
or molecules through a cell) (Hu et al., 2000; Hu et al., 2002) (Figure 1.5 A), whilst the 
tight junction contributes to the paracellular barrier function (movement of molecules or 
ions in between cells) (Varley et al., 2006; Smith et al., 2015) (Figure 1.5 B). 
 
The barrier function of epithelia is measured using two main methods: permeability 
assays (a measure of the movement of water, ions or molecules) or transepithelial 
electrical resistance (TER) (Negrete et al., 1996). An epithelium which is considered to 
be leaky has a TER of less than 1000 Ω.cm2, while epithelia which are considered to 
have tight barriers have TER values greater than or equal to 1000 Ω.cm2 (review by 
Powell, 1981). 
 
 
Figure 1.5 Barrier Function - Cell Transport 
Barrier function in epithelia regulates two types of cellular transport: 
A) Transcellular transport is the movement of ions or molecules through a cell. In 
urothelium the apical-most cells form specialised plaques from interacting uroplakin 
proteins to prevent transcellular transport of unwanted molecules or ions (Hu et al., 
2002). 
 
B) Paracellular transport is the movement of ions or molecules between cells. In 
urothelium, tight junctions regulate this form of transport (Varley et al., 2006; Smith 
et al., 2015).  
This figure was adapted from (review by Tsukita et al., 2001). 
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1.3.1.1 Uroplakin Proteins 
The superficial cell layer of urothelium contains a single layer of specialised cells called 
‘superficial’ or ‘umbrella’ cells. On the apical (luminal) surface of these cells exists 
specialised plaques which form the urothelium-specific asymmetric unit membrane 
(AUM) (Sun et al., 1996). The AUM is considered to play key roles in stabilizing the 
urothelium surface during bladder filling, and in the transcellular barrier function of the 
urothelium. 
 
The main protein components of the AUM are a group of proteins called the uroplakins 
(UPKs): UPK1A, UPK1B, UPK2, UPK3A, and UPK3B (Sun et al., 1996; Deng et al., 
2002). UPK2, UPK3A and UPK3B are single-span transmembrane proteins (Wu and 
Sun, 1993; Lin et al., 1994; Deng et al., 2002), while UPK1A and UPK1B are 
tetraspanins (Yu et al., 1994). The uroplakins are integral membrane proteins, which 
form specific heterodimers with one another; UPK1A dimerises with UPK2, while 
UPK1B dimerises with UPK3A or UPK3B (Wu et al., 1995a; Liang et al., 2001; Deng 
et al., 2002). UPK1A, UPK2 and UPK3A are specifically expressed in the superficial 
cells of urothelium, while UPK1B and UPK3B are less specific to urothelium, and can 
also be found expressed in other tissues, including corneal epithelium (Adachi et al., 
2000) and mesothelium (Kanamori-Katayama et al., 2011; Rudat et al., 2014), 
respectively. 
 
To investigate the role of uroplakin proteins, knockout mice were generated for UPK2, 
UPK3A and UPK3B (Hu et al., 2000; Hu et al., 2002; Kong et al., 2004; Rudat et al., 
2014). UPK2 deficient mice displayed smaller superficial cells of the urothelium and 
had a complete loss of plaque formation, which indicated that both sets of heterodimer 
pairs are required for successful plaque formation (Kong et al., 2004). The urothelium 
also became hyperplastic and demonstrated increased BrdU uptake (Kong et al., 2004), 
indicating a more proliferative phenotype of the epithelium. UPK3A knockout mice had 
abnormal superficial cells, and plaque size was reduced (Hu et al., 2000). The barrier 
function of the urothelium was also affected, with increased permeability to methylene 
blue (Hu et al., 2000), water, and urea (Hu et al., 2002), although TER values remained 
normal at approximately 2000 Ω.cm2 (Hu et al., 2002). UPK3B knockout mice  
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displayed no abnormalities in urothelium or plaque formation (Rudat et al., 2014). 
These results suggest a likely essential role for UPK2 and UPK3A in the barrier 
function of the urothelium, while UPK3B appears to have a non-essential role. 
 
1.3.1.2 Tight Junction Proteins 
Tight junctions are found at the apical surface of two adjacent epithelial cells, where 
they act to regulate the paracellular passage of water, molecules and ions across an 
epithelium. Tight junctions are formed through the interaction of many different 
proteins, of which the major protein components are the claudin (CLDN) proteins, 
occludin, and the zonula occludens (ZO) proteins (ZO-1, ZO-2 and ZO-3) (reviewed in 
Van Itallie and Anderson, 2014) (Figure 1.6). Occludin and the claudin proteins are 
tetraspan transmembrane proteins, which act to form the tight junction between two 
cells, while the ZO proteins anchor these transmembrane proteins on the cytoplasmic 
surface of the cell (reviewed in Van Itallie and Anderson, 2014). 
 
The claudin proteins are a critical component of the tight junction; it is believed that the 
interaction between opposing extracellular claudin loops regulates the tightness of a 
given epithelial barrier (Furuse et al., 1999). Each epithelium relies on a unique 
combination of claudin proteins in order to control the tightness of the epithelial barrier, 
with different claudin proteins being associated with either tight or leaky epithelia 
(reviewed in Krug et al., 2014). For example, the presence of claudin 2 protein in an 
epithelial tight junction is associated with leaky barrier epithelia, like that of the kidney 
proximal tubule (Amasheh et al., 2002; Muto et al., 2010); when claudin 2 was 
overexpressed in a kidney distal tubule cell type known to produce a high TER, the cells 
completely failed to form a functional barrier (Amasheh et al., 2002). 
 
Claudin proteins can have both cis- and trans- interactions: cis- interactions occur 
between adjacent claudin proteins in the same cell membrane, while trans- interactions 
occur between claudins across the intercellular space of neighbouring cells (Blasig et 
al., 2006; Piontek et al., 2008). Claudin proteins are also known to interact in both 
homo- and heterotypic fashions, with either like or differing claudins respectively 
(Furuse et al., 1999). 
 
Chapter 1 
 
39 
The ZO proteins are the main intracellular component of tight junctions. All three of the 
ZO proteins (ZO-1, ZO-2 and ZO-3) bind the C-terminal domain of claudin and 
occludin proteins to act as a link to the actin cytoskeleton in the cell (Itoh et al., 1999; 
Li et al., 2005). ZO-1 and ZO-2 are believed to be critical for organisation and 
placement of the claudin proteins in the tight junction (Umeda et al., 2006). Both ZO-1 
and ZO-2 knockout mice are embryonically lethal (Katsuno et al., 2008; Xu et al., 
2008), while ZO-3 knockout mice are viable, with no obvious defects (Xu et al., 2008), 
suggesting a more essential role for ZO-1 and ZO-2. 
 
 
 
Figure 1.6 Main Protein Components of a Tight Junction 
The main protein components of tight junctions are the claudin proteins, occludin and the 
zonula occludens proteins (reviewed in Van Itallie and Anderson, 2014). The claudin 
proteins and occludin are tetraspan transmembrane proteins, which interact with claudins 
and occludins, respectively, from neighbouring cells to facilitate paracellular barrier 
function. The ZO proteins act on the inner surface of the cell and bind to the C-terminal 
portion of the claudins and occludins. ZO proteins act as a link to the actin cytoskeleton. 
This figure is adapted from (review by Matter et al., 2005; review by Steed et al., 2010).  
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Only little work has been completed to investigate the expression or role of tight 
junction proteins in urothelium. In human urothelium, claudins 3, 4, 5 and 7 have been 
shown to be expressed, along with ZO-1 and occludin (Varley et al., 2006), while in 
mice, claudins 3, 4, 7, 8, and 12, as well as ZO-1 and occludin have been shown to be 
expressed (Acharya et al., 2004; Fujita et al., 2012). In order to investigate the role of 
claudin 4 in the urinary system, claudin 4 knockout mice were generated (Fujita et al., 
2012). These mice displayed a slightly hyperplastic urothelium, but there was no 
obvious effect on urothelial barrier function or the expression of other tight junction 
proteins, like claudins 3 or 7 (Fujita et al., 2012). This study indicated a non-crucial role 
for claudin 4 in urothelial barrier function.  
 
An in vitro system was used to examine the role of claudin 3 in the barrier function of 
human urothelium (Smith et al., 2015). Human urothelial cells with knocked-down 
claudin 3 expression were generated, and the barrier function of these cells was 
measured following differentiation to form a biomimetic urothelium equivalent (Smith 
et al., 2015). Interestingly, knockdown of claudin 3 caused a complete lack of barrier 
function, as measured by the TER (Smith et al., 2015). This indicated an essential role 
for claudin 3 in urothelial barrier function. The authors also overexpressed claudin 3 in 
human urothelial cells, but found that this was unable to improve barrier function when 
cells were induced to stratify (Smith et al., 2015). This demonstrated that the barrier 
function of urothelium is most likely reliant on the combined expression of several tight 
junction-associated proteins as opposed to primarily being reliant on the expression of a 
single claudin protein. The authors also identified the gain of ZO-1α+ protein expression, 
an alternative ZO-1 isoform, which occurred only as a result of urothelial cell 
differentiation (Smith et al., 2015). This result could suggest a possible important role 
for ZO-1α+ in urothelial barrier function. 
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1.3.2 Urothelial Cell Proliferation and Differentiation in Vitro 
When human urothelial cells are isolated from native urothelium and grown in vitro, in 
serum-free, low calcium (0.09 mM) conditions, they are highly proliferative (Southgate 
et al., 1994). Southgate et al. described the growth of normal human urothelial (NHU) 
cells in keratinocyte serum-free medium (KSFM) with added bovine pituitary extract, 
epidermal growth factor and cholera toxin (KSFMc). Under these conditions, NHU cells 
adopted a more basal-like phenotype; many of the typical markers of urothelial cell 
differentiation were lost, including the expression of tight junction proteins, CK13, 
CK20, and several of the uroplakin genes (Figure 1.7). The cells also became squamous 
in nature, and began to express CK14, a squamous epithelial cell-associated cytokeratin. 
Upon reaching confluence, the cells became contact inhibited, but they could be 
subcultured, maintaining the basal-like, proliferative phenotype for in excess of 10 
passages, before reaching senescence (Southgate et al., 1994). 
 
The proliferative and regenerative nature of urothelial cells is thought to be largely 
attributed to epidermal growth factor receptor (EGFR) signalling (Bindels et al., 2002; 
Daher et al., 2003; Varley et al., 2005). Treatment of proliferating NHU cells with an 
EGFR tyrosine kinase inhibitor, PD153035, which blocks EGFR activation, resulted in 
the cells arresting in G1 phase, and failure to reach confluence (Varley et al., 2005). 
 
Southgate et al. also demonstrated that increasing the calcium concentration of the 
medium to 2 mM caused NHU cells to stratify, forming a multi-layered tissue, although 
this failed to cause differentiation of the cells. Sugasi et al. used a similar serum-free 
technique to generate stratified human urothelial cell sheets. The authors also 
demonstrated increased calcium concentrations alone failed to completely differentiate 
the cells, but that the cell sheets did possess some barrier function (Sugasi et al., 2000). 
Cross et al. later showed that it was the combined addition of adult bovine serum (ABS) 
and an increased calcium concentration to 2 mM (termed ABS/Ca2+ protocol in this 
thesis), which was able to cause NHU cells to both stratify and differentiate. Using this 
method, NHU cells formed a multi-layered, biomimetic urothelium equivalent (Cross et 
al., 2005). The cells lost expression of CK14, and gained expression of CK13 (Figure 
1.7). The cells also formed tight junctions, and developed a tight barrier, as measured by 
electrical resistance and permeability assays (Cross et al., 2005). The exact components 
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of adult bovine serum that cause NHU cells to differentiate in vitro are not yet known, 
but signalling through PPARγ and the retinoic acid receptors (RARs) may play a major 
role. The involvement of PPARγ and the RARs in urothelial cell differentiation is 
described in more detail in sections 1.3.3.1 and 1.3.4, respectively. 
 
An interesting feature of urothelium is that all cells of the epithelium appear to be 
capable of becoming more or less differentiated (ie. differentiation is not irreversible) 
(Wezel et al., 2014). When urothelial cells are isolated from native tissue, nearly all of 
the cells survive and contribute to the culture (Southgate et al., 1994). Work by Wezel et 
al. showed that when urothelial cells were separated into basal and suprabasal fractions 
at isolation, both cell populations were able to be propagated in vitro, and they were 
both able to be differentiated to form functional barrier epithelia with a basal cell 
compartment. This work suggested that unlike other epithelia (eg. skin) where cell fate 
is unidirectional, in urothelium, cell fate appears to be much more plastic in nature. 
  
Chapter 1 
 
43 
 
Figure 1.7 Basic Characteristics of NHU Cells in Vitro Compared to Native Human 
Urothelium 
a) Native human urothelium exhibits expression of CK13, and the superficial cell-
associated cytokeratin, CK20. All five of the uroplakin genes are expressed, as 
well as an array of tight junction (TJ) proteins, which contribute to native 
urothelium having one of the tightest barriers in the human body. Urothelium is 
normally quiescent, but in response to injury adopts a regenerative phenotype 
(Pust et al., 1976). 
 
b) NHU cells grown in serum-free, low calcium (0.09 mM) medium (KSFMc) adopt 
a monolayer squamous phenotype, expressing CK14, and are highly proliferative 
(Southgate et al., 1994). The cells lose expression of differentiation-associated 
genes.  
 
c) Following use of 5% ABS and 2 mM Ca2+, NHU cells form a multilayered 
urothelium, which expresses many differentiation-associated genes (Cross et al., 
2005). They also gain barrier function, and are highly regenerative following 
scratch wounding. 
 
(-) Negative/ Does not occur, (+) Weak Expression, (++) Strong Expression/Does occur. 
This table was adapted from (Cross et al., 2005). 
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1.3.3 Transcription Factors Involved in Urothelial Cell 
Differentiation 
In cell culture systems, differentiation of urothelial cells is controlled by a tightly 
regulated cascade of transcription factor activation and repression, which leads to the 
differentiation of the cells. Several key transcription factors have been shown to be 
involved in the differentiation of urothelial cells, but the full hierarchical network is still 
far from being elucidated. Upregulation of the transcription factors PPARγ, interferon 
regulatory factor 1 (IRF1), forkhead box protein A1 (FOXA1) and E74-like factor 3 
(ELF3), has been shown to prequel the upregulation and de novo induction of 
expression of multiple differentiation markers in NHU cells in vitro (CK20, the 
uroplakin genes, and tight junction-associated genes) (Varley et al., 2004a; Varley et al., 
2004b; Varley et al., 2006; Varley et al., 2009; Böck et al., 2014). 
 
Other transcription factors that have been shown to be involved in the development and 
differentiation of urothelium include Kruppel-like factor 5 (KLF5) (Bell et al., 2011), 
grainyhead-like 3 (GRHL3) (Yu et al., 2009), GATA4 (Mauney et al., 2010) and 
GATA6 (Mauney et al., 2010); all of these studies were completed in mice, or using 
mouse cells. Studies investigating KLF5 have shown that targeted germ cell deletion 
prevents the urothelium from being able to stratify and differentiate; the mice had a 
single layer bladder epithelium (Bell et al., 2011). GRHL3 has been shown to play a key 
role in the differentiation of urothelium and the formation of the superficial cell layer 
(Yu et al., 2009). It has also been suggested that UPK2 is a direct target of GRHL3 (Yu 
et al., 2009). GATA4 and GATA6 have also been implicated in urothelial cell 
differentiation (Mauney et al., 2010). Both transcription factors were shown to be 
upregulated during the differentiation of mouse embryonic stem cells (ESCs) into 
urothelial-like cells. The authors also demonstrated that mouse ESCs which were null 
for either GATA4 or GATA6 had significantly reduced expression of UPK1A, UPK1B, 
UPK2, and UPK3A following differentiation. 
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1.3.3.1 PPARγ 
Activation of PPARγ has been shown to play an important role in the differentiation 
program of urothelial cells (reviewed in Varley and Southgate, 2008)(Figure 1.8). 
Urothelial cells treated with both the PPARγ agonist, troglitazone (TZ), and the EGFR 
tyrosine kinase inhibitor, PD153035 (PD) (treatment protocol termed TZ/PD in this 
thesis), have been shown to downregulate CK14 expression and upregulate CK13 
expression (Varley et al., 2004b). Use of the TZ/PD protocol has also been shown to 
upregulate expression of urothelial differentiation markers: CK20 (Varley et al., 2004b) 
and the uroplakins (Varley et al., 2004a). Additionally, activation of PPARγ has been 
shown to upregulate the expression of several tight junction proteins, including claudin 
3, claudin 4 and claudin 5, which are all implicated in maintaining the tight barrier 
function of the urothelium (Varley et al., 2006). In all cases, the effects of the TZ/PD 
protocol were shown to be specific to PPARγ activation using specific PPARγ 
antagonists, GW9662 or T0070907, or PPARγ knockdown, which abrogated the effect. 
 
In terms of identifying a transcription factor hierarchy involved in the differentiation of 
urothelial cells, PPARγ has been shown to act upstream of the transcription factors, 
ELF3, FOXA1 and IRF1 (Varley et al., 2009; Böck et al., 2014). These three 
transcription factors were identified using gene chip microarray data generated from 
NHU cells which had been treated with and without the TZ/PD or ABS/Ca2+ protocols. 
FOXA1 and IRF1 were shown to be upregulated as a result of TZ/PD treatment at all of 
the time points assessed. Likewise, ELF3 was shown to be upregulated during both the 
TZ/PD and ABS/Ca2+ protocols. The upregulation of these transcription factors was 
shown to be directly as a result of PPARγ activation using the PPARγ-specific 
antagonists, GW9662 or T0070907. 
 
PPARγ is highly associated with bladder cancer, and in particular luminal muscle 
invasive bladder cancers (Biton et al., 2014; Cancer Genome Atlas Research, 2014; 
Choi et al., 2014). Luminal bladder cancers have a more differentiated urothelial cell 
phenotype, and exhibit high levels of PPARγ gene expression (Biton et al., 2014; Choi 
et al., 2014). A recent large scale study of muscle invasive, high-grade urothelial 
tumours demonstrated that 17% of the specimens examined exhibited gene 
amplification of PPARγ (Cancer Genome Atlas Research, 2014). Using in vitro models, 
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Biton et al. demonstrated that knockdown of PPARγ, by the use of specific siRNA, in 
bladder carcinoma-derived cell lines (SD48, UMUC9 and MGHU3) caused a significant 
decrease in cell viability. For the SD48 and UMUC9 cell lines, it also caused a 
significant reduction in colony formation. This work suggested a role for PPARγ in 
maintaining a pathway of urothelial cancer cell growth and viability. 
 
Research has also indicated that the use of thiazolidinediones (synthetic PPAR ligands, 
with specificity to PPARγ), some of which were prescribed to treat type 2 diabetes in 
humans, leads to a significant increase in bladder cancer incidence (Azoulay et al., 
2012; Neumann et al., 2013). These studies suggest a possible role for sustained PPARγ 
activation in bladder cancer development. 
 
 
 
 
Figure 1.8 Activation of PPARγ in NHU Cells Using the TZ/PD Protocol 
Combined treatment of NHU cells with troglitazone and PD153035 results in the 
upregulation of transcription factors ELF3, FOXA1, and IRF1 within 24-48 hours 
(Varley et al., 2009; Böck et al., 2014). Within six days, the cells express CK13, and 
upregulate the urothelial terminal differentiation associated genes CK20 and the UPKs 
(Varley et al., 2004a; Varley et al., 2004b). Several tight junction proteins are also 
upregulated as a result of PPARγ activation, including CLDN3, CLDN4 and CLDN5, 
although the cells do not form a functional barrier epithelium (Varley et al., 2006). 
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1.3.3.2 GATA3  
GATA3 is a zinc finger, pioneer transcription factor. In the urinary bladder, GATA3 has 
been identified as both a key diagnostic (Higgins et al., 2007; Zhao et al., 2013), and 
prognostic marker of bladder cancer (Miyamoto et al., 2012). In general, decreased 
GATA3 expression is associated with bladder cancer, when compared to normal 
urothelium (Miyamoto et al., 2012). This has also been demonstrated using an in vitro 
model, where it was shown that urothelial carcinoma-derived cell lines (5637, TCC-
SUP, J82 and UMUC3) expressed less GATA3 than normal urothelial cells (Li et al., 
2014a). The authors also showed that when GATA3 expression was further decreased in 
these bladder carcinoma-derived cell lines by GATA3 knockdown, it caused an increase 
in cell migration and invasion (Li et al., 2014a). As a result, this work suggested that 
decreased GATA3 expression may be necessary for either instigating or maintaining 
essential bladder tumour cell characteristics.  
 
It has been suggested that the decreased GATA3 expression in urothelial carcinomas 
may be as a result of androgen receptor activation (Li et al., 2014b).  Li et al. 
demonstrated that treatment of an immortalised non-neoplastic urothelial cell line with a 
specific androgen receptor agonist caused a concentration-dependent downregulation of 
GATA3 expression. 
 
GATA3, among other factors, is also useful for distinguishing different subtypes of 
urothelium-derived cancers. For examples, upregulated GATA3 expression is 
associated with the luminal muscle invasive bladder cancer subtype (Damrauer et al., 
2014). It can also be used to identify squamous cell carcinoma of the bladder, which is 
associated with low/absent GATA3 expression (Eriksson et al., 2015). 
 
The role of GATA3 in normal urothelial cell differentiation has yet to be elucidated. 
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1.3.3.3 FOXA1 
FOXA1 is a transcription factor that has been shown to have important roles in many 
cell types, in particular cells of endodermal origin (reviewed in Bernardo and Keri, 
2012). FOXA1, like GATA3, is considered to be a pioneer transcription factor, and 
therefore it is able to act in areas of heterochromatin (reviewed in Zaret and Carroll, 
2011).  
 
FOXA1 has been shown to have important roles in the development and differentiation 
of urothelium (Oottamasathien et al., 2007; Thomas et al., 2008; Varley et al., 2009). 
Studies in mouse have found that both FOXA1 and FOXA2 are expressed during the 
early development of the urothelium (Oottamasathien et al., 2007; Thomas et al., 2008). 
When urothelium begins to mature to its fully differentiated state, FOXA2 expression 
becomes absent as the uroplakin proteins begin to be expressed (Oottamasathien et al., 
2007). FOXA1 expression was shown to be present during both embryonic 
development and in the mature adult murine urothelium (Oottamasathien et al., 2007). 
 
To investigate the effect of FOXA1 loss in urothelium, mice with urothelium-specific 
FOXA1 knockout were generated (Reddy et al., 2015). Reddy et al. demonstrated that 
FOXA1 knockout resulted in changes to the urothelium which were gender-specific. 
Male mice displayed areas of hyperplastic urothelium with increased expression of 
CK14 in basal cells. Female mice, by contrast, developed areas of keratinising 
squamous metaplasia, which had significant CK14 expression. This work demonstrated 
a role for FOXA1 in maintaining urothelial-type differentiation, and specifically in 
preventing squamous-type differentiation. 
 
In vitro study has shown that FOXA1 acts downstream of PPARγ in urothelial cell 
differentiation (Varley et al., 2009). The authors also demonstrated that knockdown of 
FOXA1 expression in NHU cells, during treatment with the TZ/PD protocol, resulted in 
the downregulation of several urothelial differentiation genes, including CLDN3, CK13, 
UPK1A, UPK2 and UPK3A. The knockdown also resulted in the slight upregulation of 
UPK1B and UPK3B. This work demonstrated the importance of FOXA1 as a key 
regulator of several aspects of urothelial cell differentiation. 
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FOXA1 has also been shown to be involved in bladder cancer. Loss of FOXA1 in 
bladder cancer is significantly associated with poor patient prognosis (Reddy et al., 
2015). In general, decreased FOXA1 expression correlates with both increased stage 
and grade of bladder cancer (DeGraff et al., 2012). In vitro studies completed to 
investigate the role of FOXA1 in bladder cancer demonstrated that FOXA1 knockdown 
in a bladder carcinoma-derived cell line, with high FOXA1 expression (RT4 cells), 
resulted in significantly increased cell proliferation (DeGraff et al., 2012). By contrast, 
overexpression of FOXA1 in a bladder carcinoma-derived cell line with low FOXA1 
expression (T24 cells) resulted in a significant decrease in both cell proliferation and 
invasion (DeGraff et al., 2012). This work supported the important role of FOXA1 loss 
in bladder carcinoma progression. 
 
Recent work has demonstrated the presence of FOXA1 mutations in bladder cancers; 
the authors demonstrated that 5% of the bladder cancer specimens examined had either 
a frameshift or missense mutation (Cancer Genome Atlas Research, 2014). It has also 
been shown that FOXA1 expression differs between the bladder cancer subtypes. 
Upregulated FOXA1 expression is associated with the luminal muscle invasive bladder 
cancer subtype (Damrauer et al., 2014), while low/absent FOXA1 expression is 
associated with squamous cell carcinoma of the bladder (DeGraff et al., 2012; Eriksson 
et al., 2015). 
 
 
1.3.4 Role of Retinoic Acid Receptors in Urothelial Cell 
Differentiation 
The retinoic acid receptors (RARs) are nuclear receptors which have been shown to 
have important roles in the development and differentiation of many cell types 
(reviewed in Duester, 2008). There are three retinoic acid receptors, RARα, RARβ and 
RARγ. Similar to PPARγ signalling, the RARs must form heterodimers with RXRs, and 
upon ligand binding the complex can activate transcription at specific sequences in 
promoter regions called retinoic acid response elements (RAREs) (Mader et al., 1993). 
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Early evidence of the importance of retinoic acid receptor signalling in urothelium was 
demonstrated in mice fed vitamin-A deficient diets; in these mice, keratinising 
squamous metaplasia of the bladder occurred (Molloy and Laskin, 1988; Liang et al., 
2005). When pregnant mice were fed a vitamin-A deficient diet, and their resulting 
offspring were also fed a vitamin-A deficient diet, female offspring displayed evidence 
of squamous metaplasia of the bladder as early as 8 weeks of age (Liang et al., 2005). 
Male offspring, in the same study, took much longer for the squamous metaplasia to 
occur, with the phenomenon not occurring until approximately 48 weeks of age.  
 
Mouse models have subsequently been used to demonstrate an important regulatory role 
of retinoic acid in the development and differentiation of urothelium (Gandhi et al., 
2013). Gandhi et al. demonstrated, using a RARE-LacZ system in mice, that RAR 
activity was present predominantly in urothelial progenitor cells at E12. By E14, the 
RAR activity was much more prevalent in the intermediate and superficial cells of the 
developing urothelium. Adult urothelium, by contrast, showed only little RARE-LacZ 
activity, with the authors suggesting that less retinoic acid signalling was necessary to 
maintain the mature urothelial phenotype. When retinoic acid signalling was blocked 
using a dominant negative RAR mutant, it prevented differentiation of urothelium, with 
the mice displaying only a single layered basal epithelium, and nearly absent superficial 
cells (Gandhi et al., 2013). 
 
Retinoic acid signalling has also been investigated in urothelial cells in vitro. In 
proliferating NHU cell cultures, treatment of the cells with 13-cis-retinoic acid was 
shown to inhibit CK14 expression, a squamous epithelial cell marker, and increase 
CK13 expression (Southgate et al., 1994). Retinoic acid treatment has also been shown 
to have potential roles in the conversion of stem cells into urothelial cells, where it has 
been demonstrated that treatment of pluripotent stem cells (human ESCs and iPSCs, and 
murine ESCs) with retinoic acid was able to cause upregulation of uroplakin gene 
expression (Mauney et al., 2010; Kang et al., 2014b). 
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 Buccal Epithelium 
Buccal epithelium is a non-cornified, stratified squamous epithelium which is found on 
the inner surface of the cheek and lips (Figure 1.9). It averages 20-30 cell layers thick, 
functions as a barrier epithelium, and is derived from the embryonic ectoderm 
(reviewed in Winning and Townsend, 2000). Buccal epithelial cells express 
cytokeratin 14, the squamous-associated epithelial cell protein, as well as several other 
cytokeratins (CK4, CK5, CK13 and CK19), which can be used to characterise the 
epithelium (reviewed in Presland and Dale, 2000).  
 
Buccal epithelium has four epithelial cell layers: the basal layer, spinous layer, 
intermediate layer and superficial layer (Landay and Schroeder, 1979). It is a 
non-cornified stratified squamous epithelium, and as a result lacks layers of dead cells 
on its surface, which is associated with cornified epithelia like the epidermis. Buccal 
epithelial cells commit to terminal differentiation in the basal and spinous layers and 
later migrate up through the epithelial cell layers undergoing a progressive 
differentiation process similar to that observed in skin. Protein markers which can be 
used to identify terminal differentiation in stratified squamous epithelia include 
transglutaminases (TGMs) and small proline rich proteins (SPRRs), which are 
expressed only in the upper layers of the epithelium (reviewed in Presland and Dale, 
2000). Absence of loricrin (LOR) can be used to distinguish a non-cornified, stratified 
squamous epithelium from a cornified epithelium (Gibbs and Ponec, 2000). 
 
Much of the work completed to investigate the differentiation and barrier function 
properties of stratified squamous epithelia has been completed using epidermis, and 
particularly using mouse models. Very little work of this nature has been focused on 
oral epithelial cells. 
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Figure 1.9 Human Buccal Mucosa 
Haematoxylin and Eosin stained section of human buccal mucosa. Buccal mucosa consists of 
a non-cornified, stratified squamous epithelium, and an underlying connective tissue layer. 
 
1.4.1 Differentiation of Oral Epithelia 
The differentiation process of oral epithelia is thought to be similar to that of skin 
(reviewed in Jones and Klein, 2013). There are believed to be at least two populations 
of cells in stratified squamous epithelia: a mitotically-active population of 
stem/progenitor cells found in the basal most layers, and mitotically-inactive, terminally 
differentiating cells in the suprabasal layers. (reviewed in Mascre et al., 2012; reviewed 
in Jones and Klein, 2013). Committed progenitor cells become terminally 
differentiating and migrate through the layers of the epithelium undergoing a 
progressive differentiation process (reviewed in Jones and Klein, 2013). This process 
leads to cell death in cornified epithelia, with complete loss of organelles, including the 
nucleus. In non-cornified stratified squamous epithelia, superficial cells remain alive 
and still contain their nuclei (Landay and Schroeder, 1979). Ultimately, cells of the 
superficial layer of both the cornified and non-cornified oral epithelia are sloughed off 
and replaced by new terminally differentiating cells (reviewed in Presland and Dale, 
2000). 
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For the differentiation of stratified squamous epithelia, much of the work to determine 
the transcription factors involved in development and differentiation has been 
performed in mouse epidermis (reviewed in Dai and Segre, 2004). Example 
transcription factors which have been found to play a key role in mouse epidermal 
terminal differentiation and barrier formation include p63, KLF4 and GRHL3 (Segre et 
al., 1999; Yang et al., 1999; Ting et al., 2005). Mice lacking p63 failed to form a 
stratified epithelium, and instead formed only a single layered epidermis, which 
expressed several terminal differentiation-associated proteins including, loricrin, 
involucrin and filaggrin (Yang et al., 1999). p63 is suspected to play a role in the 
maintenance of the basal/progenitor cell population of stratified squamous epithelia 
(Yang et al., 1999). Both KLF4-deficient and GRHL3-deficient mice die due to defects 
in barrier function, which was attributed to both an imbalance in barrier-associated 
lipids and proteins (Segre et al., 1999; Ting et al., 2005). 
 
In the culture of squamous epithelial cells from skin, treatment of the cells with PPARγ 
agonists has been shown to increase the expression of squamous differentiation-
associated genes, involucrin and transglutaminase-1 (Westergaard et al., 2001; Mao-
Qiang et al., 2004), as well as inhibit proliferation (Ellis et al., 2000). Targeted 
knockout of PPARγ in the skin of mice showed only a slight thickening of the 
epithelium, but was not associated with any functional abnormalities (Mao-Qiang et al., 
2004). The study suggested a non-crucial role of PPARγ in mouse skin differentiation 
and barrier function. 
 
The effect of retinoic acid on oral epithelial cells has been investigated. In an 
immortalised mouse gingival epithelial cell line it was shown that treatment of the cells 
with retinoic acid caused downregulation of both CK13 and CK14 expression 
(Hatakeyama et al., 2004), as well as downregulated expression of the tight junction-
associated genes, claudins 1 and 5 (Hatakeyama et al., 2010). In primary human oral 
epithelial cells (obtained from cornified oral epithelia), retinoic acid treatment abrogated 
the cells’ ability to form a cornified cell layer (Kautsky et al., 1995; Kato et al., 2013), 
and reduced the overall epithelium thickness (Chung et al., 1997) when cells were 
induced to differentiate with fetal bovine serum. Retinoic acid also caused decreased 
expression of the terminal squamous  
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differentiation markers, profilaggrin and keratin 1 (Kautsky et al., 1995; Chung et al., 
1997). In general, it appears that retinoic acid treatment of oral epithelial cells has a 
negative effect on squamous-type differentiation of the cells. 
 
1.4.2 Barrier Function of Oral Epithelia 
The barrier function of stratified squamous epithelia is attributed to two main 
components: the presence of a cross-linked protein meshwork on the inside of the 
plasma membrane, and the presence of a unique composition of lipids on the outer 
surface of the cells of the most superficial cell layers (reviewed in Kalinin et al., 2002).  
 
As cells commit to terminal differentiation, they begin to produce a new set of proteins, 
including filaggrin, involucrin, loricrin, and small proline rich region (SPRR) proteins 
(reviewed in Presland and Dale, 2000). By the time the cells reach the superficial layer, 
these proteins are cross-linked by a group of enzymes, the transglutaminases, to form 
the cornified cell envelope (reviewed in Candi et al., 2005). This cornified cell envelope 
eventually replaces the cell membrane of the cells of the stratum corneum in cornified 
oral epithelia. In non-cornified oral epithelia, the process is less well organised, with not 
all of these proteins being produced (loricrin is absent in buccal epithelium), and the cell 
membrane remains intact (Gibbs and Ponec, 2000). 
 
As the cells migrate through the epithelium, the committed differentiating cells produce 
a new type of organelle called membrane coating granules, which occurs in the upper 
spinous layers (Squier, 1977). These granules contain glycolipids and as the cells reach 
the superficial layer the granules bind to the plasma membrane and release their lipid 
contents into the intercellular space. The lipids form a water-tight barrier. The particular 
combination of lipids released by the membrane coating granules differs among the 
types of oral epithelia (Wertz et al., 1986). This differing combination of lipids gives 
each type of oral epithelium a unique permeability to water; in order of increasing 
permeability to water are hard palate > buccal mucosa >  the floor of the mouth (Lesch 
et al., 1989). 
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 Bladder Tissue Engineering 
Tissue engineering is the concept of generating functional tissue replacements in vitro 
for patients whose tissues or organs are affected by injury, disease, or cancer. For 
patients with end-stage diseased bladders or bladder cancer, bladder tissue engineering 
aims to provide an alternative to the current surgical approaches, which can have many 
associated complications.  
 
Bladder augmentation (enlargement of the bladder) and reconstruction following 
cystectomy (part or full removal of the bladder) are the two main surgical procedures 
where bladder tissue engineering could be useful. The current widely used clinical 
method for enlarging or creating an entirely new bladder involves taking a vascularised 
segment of the patients own intestine and either grafting it into the bladder (method 
called enterocystoplasty) to increase its size, or using a portion of the intestine to form a 
bag-like structure to act as a neo-bladder (reviewed in Biers et al., 2012). While these 
types of surgical procedures are widely used with success, a variety of complications 
arise as a result of the inherent nature of the intestinal epithelium (it is an absorptive 
epithelium): metabolic imbalance, mucus production, infection, and risk of stones 
(reviewed in Gilbert and Hensle, 2005). 
 
Tissue engineering-based alternatives to using gastrointestinal grafts have been the 
subject of active research since the mid-1990’s (reviewed in Lam Van Ba et al., 2015). 
An early study involved seeding autologous, in vitro cultivated urothelial cells onto the 
luminal side of an allogeneic piece of bladder submucosa and autologous smooth 
muscle cells on the opposite surface (Yoo et al., 1998). The tissue construct was 
allowed to grow for up to ten days in vitro, and then used to augment the bladder of 
dogs. Following 3 months of implantation, the grafted tissue was reported to display a 
full thickness urothelium on the luminal surface, and smooth muscle with an angiogenic 
response on the opposite surface. The bladders were successfully increased in capacity 
by up to 99%, and had maintained a normal compliance. 
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Subsequent studies by the same group attempted full bladder replacement, first using an 
animal model (Oberpenning et al., 1999), and later in humans (Atala et al., 2006). This 
method of bladder tissue engineering involved the use of a biodegradable scaffold 
(made from collagen and/or polyglycolic acid) formed in the shape of the bladder. 
Autologous, in vitro grown urothelial cells were seeded on the luminal surface of the 
scaffold, and autologous smooth muscle cells were seeded on the external surface. The 
cells were allowed to grow in vitro for several days before the construct was used for 
surgical replacement of the bladder. While results were quite successful in the animal 
model, initial positive hype from the human study was later called in to question by a 
subsequent clinical trial by another group (Joseph et al., 2014). The follow-up clinical 
trial concluded that the bladder tissue-engineering technique resulted in high risk of 
complication and harm to patients. This prompted a call for further basic bladder 
research before any other similar human studies were carried out (Cheng, 2014; Farhat, 
2014). 
 
The other main approach to bladder tissue engineering, termed “composite cystoplasty”, 
involves using a vascularised, demucosalised segment of the patients’ intestine, which is 
lined by an autologous, in vitro produced, urothelium (Fraser et al., 2004; Turner et al., 
2011). The resulting construct eliminates the harm-causing component of a pedicle 
intestinal graft, by replacing the intestinal epithelial layer with a layer of cultured 
bladder epithelium. Early work in this area saw the use of autologous islets of 
urothelium (not in vitro produced) placed on a de-epithelialised bowel, which resulted 
in decreased shrinkage of the grafts in comparison to grafts which contained no 
urothelium patches (Lutz and Frey, 1995). This work showed initial promise for the 
technique. More recent work has shown this method of bladder tissue engineering to be 
much simpler than others, as only the epithelial layer must be produced in vitro, and it 
adapts current gold standard surgical procedures, making it potentially less risk-
associated for patients. The method has been tested successfully in autologous pig 
surgical models (Fraser et al., 2004; Turner et al., 2011), and waits further animal-based 
model testing before possible translation to human patients. 
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1.5.1 Epithelial Cells for Bladder Tissue Engineering 
The production of epithelia in vitro for use in tissue-engineering applications is well 
advanced. However, the vast majority of these epithelia are produced using epithelial 
cells isolated from the donor tissue of healthy organs, and the pre-clinical surgical 
studies are completed using healthy animal models. A problem can arise when 
attempting to translate these models into patients with chronically diseased tissues or 
organs. 
 
All clinically relevant bladder tissue engineering techniques require the use of in vitro 
cultured, autologous epithelial cells; the most ideal epithelial cell type for this being the 
patient’s own bladder epithelial cells. More recent work has intimated that the use of 
autologous urothelial cells may not be possible for some patients with bladder disease; 
urothelial cells isolated from patients with neuropathic bladders senesced much earlier 
in culture, and were less likely to form a functional barrier epithelium when induced to 
differentiate, in comparison to urothelial cells from healthy bladders (Subramaniam et 
al., 2011). This work suggested that urothelial cells were affected by the disease 
environment, and could not be considered normal, healthy urothelial cells. 
 
The main research strategy for generating other autologous epithelial cells for bladder 
tissue engineering has been to differentiate various types of multipotent or pluripotent 
stem cells into urothelial cells (reviewed in Osborn and Kurzrock, 2015) (Figure 1.10 
A). Aside from this, others have suggested simply using another autologous barrier-
forming epithelial cell type, such as buccal epithelial cells (Lu et al., 2010; Watanabe et 
al., 2011) (Figure 1.10 B). The other plausible method of generating surrogate 
autologous epithelial cells is via in vitro transdifferentiation (Figure 1.10 C). 
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Figure 1.10 Methods of Generating Epithelial Cells for Bladder Tissue Engineering 
A) Differentiation of autologous multipotent or pluripotent stem cells into urothelial 
cells using growth factors and agonists. 
B) Use of another easily harvestable and expandable autologous barrier-forming 
epithelial cell type. 
C) Transdifferentiation using direct transcription factor reprogramming of one 
autologous differentiated cell type into urothelial cells. 
 
1.5.1.1 Differentiation of Multipotent and Pluripotent Stem Cells into Urothelial 
Cells 
In recent years, there have been a number of attempts to differentiate various types of 
multipotent and pluripotent stem cells into urothelial cells, with the aim of providing a 
possible alternate autologous cell source for bladder tissue engineering. In order to do 
this, three main methods have been employed: the use of conditioned medium (Shi et 
al., 2012; Moad et al., 2013; Wu et al., 2013; Kang et al., 2014a; Zhao et al., 2014), co-
culture (Liu et al., 2009; Tian et al., 2010; Ning et al., 2011; Chung and Koh, 2013), and 
the use of a specific medium/specific agonists (Bharadwaj et al., 2013; Lang et al., 
2013; Kang et al., 2014b; Osborn et al., 2014). All of the methods have produced a 
similar outcome, the production of a population of cells which had upregulated 
expression of some epithelial and urothelial-associated genes – best classified as 
‘urothelial-like’ cells. 
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One of the first reports of multipotent stem cell to urothelial-like cell differentiation 
used human bone marrow derived mesenchymal stem cells; this was performed by the 
use of indirect co-culture, and also by urothelial cell-derived conditioned medium (Tian 
et al., 2010). The authors demonstrated an upregulation of UPK1A, CK7 and CK13 
expression by RT-PCR as a result of the culture conditions. Others have shown the 
differentiation of human adipose-derived stem cells (Shi et al., 2012), amniotic fluid 
stem cells (Kang et al., 2014a), and umbilical cord stem cells (Wu et al., 2013) into 
urothelial-like cells using conditioned medium (generated from human urothelial cells, a 
bladder cancer cell line, or an immortalised urothelial cell line), and observed an 
upregulation of CK18 and UPK2 expression. Induced pluripotent stem cells (iPSCs), 
derived from urinary tract stromal cells, have also been shown to have upregulated 
UPK1B, UPK2, UPK3A and UPK3B expression as a result of growth in human 
urothelial cell-derived conditioned medium (Moad et al., 2013). 
 
The notion that urothelial cell conditioned medium or co-culture with urothelial cells 
alone should have the ability to completely differentiate stem cells into urothelial cells 
is unsupported. While the use of these techniques in the work described above appeared 
to have some ability to upregulate both epithelial cell-specific and urothelial cell-
specific genes, their ability to cause complete conversion to a functional urothelium was 
not shown. This work is likely more important for its demonstration that human 
urothelial cells appear to be excreting factor/s which are able to induce expression of 
epithelial cell and urothelial cell-specific genes. Identification of these excreted factors 
could be beneficial for the understanding of how urothelial cells in vivo maintain their 
differentiated state. 
 
The discovery of multipotent stem cells collected from voided urine (Zhang et al., 
2008), and the subsequent attempt to convert these cells into urothelial cells (Bharadwaj 
et al., 2013) provided another possible surrogate urothelial cell source. Following 
growth in a specific medium (a combination of KSFM and embryonic fibroblast 
medium) with added EGF and 2 % FBS, the cells had increased expression of UPK1A, 
UPK3 and CK20 (shown by RT-PCR and/or immunofluorescence microscopy) 
(Bharadwaj et al., 2013). The authors were also able to demonstrate an increase in 
barrier function (decreased permeability to FITC-dextran) of these cells in comparison 
to non-differentiated cells.  
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The idea that simply culturing multipotent or pluripotent stem cells in a generic 
epithelial cell medium should have the ability to induce urothelial cell-specific 
differentiation is unfounded. This work must suggest that these urine-derived stem cells 
were pre-primed for urothelial-type differentiation above all other epithelial cell types. 
This notion was shown by another group (Moad et al., 2013), who compared the 
urothelial differentiation potential of human dermal-derived iPSCs and human urinary 
tract stroma-derived iPSCs; when both cell types were treated with human urothelial 
cell-derived conditioned medium, the urinary tract stroma-derived iPSCs had 
significantly greater upregulation of UPK1B, UPK2, UPK3A, UPK3B, CLDN1, 
CLDN5 and CK7, than the dermal-derived iPSCs. 
 
More recently, attempts at a more ‘directed’ approach have been undertaken, using a 
two-step process whereby pluripotent stem cells are first differentiated into definitive 
endoderm-type (DE) cells, and then further differentiated into a urothelial cell lineage 
(Kang et al., 2014b; Osborn et al., 2014). Osborn et al. used this method starting with 
human embryonic stem cells. For urothelial-type differentiation, the DE cells were 
cultured in ‘Uromedium’ for 21 days, with PPARγ activation, by use of Troglitazone, at 
day 18. The authors demonstrated upregulated expression of all five of the uroplakin 
genes. In addition to this report, Kang et al. demonstrated differentiation of iPSCs using 
this two-step method, choosing to use KSFM with added retinoic acid for urothelial-
type differentiation. The authors showed upregulated expression of UPK1B, UPK2, 
UPK3A and CK20, as well as increased barrier function (decreased permeability to 
FITC-dextran) in comparison to non-urothelial differentiated cells (definitive endoderm-
type cells). The authors also demonstrated upregulation of epithelial cell-associated 
genes including CK7, CLDN5, ZO-1, and E-cadherin. 
 
While the two-step directed approach to cell conversion applies a more logical 
approach, the actual urothelial cell differentiation step in both studies still lacked clear 
foundation. In both cases, the authors’ primary method for demonstrating urothelial cell 
specification, over any other epithelial cell type, was to show fold change increase in 
uroplakin gene expression. It is well established that other epithelial cell types can at the 
very minimum express UPK1B and UPK3B (Adachi et al., 2000; Rudat et al., 2014). 
Therefore, the use of uroplakin gene expression as the sole basis for demonstrating  
Chapter 1 
 
61 
successful conversion to urothelial cells is not enough. More work is still necessary to 
determine useful sets of markers that can more fully distinguish urothelial cells from 
other epithelial cell types. 
 
1.5.1.2 Use of Buccal Epithelial Cells for Bladder Tissue Engineering 
Two forms (free graft and tissue-engineered graft) of buccal mucosa have been used and 
investigated for use in the urinary system. Currently, buccal mucosa is used commonly 
for urethroplasty, where a buccal mucosa graft is taken from the mouth, and directly 
transplanted to fix a urethral defect; this occurs in cases where tissue local to the urethra 
is not usable (reviewed in Markiewicz et al., 2007). Tissue-engineered versions of 
buccal mucosa have also been produced for urethroplasty patients who would need 
larger portions of buccal mucosa than are attainable via an intact free graft. While 
several healthy animal model-based studies have shown success (Li et al., 2008; 
Mikami et al., 2012), a clinical trial in human patients revealed poor outcomes, with two 
of the five patients needing full or part removal of the graft due to fibrosis (Bhargava et 
al., 2008). 
 
Investigation into the use of buccal mucosa or buccal epithelial cells in the bladder is 
limited, with only a few animal studies having been performed; two studies have 
examined the effect of urine on buccal mucosa tissue for use in urethroplasty (Filipas et 
al., 1999; Xu et al., 2005), while a further two studies investigated the potential use of 
buccal epithelial cells for bladder tissue engineering (Lu et al., 2010; Watanabe et al., 
2011). 
 
A study published in 1999 compared the robustness of full-skin grafts and buccal 
mucosa grafts in the bladder of pigs (Filipas et al., 1999). Following 7 months of 
implantation, a histological analysis was completed which found that the buccal mucosa 
grafts fared better in the bladder than the full skin grafts following long-term exposure 
to urine; buccal mucosa grafts showed only little inflammation, while the majority of 
the skin grafts showed significant inflammation or necrosis. 
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The presence of buccal mucosa and colonic mucosa in the bladder has also been 
compared (Xu et al., 2005). Autologous buccal mucosa and colonic mucosa grafts were 
transplanted into opposite sides of the bladder in dogs. Upon histological analysis, 
following 6-10 months of the grafts' implantation, both the buccal mucosa and colonic 
mucosa grafts survived with only minimal inflammation present. The authors observed 
transitional-type epithelium on top of portions of some of the buccal mucosa and 
colonic mucosa grafts, likely indicating that overgrowth of adjacent urothelium had 
occurred. 
 
More recently, autologous buccal mucosa grafts have been transplanted into the 
bladders of pigs, to determine their possible use for bladder tissue engineering (Lu et al., 
2010). Following 3 and 6 months of implantation, the grafts displayed a normal non-
cornified, stratified squamous epithelium. Following 12 months of implantation, the 
authors noted some histological changes to the grafted epithelium, which began to look 
less stratified squamous. The authors observed CK14 expression by 
immunohistochemical and transcript analysis at all of time points, indicating that the 
epithelium maintained its squamous phenotype throughout. UPK2 expression was 
observed by both immunohistochemical and transcript analysis at the 6 and 12 month 
time points. The authors suggested that this finding could highlight the 
transdifferentiation potential of buccal epithelial cells towards a more transitional 
epithelial cell phenotype. 
 
Previous work has shown that patients with urine-deprived bladders display a normal 
urothelium phenotype, as characterised by morphology, and the expression of UPK1A, 
UPK1B, UPK3A, CK20, PPARγ and RXRα (Stahlschmidt et al., 2005). The work 
suggested that urine plays little or no role in maintaining the differentiation state of 
urothelial cells. Therefore, it is unlikely that urine should be able to cause any sort of 
urothelial-type differentiation of buccal epithelial cells. Changes observed in the studies 
described above were more likely attributed to urothelial cell ingrowth as opposed to 
transdifferentiation or metaplasia, as suggested by the authors. The other possible cause 
for the changes observed could be due to signalling from the underlying bladder stroma. 
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A tissue-engineered version of buccal mucosa has also been produced, where epithelial 
cell sheets were grown from autologous oral keratinocytes, then grafted onto gastric 
flaps and transplanted to augment the bladder of dogs (Watanabe et al., 2011). The 
epithelial cell sheets were produced using a serum and feeder layer-based cell culture 
method and appeared 2-5 cell layers thick. Following 3 weeks of implantation in the 
bladder, the grafts had an absence of oral epithelium and instead an ingrowth of 
urothelium on 20-30% of the grafts, with the other 70% of the grafts containing no 
epithelium. The authors also attempted a two-part surgery, where first the gastric flaps 
with buccal epithelial cell sheets where placed into a protective latex pouch in the 
abdomen for 5 days, and then they were transferred to augment the bladder for a 
duration of 3 weeks. Upon histological analysis, all of the grafts had a multi-layered 
stratified squamous epithelium similar to native buccal epithelium. The authors noted 
significant contraction of the grafts (up to 70 %) had occurred in all of the cases. This 
work demonstrated that oral epithelial cells directly implanted into the bladder are 
unable to survive. In order to survive and function in the bladder, they required pre-
implantation in the body away from the bladder microenvironment. A much longer term 
study needs to be completed to assess the true long term potential of these cells in the 
bladder. 
 
 Transdifferentiation 
Transdifferentiation (also termed lineage reprogramming) is the conversion of one 
differentiated cell type into another differentiated cell type, without reversion back to 
the pluripotent state (reviewed in Slack, 2007). Directed transdifferentiation is 
traditionally performed in vitro by the forced, exogenous expression of one or more 
critical transcription factors. This is typically fulfilled by using either lentiviral or 
retroviral-based transduction. More recently the use of microRNAs (miRNAs) and 
small molecules has also been employed (reviewed in Xu et al., 2015). 
 
The first example of transdifferentiation was demonstrated in 1987, where it was shown 
that exogenous expression of the transcription factor, MyoD, in fibroblasts, could lead 
to conversion to myoblast-type cells. Since then, many groups have reported in vitro 
transdifferentiations of numerous cell types (reviewed in Xu et al., 2015). Much of the 
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transdifferentiations reported have been completed through conversion of cells of the 
same embryonic germ layer derivation. These include the conversion of myoblasts to 
adipocytes (Hu et al., 1995), B lymphocytes to macrophages (Xie et al., 2004), 
fibroblasts to myoblasts (Davis et al., 1987), and fibroblasts to cardiomyocytes (Ieda et 
al., 2010), which are all mesoderm to mesoderm cell conversions. Transdifferentiation 
of cell types across different embryonic lineages has also been shown to be possible: the 
conversion of fibroblasts to neurons is a mesoderm to ectoderm conversion (Vierbuchen 
et al., 2010). Work in the field of transdifferentiation has led to the new idea that 
differentiated cells are not lineage restricted, and can likely be converted into any other 
cell type by reprogramming once the key transcription factors are known. 
 
The choice of transcription factors used for transdifferentiation is almost always derived 
from transcription factors known to play an important role in the embryonic 
development of the cell type. It has also been shown that a combination of both 
embryonic development-associated and mature differentiation-associated transcription 
factors can be required for the full transdifferentiation of some cell types (ie. the 
conversion of human fibroblasts into hepatocytes (Du et al., 2014)). 
 
The main perceived advantage of transdifferentiation over the use of differentiated stem 
cells or induced pluripotent stem cells (iPSCs) is that transdifferentiated cells 
theoretically have no propensity to form teratomas, while cells derived from embryonic 
stem cells and iPSCs do form teratomas by definition (Miura et al., 2009). 
 
1.6.1 Conversion of Fibroblasts to Cardiomyocytes and Neurons in 
vitro 
Two of the most well studied types of transdifferentiation are the conversion of 
fibroblasts to cardiomyocytes, and the conversion of fibroblasts to neurons. 
 
Direct reprogramming of fibroblasts into cardiomyocyte-like cells was first completed 
in 2010 by Ieda et al. using murine fibroblasts; three transcription factors, GATA4, 
Mef2c and Tbx5 were required (Ieda et al., 2010). Subsequent groups reported that the 
addition of up to four additional transcription factors, to the originally discovered three, 
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could lead to improved conversion to cardiomyocytes (Addis et al., 2013; Christoforou 
et al., 2013). In the attempt to translate these findings in the murine system to that of the 
human system, it was found that the original set of three transcription factors discovered 
in the mouse model (GATA4, Mef2c and Tbx5) was unable to cause successful 
transdifferentiation of human fibroblasts; additional genes were required for a more 
complete transdifferentiation (Fu et al., 2013; Wada et al., 2013). Another group 
discovered that murine fibroblasts could be converted to cardiomyocytes using four 
microRNAs (miR-1, miR-33, miR-208, and miR-499) (Jayawardena et al., 2012). They 
also found that the combined use of the microRNAs with a specific inhibitor was able to 
enhance the reprogramming 10-fold. 
 
The first report of directed conversion of fibroblasts into functional neurons was 
published in 2010, where it was demonstrated that a combination of three transcription 
factors, Ascl1, Brn2, and Myt1l, could convert mouse fibroblasts into neuron-like cells 
(Vierbuchen et al., 2010). The authors originally started with 19 candidate genes known 
to have a role in neuron development and maintenance, before narrowing it down to the 
final three factors. The same group later demonstrated that when these three factors 
were combined with a fourth factor, NeuroD1, that fetal and postnatal human fibroblasts 
could be successfully converted into neurons (Pang et al., 2011). More recently this 
group further showed that neuron-like cells could be generated from both mouse and 
human fibroblasts using the overexpression of the transcription factor, Ascl1, alone 
(Chanda et al., 2014). Other groups have also shown the conversion of fibroblasts into 
neuron-like cells using various methods, including single gene knockdown (Xue et al., 
2013), combined use of microRNA and transcription factor overexpression (Yoo et al., 
2011), and the combined use of transcription factor overexpression with small 
molecule-based inhibition (Ladewig et al., 2012). A problem that arose with neuronal 
conversions, was that the final neuronal cells produced were post-mitotic, and therefore 
unable to be expanded further in vitro. As a result, several groups have worked on the 
transdifferentiation of fibroblasts into neural stem/progenitor cells, which can be 
propagated in vitro for many passages, and later induced to differentiate into multiple 
neuronal lineages (Han et al., 2012; Lujan et al., 2012; Ring et al., 2012; Thier et al., 
2012; Cheng et al., 2014). 
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The main issue with all types of reprogramming and transdifferentiation-type 
experiments is being able to demonstrate complete conversion to the new cell type (ie. 
is the epigenetic signature from the starting cell type completely overwritten?). In many 
cases, authors are quick to make claims of achieved full conversion, without providing 
adequate evidence. Recently, Cahan et al. studied whether the reported 
transdifferentiations of fibroblasts to neurons or cardiomyocytes was complete. 
Unsurprisingly, they demonstrated that the generated cells failed to silence all of the 
fibroblast gene regulatory networks (Cahan et al., 2014), and as a result, the cells were 
likely in a much more immature state than they were originally described. This work 
demonstrated the need for much more rigorous testing in order to show true 
transdifferentiation to the new cell type. This notion is very much applicable to stem 
cell differentiation experiments. It is clear that a change in the reporting of results in this 
field needs to occur. Authors need to be a much more cautious in their description of 
findings, rather than the current trend of being overly acclamatory. 
 
1.6.2 Transdifferentiation to Urothelial Cells 
The only demonstration of possible transdifferentiation of a cell type into urothelial 
cells was demonstrated by Strand et al. The authors were investigating the role of 
PPARγ in prostate epithelium and found that the knockdown of PPARγ2 in benign 
human prostatic epithelial cells caused them to transdifferentiate into urothelial-like 
cells (Strand et al., 2013). Human prostate epithelial cells expressed both PPARγ1 and 
PPARγ2. Using shRNA, the authors demonstrated that PPARγ2 knockdown resulted in 
de novo CK20 protein expression, and increased p63 expression. When the PPARγ2 
knockdown cells were grown on rat embryonic bladder mesenchyme, and transplanted 
under the renal capsule of immunocompromised mice, approximately 40% of the 
resulting epithelium was positive for pan-uroplakin protein expression. Portions of the 
epithelium also had CK14 expression in the basal cells. When both PPARγ1 and 
PPARγ2 were knocked down, there was no uroplakin protein expression, and increased 
CK14 expression. Although this work failed to fully demonstrate complete 
transdifferentiation to urothelial cells, it identified an essential role of PPARγ1 
urothelial cell differentiation. It also demonstrated that loss of the PPARγ2 isoform was 
necessary for urothelial-type differentiation.  
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 Thesis Aims 
The overall aim of this research project was to investigate the potential use of oral 
epithelial cells as a surrogate epithelial cell source for bladder tissue engineering. More 
specifically, the aim was to attempt to transdifferentiate buccal epithelial cells into 
urothelial-like cells; the hypothesis being that there existed the ability to reprogramme 
one epithelial cell type to have the function of another epithelial cell type. In order to 
achieve this, the project had three key objectives: 
 
1. Perform an in vitro characterisation of buccal epithelial cells with reference to 
urothelial cells, and in doing so determine a set of transcription factors which 
could be used to transdifferentiate buccal epithelial cells into urothelial-like cells 
(Chapter 3). 
 
2. Investigate the expression and role of these determined transcription factors in 
maintaining urothelial cell identity and differentiation (Chapter 4). 
 
3. Overexpress the determined transcription factors in buccal epithelial cells and 
determine their propensity to cause successful transdifferentiation (Chapter 5). 
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2 Materials and Methods 
 Practical Work 
All laboratory work was carried out in the Department of Biology at the University of 
York in York, UK. Day-to-day laboratory work was carried out in the Jack Birch Unit 
of Molecular Carcinogenesis under the supervision of Professor Jennifer Southgate. 
 
 H2O and Buffers 
All water used for experiments and making buffers was ultrapure water (ELGA purified 
water), with a water purity of 18.2 MΩ-cm, which was generated using a type 1 
ultrapure water purification system (ELGA, PURELAB® Ultra). Any water used for 
tissue culture was autoclaved (121 oC for 20 minutes) (Priorclave, 60L compact 
Priorclave) prior to use. 
 
For molecular biology-based experiments, where nuclease-free water was required, 
diethylpyrocarbonate (DEPC) -treated ELGA purified water was used. To generate, 
DEPC-treated water, DEPC (Sigma-Aldrich, D5758) was added to ELGA purified 
water to a final concentration of 0.1 %, and then autoclaved (121 oC for 20 minutes). 
 
Various buffer and solution recipes can be found in Appendix 7.1. All buffers and 
solutions were prepared using ELGA-purified water unless indicated (by use of a 
reference to see the Appendix). 
 
 Ethical Approval 
Buccal mucosa and urological (renal pelvis and ureter) samples were obtained with 
National Health Service (NHS) Research Ethics Committee (REC) approval, from 
consented patients where applicable. Only the patients’ age and gender were collected 
for the purpose of the research. The samples were sent unlinked and anonymised to the 
laboratory. Local ethical approval was also obtained from the University of York 
Biology Ethics Committee. Upon arrival to the laboratory, urological tissue specimens 
were given a unique ‘Y’ number (eg. Y1400) (Table 2.1). Buccal mucosa tissue 
specimens were given either a ‘Y’ number, or an ‘AS’ number (eg. AS001b)  
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(Table 2.2). When the epithelial cells were isolated from the tissue samples they 
retained their unique identifier, and thus were each defined as named distinct finite cell 
lines after serial passage. 
 
Table 2.1 List of ‘Y’ Numbers Pertaining to Urological Tissue Samples 
Sample ID 
Number 
Type of Operation Tissue Type Age (yr.)/Sex 
Y938 Nephrectomy Ureter ?/? 
Y939 Pyeloplasty Renal Pelvis ?/? 
Y1153 Nephrectomy Ureter ?/? 
Y1156 Nephrectomy Ureter ?/? 
Y1281 Nephrectomy Ureter 79/F 
Y1282 Nephrectomy Ureter 55/M 
Y1288 Nephrectomy Ureter 57/M 
Y1289 Nephrectomy Ureter 54/F 
Y1334 Renal Transplant Ureter 24/M 
Y1336 Nephrectomy Ureter 63/F 
Y1356 Renal Transplant Ureter 63/M 
Y1358 Pyeloplasty Renal Pelvis 51/F 
Y1361 Nephrectomy Ureter 52/M 
Y1390 Renal Transplant Ureter 31/F 
Y1393 Renal Transplant Ureter 60/M 
Y1453 Renal Transplant Ureter ?/? 
Y1541 Renal Transplant Ureter 59/F 
Y1642 Nephrectomy Ureter 63/M 
Y1677 Pyeloplasty Renal Pelvis 1/M 
Y1691 Nephrectomy Ureter 59/F 
Y1752 Renal Transplant Ureter 41/M 
Y1772 Renal Transplant Ureter 50/M 
Y1773 Renal Transplant Ureter 46/M 
Y1774 Pyeloplasty Renal Pelvis 26/F 
Y1815 Renal Transplant Ureter 23/? 
‘?’ means information not known. 
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Table 2.2 List of ‘AS’ and ‘Y’ Numbers Pertaining to Buccal Mucosa Tissue Samples 
Sample ID 
Number 
Type of Operation Tissue Type Age (yr.)/Sex 
AS001b Urethroplasty Buccal Mucosa 37/M 
AS003b Urethroplasty Buccal Mucosa 47/M 
AS005b Urethroplasty Buccal Mucosa 40/M 
AS006b Urethroplasty Buccal Mucosa ?/M 
AS007b Urethroplasty Buccal Mucosa 62/M 
AS008b Urethroplasty Buccal Mucosa 50/M 
AS010b Urethroplasty Buccal Mucosa 65/M 
AS011b Urethroplasty Buccal Mucosa 52/M 
AS021b Urethroplasty Buccal Mucosa 24/M 
AS027b Urethroplasty Buccal Mucosa 54/M 
Y1590 Urethroplasty Buccal Mucosa 13/M 
Y1595 Urethroplasty Buccal Mucosa 3/M 
Y1600 Urethroplasty Buccal Mucosa 5/M 
Y1656 Urethroplasty Buccal Mucosa 4/M 
Y1721 Urethroplasty Buccal Mucosa 3/M 
Y1778 Urethroplasty Buccal Mucosa 6/M 
‘?’ means information not known. 
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 Tissue Culture 
2.4.1 General 
Cell culture work was performed under aseptic working conditions, in BioMat2 laminar 
recirculating airflow, class 2 safety cabinets (Contained Air Solutions Ltd.). Any cell 
culture work which involved the use of viruses was performed in an externally vented, 
Bio2+ laminar airflow, class 2 safety cabinet (Envair Ltd.).   
 
All normal human buccal (NHB) epithelial cells and normal human urothelial (NHU) 
cells were maintained in Keratinocyte Serum Free Medium (KSFM) (Gibco®, 17005-
034) containing 0.05 mg/ml bovine pituitary extract (Gibco®, 37000-015), 5 ng/ml 
epidermal growth factor (Gibco®, 37000-015) and 30 ng/ml cholera toxin, which was 
referred to as KSFM-complete (KSFMc) in this thesis. 
 
Cultures were incubated in humidified HERAcell™ 240 CO2 incubators (Thermo 
Scientific, 51026331). Buccal epithelial cells and urothelial cells were grown at 37 oC in 
5% CO2 in air, in Cell+ tissue culture plasticware (Sarstedt Ltd., Cell+). 
 
For cell counting, cell suspension was pipetted into each chamber of an Improved 
Neubauer haemocytometer (Hawksley, AC1000). The total number of cells present in 
0.0001 cm3 volume (1 mm2 area) was counted for each chamber. The average number 
of cells was calculated from the two chambers, and then multiplied by 1.0 x 104 to 
obtain the number of cells/ml in the cell suspension. 
 
All cell culture centrifugation steps were performed using a benchtop Sigma-Aldrich 2-
6E centrifuge (SciQuip, 10223) at 250 g for 4 minutes. 
 
All solutions required for tissue culture were either filter-sterilised using a 0.2 μm 
syringe filter (Appleton Woods, BC694) or, if heat stable, were autoclaved (121 oC for 
20 minutes), prior to use. 
 
Phase contrast images of cells were taken using an EVOS® XL Core cell imaging 
system (Life Technologies) microscope. 
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2.4.2 Tissue Sample Collection 
In order to ensure that the cells present in the tissue samples remained viable once 
removed from the patient, the tissue samples were placed into a transport medium 
shortly after removal from the patient in theatre. The transport medium was made using 
Hanks’ Balanced Salt Solution (HBSS) (containing Ca2+ and Mg2+) (Gibco®, 24020-
091) with 10 mM HEPES (Gibco®, 15630-056), and 20 KIU/ml aprotonin (Nordic 
Pharma Ltd.) (Southgate et al., 1994). 100 U/mL penicillin-streptomycin (Gibco®, 
15140-122) was added to the transport medium for collection of buccal mucosa tissue 
samples. The tissue samples were kept at 4 oC for up to five days until they were 
processed for epithelial cell isolation and histology. 
 
2.4.3 Epithelial Cell Isolation 
Prior to epithelial cell isolation from the tissue samples, a small representative piece of 
tissue (<0.5 cm2), from each sample, was cut and fixed in a 10 % (v/v) formalin solution 
(see Appendix) for 48 hours. The tissue was then stored in 70 % (v/v) ethanol (Fisher 
Scientific, E/0650DF/P17) for later histological analysis. 
 
2.4.3.1 Buccal Epithelial Cells 
The isolation protocol for NHB epithelial cells was adapted from (Oda and Watson, 
1990). Buccal mucosa tissue samples were cut, using scissors (World Precision 
Instruments, 14394), into 0.5 cm2 pieces, and incubated in 10 ml of 0.5 % (w/v) 
Dispase® II (Roche, 04942078001) solution (see Appendix) at 37oC for 3-4 hours. The 
epithelium was separated from the underlying connective tissue using forceps (World 
Precision Instruments, 501976 & 504156), and each 0.5 cm2 portion of buccal 
epithelium was cut into approximately 10-15 pieces. The tissue pieces were incubated in 
2 ml of trypsin versene (TV) (see Appendix) at 37 oC for 5 minutes to disaggregate the 
cells. 200 μl of 20 mg/ml trypsin inhibitor (TI) (see Appendix) was added to 5 mL of 
KSFMc, and the 5.2 ml solution was added to the disaggregated cell suspension. The 
cell suspension was centrifuged, and the cells were resuspended in 2 ml of 100 U/ml 
collagenase (see Appendix) for 20 minutes at 37 oC, before centrifugation and  
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resuspension in KSFMc. The cells were counted, and seeded into Cell+ cell culture 
plasticware at a seeding density of 4.0 x 104 cells/cm2. 1 % (v/v) penicillin-streptomycin 
was added to the medium for the initial 24 hours after seeding. 
 
2.4.3.2 Urothelial Cells 
NHU cells were isolated from patient tissue samples as previously described (Southgate 
et al., 1994). Tissue samples were cut into 0.5-1.0 cm2 pieces using scissors, and placed 
in ‘stripper medium’ (see Appendix) for 4 hours at 37 oC. The epithelium was separated 
from the underlying connective tissue using forceps, and collected by centrifugation. 
The cells were resuspended in 2 ml of 100 U/ml collagenase for 20 minutes at 37 oC, 
before being centrifuged, and resuspended in KSFMc. The cells were counted using a 
haemocytometer, and seeded at a density of 4.0 x 104 cells/cm2 into Cell+ cell culture 
plasticware. 
 
2.4.4 Maintenance and Subculture (Passage) of Finite Epithelial Cell 
Lines 
NHB epithelial cell and NHU cell cultures were maintained in KSFMc, and the medium 
was changed every 2-3 days. Upon reaching confluence, the cultures were passaged and 
reseeded into new flasks. To passage, cultures were treated with 0.1 % (w/v) EDTA 
(BDH, 100935V) for 5-10 minutes at 37oC until the cells started to separate from one 
another, and become rounded in appearance. The EDTA solution was removed, and 
1 ml of TV was added for approximately 1 minute at 37 oC, until cells detached from 
the plasticware upon tapping. 100 μl of 20 mg/ml TI in 5 mL of KSFMc was added to 
the cells. The resulting cell suspension was centrifuged to pellet, and the cells were 
resuspended in KSFMc. The cells were seeded onto plasticware at a minimum seeding 
density of 1.0 x 104 cells/cm2. Normal human buccal epithelial and urothelial cell lines 
were used for experiments between passages 1-5 (P1-P5). Experiments were replicated 
using up to four independent donor finite cell lines. 
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2.4.5 Freezing and Thawing Cells 
Cell lines were cryopreserved and stored in liquid nitrogen-containing dewars (Taylor-
Wharton, LS6000). Cells were harvested as described in section 2.4.4, and the cell 
pellet was resuspended in ‘freeze mix’ made using KSFMc with 10 % (v/v) FBS and 
10 % (v/v) DMSO (Sigma-Aldrich, D2650). 1 ml of ‘freeze mix’ with cells was 
pipetted into each 2 ml cryo vial (Sarstedt, 73.380.992). The vials were placed at -80 oC 
in a Mr. Frosty™ Freezing Container (Thermo Scientific, 5100-0001) for 24 hours in 
order to allow for controlled reduction of the temperature at a rate of -1 oC/min. The 
vials were transferred to liquid nitrogen-containing dewars for long term storage. 
 
To recover cells from frozen, vials were removed from the liquid nitrogen dewars, and 
thawed rapidly in a 37 oC water bath. The contents of the vial were resuspended in 
10 ml of KSFMc, and centrifuged to pellet. The cells were resuspended in KSFMc, and 
seeded as required. 
 
2.4.6 ABS/Ca2+ Protocol 
The ABS/Ca2+ protocol has been previously described to cause differentiation of NHU 
cells, and generation of biomimetic urothelium equivalents (cell sheets) (Cross et al., 
2005) (Figure 2.1). Cells were grown to 80-90 % confluence, and the medium was 
changed to KSFMc containing 5 % adult bovine serum (ABS) (SeraLab, S-202) for 4-5 
days. Cultures were harvested, and seeded onto either 12 mm Snapwell membranes 
(pore size 0.4 μm) (Fisher Scientific, TKT-541-030W) or 12-well Thincert™ cell 
culture inserts (Greiner Bio-One, 665640). 5.0 x 105 cells were seeded per membrane in 
a volume of 500 μl. The cells were grown in KSFMc with 5 % ABS for 24 hours, and 
then the medium was changed to KSFMc with 5 % ABS and 2 mM [Ca2+]. The calcium 
concentration of the medium was increased to 2 mM (near physiological levels) by 
adding the appropriate amount of a sterile 1 M CaCl2 stock solution; it was taken into 
account that KSFMc contains approximately 0.09 mM [Ca2+] and ABS contains 
approximately 2.2 mM [Ca2+]. The cultures were maintained in the 5 % ABS and 2 mM 
[Ca2+] medium for 7 days, with the medium changed every 2-3 days. 0.5 ml of medium 
was placed on top of the cells (in the upper well) and 2 ml of medium was placed 
underneath the cells (in the lower well). 
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To differentiate cell cultures for the purpose of taking protein lysates, the cells were 
established as above in 6-well plates, but the passage step, and subsequent seeding onto 
the membranes was omitted; following 5 days in KSFMc containing 5 % ABS, the 
medium was changed to KSFMc containing 5 % ABS and 2 mM [Ca2+]. The cultures 
were medium changed every 2-3 days. 
 
 
Figure 2.1 ABS/Ca2+ Differentiation Protocol 
A) 5% ABS pre-treatment of the cells for 4 days.  
B)  7 day differentiation with near physiological calcium concentrations (2 mM). 
 
2.4.7 Measurement of Transepithelial Electrical Resistance (TER)  
The transepithelial electrical resistance (TER) was used as a measurement of the barrier 
function of cell sheets produced on Snapwell and ThinCert™ membranes. For the TER 
measurement, chopstick electrodes (World Precision Instruments, STX2) and an 
Epithelial Voltohmmeter X (World Precision Instruments, EVOMX) were used. The 
electrode was first disinfected using Cidex Plus solution (World Precision Instruments, 
7364) and then equilibrated in 37 oC pre-warmed medium (KSFMc) for 10 minutes. To 
take the TER measurement, the electrode was placed so that the shorter prong was just 
above the cell surface in the inner well, and the longer prong of the electrode was placed 
in the medium in the outer well. The electrode was held in place for up to 30 seconds, 
and the TER value was recorded. The TER of Snapwell and ThinCert™ membranes 
containing medium only (ie. no cells) was taken, and subtracted from all recorded 
values. 
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2.4.8 Dispase Lifting of Cell Sheets 
Cell sheets (created as described above in section 2.4.6) were harvested from Snapwell 
and ThinCert™ membranes, by incubating the cultures in a 2 % (w/v) dispase solution 
for 30 minutes at 37 oC; 0.5 ml of dispase solution was placed on top of the cells, and 2 
ml of dispase solution was placed in the well below the cells. The lifted cell sheet was 
carefully floated into a CellSafe+ biopsy capsule (CellPath, EBE-0301-02A). The 
capsules were placed into System III Hex embedding cassettes (CellPath, EAI-0106-
10A), and labelled appropriately. Cell sheets were fixed in 10 % (v/v) formalin for 
24 hours. The cassettes were transferred into 70 % (v/v) ethanol for storage before 
processing for histological analysis (see section 2.5.2.1). 
 
2.4.9 TZ/PD Protocol 
To investigate the response of cultures to PPARγ activation, the protocol described by 
Varley et al., termed TZ/PD in this thesis, was used (Figure 2.2). The combined use of 
troglitazone (a PPARγ agonist) and PD153035 (an EGFR-TK inhibitor) has been shown 
to cause the upregulation of urothelial differentiation-associated genes, including the 
uroplakins, CK20, and several tight junction-associated proteins, in NHU cells (Varley 
et al., 2004a; Varley et al., 2004b; Varley et al., 2006). 
 
Cultures were grown to 70-80 % confluence, and treated with 1 μM troglitazone (TZ) 
(Tocris, 3114) and 1 μM PD153035 (PD) (Merck Millipore, 234490) in KSFMc for 24 
hours. The medium was then changed to KSFMc containing 1 μM of PD153035 only. 
The cultures were maintained as such for up to 6 days, with the medium changed on the 
3rd day. Cultures grown in KSFMc containing 0.1 % dimethyl sulphoxide (DMSO) 
acted as a vehicle control. The amount of vehicle solution (DMSO) used for drug 
treatments was kept constant at 0.1 %. 
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Figure 2.2 TZ/PD Protocol. 
NHB epithelial cell cultures and NHU cell cultures were grown in KSFMc containing 
1 μM troglitazone (TZ) and 1 μM PD153035 (PD) for 24 hours. The medium was then 
changed to contain only 1 μM PD153035 for all subsequent medium changes. 
 
 
2.4.10 atRA/PD Protocol 
Retinoic acid receptor (RAR) activation has been implicated as a key regulator in the 
maintenance of the urothelial cell identity, with a particular role in preventing squamous 
metaplasia (Southgate et al., 1994; Liang et al., 2005; Gandhi et al., 2013). To 
investigate the effect of RAR activation on regulating urothelial-associated genes in 
NHB epithelial cells, a combination of all-trans retinoic acid (atRA), a RAR ligand, and 
PD153035 were used. The protocol employed was based on the already established 
TZ/PD protocol, and was developed by Dr. Simon Baker, a post-doctoral researcher at 
the Jack Birch Unit. 
 
Cultures were grown to approximately 70 % confluence, and the medium was changed 
to either KSFMc containing 1 μM PD153035 (control), or KSFMc containing 1 μM 
PD15035 and atRA (10 nM, 100 nM and/or 1 μM) for 72 hours (Figure 2.3). Some 
treatments also included 1 μM TZ to investigate the effect of simultaneous PPARγ and 
RAR activation. If TZ was being used, then the medium was changed after 24 hours to 
remove TZ from any cultures which contained it, in keeping with the standard TZ/PD 
protocol. The amount of vehicle solution (DMSO) used for drug treatments was kept 
constant at 0.1 %. 
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Figure 2.3 atRA/PD Protocol 
NHB epithelial cells were grown to approximately 70 % confluence. The medium was 
changed to either KSFMc containing 1 μM PD153035 or KSFMc containing 1 μM 
PD153035 plus atRA (10 nM, 100 nM or 1 μM) for 72 hours. Some treatments also 
included 1 μM Troglitazone. The medium was changed after 24 hours to remove TZ from 
any cultures which contained it, in keeping with the standard TZ/PD protocol 
 
2.4.11 Culture of Immortalised Cell Lines 
Three immortalised cell lines (MCF-7, UMUC9 and PT67) were cultured, and used for 
experiments in this thesis; MCF-7 cells are a breast carcinoma-derived cell line, 
UMUC9 cells are a bladder carcinoma-derived cell line, and PT67 cells are a retroviral 
packaging cell line (3T3 variant). Cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Gibco®, 21969-035) with 10 % Fetal Bovine Serum (FBS) 
(SeraLab, EU-000) (batch selected) and 1 % L-glutamine (LG) (Gibco®, 25030-024), 
which was referred to as DMEM10% medium. Cultures were grown at 37 oC in 10 % 
CO2 in air, in Corning
® cell culture plasticware (Sigma-Aldrich). 
 
For the subculture of immortalised cell lines, the same protocol as described in section 
2.4.4 was employed, except DMEM10% medium was used in place of KSFMc. The use 
of trypsin inhibitor was omitted, due to the presence of serum in the medium, which 
also has the capacity to inhibit trypsin activity. 
 
Immortalised cell lines were frozen, as previously described in section 2.4.5, except 
‘Freeze mix’ was made using DMEM with 10 % (v/v) FBS and 10 % (v/v) DMSO 
(Sigma-Aldrich, D2650). 
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 Protein Analysis 
2.5.1 Indirect Immunofluorescence Microscopy 
Indirect immunofluorescence (IF) is a technique used to determine the localisation of a 
protein in cultured cells or tissue samples. It relies on the use of fluorescently-labelled 
secondary antibodies, which bind to the protein-specific primary antibodies. Cells or 
tissue are first fixed, and then permeabilised by lipid extraction or detergent, in order to 
allow for detection of the intracellular antigens. 
 
2.5.1.1 Slide Preparation 
Cells were seeded and grown on 12-well glass slides (C A Hendley Essex Ltd., PH-057 
Royal blue) in quadriPERM® 4-well slide boxes (Sarstedt, 94.6077.308). Upon 
completion of the cell growth or treatment protocol, slides were washed twice with 
phosphate buffered saline (PBS) (see Appendix). Cells were fixed with either 
methanol:acetone (50:50) (Fisher Chemical, M/4000/PC17 & A/0600/PC17) for 30 
seconds, or 10 % (v/v) formalin solution for 10 minutes. Slides fixed with 
methanol:acetone were air dried for 10 minutes, and stored desiccated at -20 oC until 
use. Slides fixed with formalin were washed twice with PBS to remove any remaining 
formalin solution, and stored in PBS at 4 oC for up to one week. Directly prior to 
antibody labelling, formalin-fixed slides were incubated in PBS containing 0.5 % Triton 
X-100 (SLS, 93443) for 30 minutes to permeabilise the cells. The slides were washed 
once with PBS. 
 
2.5.1.2 Antibody Labelling 
Slides were brought to ambient temperature, and an ImmEdge hydrophobic barrier pen 
(Vector, H-4000) was used to outline each well to prevent antibody movement. 20 μl of 
primary antibody, diluted (as required) in Tris Buffered Saline (TBS), pH 7.6 with 
0.1 % NaN3 (Sigma-Aldrich, S8032) and 0.1% bovine serum albumin (BSA) (Thermo 
Fisher Scientific, 37520) was pipetted onto wells of the 12-well slides. Cells were 
incubated with the primary antibody (see Table 2.3) overnight (16 hours) at 4 oC. 
Negative control wells were incubated with the antibody diluent only. Primary antibody 
was removed by 4x 5 minute washes with PBS on an orbital shaker (Jencons-PLS, 
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R100T/W). 20 μl of the appropriate secondary antibody (see Table 2.4) (diluted in TBS 
pH 7.6 with 0.1 % NaN3 and 0.1% BSA) was applied to each well for 1 hour at ambient 
temperature. Slides were protected from light to prevent bleaching of the fluorescence. 
For red fluorescent labelling, a secondary antibody conjugated to Alexa Fluor 594 was 
used, and for green fluorescent labelling, a secondary antibody conjugated to Alexa 
Fluor 488 was used. The slides were washed with PBS, on the orbital shaker, for 2x 5 
minutes to remove excess secondary antibody. Each slide was incubated in 5 mL of 
PBS with 0.1 μg/ml Hoechst 33258 (fluorescent DNA stain) (Sigma-Aldrich, 861405) 
to label the nuclei, which fluoresced blue. The slides were mounted with an antifade 
mountant (see Appendix), and a 22x64 mm coverslip (SLS, MIC3208). Coverslips were 
sealed to the slide using clear nail varnish around the coverslip edge. 
 
For every immunofluorescence experiment, additional slides were generated and used 
as positive controls; slides contained cells that were known to express the protein of 
interest. Positive control slides typically contained NHU cells treated with TZ/PD for 
either 72 hours or 6 days. Slides seeded with MCF-7 cells or UMUC9 cells were also 
used in some instances. 
 
Negative control wells (no primary antibody) were included on each slide, for each 
secondary antibody used, to determine if non-specific absorption of the secondary 
antibody had occurred. 
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Table 2.3 List of Primary Antibodies used for Indirect Immunofluorescence 
Antigen Antibody 
Clone or 
Catalogue # 
Host 
(Production) 
Supplier Dilution* 
CK5  PH607 Sh The Binding 
Site 
1:100 
CK7 OV-TL12/30 M (monoclonal) Novocastra 1:40 
CK13 1C7 M (monoclonal) abnova 1:500 
CK14 LL001 M (monoclonal) ICRF (gift)  1:5 
CK18 CY-90 M (monoclonal) Sigma-Aldrich 1:1000 
CK19 LP2K M (monoclonal)  ICRF (gift)   1:5 
CK20.3 IT–Ks20.3 M (monclonal) Cymbus 
Bioscience Ltd. 
1:100 
ELF3 EPESER1 Rb (monoclonal) Abcam 1:1000 
GATA3 D13C9 Rb (monoclonal) Cell Signaling 1:800 
HNF-3 α 
(FOXA1) 
Q6 M (monoclonal) Santa Cruz 1:200 
HNF-3α/β 
(FOXA1/2) 
C-20 Gt (polyclonal) Santa Cruz 1:200 
PPARγ E-8 M (monoclonal) Santa Cruz 1:200 
PPARγ 81B8 Rb (monoclonal) Cell Signalling 1:100 
PPARγ D69 Rb (polyclonal) Cell Signalling 1:100 
PPARγ P&A53.25 M (monoclonal) GSK (gift) 1:400 
Sh – Sheep, M – Mouse, Rb- Rabbit, ICRF – Imperial Cancer Research Fund 
* Dilution previously determined by titration. 
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Table 2.4 List of Secondary Antibodies used for Indirect Immunofluorescence  
2o Antibody Conjugated Alexa 
Fluor® 
Company, Code Dilution* 
Goat anti Rabbit 
(IgG) 
594 (red) Life Technologies, 
A11012 
1:700 
Goat anti Rabbit 
(IgG) 
488 (green) Life Technologies, 
A11008 
1:400 
Goat anti Mouse 
(IgG) 
594 (red) Life Technologies, 
A11005 
1:500 
Goat anti Mouse 
(IgG) 
488 (green) Life Technologies, 
A11001 
1:500 
Donkey anti Goat 
(IgG) 
594 (red) Life Technologies, 
A11058 
1:500 
* Dilutions previously determined by titration. 
 
2.5.2 Immunohistochemistry 
Immunohistochemistry is an antibody-based labelling method used to determine the 
localisation of a protein of interest in a tissue sample or cell sheet. It relies on the use of 
secondary antibodies that are conjugated to horseradish peroxidase. Horseradish 
peroxidase reacts with the substrate, diaminobenzidine (DAB), to produce an insoluble 
product that can be used to visualise the protein of interest. 
 
2.5.2.1 Embedding Tissue Samples and Cell Sheets 
Prior to embedding, all tissue samples and cell sheets were fixed in a 10 % (v/v) 
formalin solution for 24-48 hours. Samples were transferred to a 70 % (v/v) ethanol 
solution for long term storage at ambient temperature. 
 
Tissue samples were cut into pieces less than 0.5 cm2. The tissue samples and cell 
sheets (in CellSafe+ biopsy capsule) were placed into System III Hex embedding 
cassettes (CellPath, EAI-0106-10A). To dehydrate the samples, which allows for the 
paraffin wax to fully penetrate the tissue/cell sheets, the samples underwent a series of 
washes as follows: 70 % ethanol for 10 minutes, 4x 10 minute washes in 100 % ethanol 
Chapter 2 
 
84 
(Fisher Chemical, E/0650DF/P17), 2x 10 minute washes in isopropanol 
(Sigma-Aldrich, 33539) and 4x 10 minute washes in xylene (Fisher, X/0250/PB17). 
Excess xylene was removed from the cassettes by blotting, and they were incubated in 
melted paraffin wax (Thermo Scientific, 6774060) for 4x 15 minutes at 65 oC. The 
samples were embedded in fresh paraffin wax using metal embedding moulds (Leica 
Biosystems, 38VSP58167), and left to harden on a cold block (RA Lamb, E6613) 
at -12 oC. Once set, the wax blocks were removed from the moulds and stored at 
ambient temperature until use. 
 
2.5.2.2 Sectioning of Samples and Slide Preparation 
Prior to sectioning of samples, the wax blocks were cooled to -12 oC on a cold block for 
approximately 1 hour. 5 μm sections were prepared using a rotary microtome (Leica 
Biosystems, RM2135). The sections were transferred to a paraffin section floatation 
water bath set to 40 oC (RA Lamb, E66.2), before being collected onto Superfrost™ Plus 
microscope slides (Thermo Scientific, 4951PLUS4). The slides were left to air dry 
overnight, and then placed on a 50 oC slide drying heat block (RA Lamb, E18.1) for 
1 hour to adhere the tissue/cell sheet to the slide. Slides were stored at ambient 
temperature until use. 
 
Sections were dewaxed by: 2 x 10 minute washes in xylene, 2 x 1 minute washes in 
xylene, 4 x 1 minute washes in 100 % ethanol, 1 x 1 minute wash in 70 % ethanol. The 
slides were washed for 1 minute in running tap water to remove any remaining ethanol. 
Tissue sections were blocked using 3 % (v/v) hydrogen peroxide (Fisher, H/1800/15) 
for 10 minutes (this blocking step was used to prevent background signal from any red 
blood cells present in the tissue), and washed with running tap water for 10 minutes. 
 
To reverse the cross-linking of proteins caused by formalin fixation, and allow for the 
epitope of interest to be more easily accessible to the primary antibody, one of four 
antigen retrieval methods was used (see Table 2.5). The antigen retrieval method used 
was specific to each primary antibody, and was determined prior to starting 
experiments. 
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Following antigen retrieval, slides were washed in distilled water, and loaded into 
Shandon Sequenza® slide racks (Fisher Scientific, 73310017) using Coverplates™ 
(Fisher Scientific, 11927774). Slides were rinsed with TBS. Depending on the primary 
antibody, either the standard immunohistochemistry procedure (described in section 
2.5.2.3) was used, or a more sensitive polymer staining kit (described in section 2.5.2.4) 
was used. 
 
Positive control slides, containing tissue known to express the protein of interest, were 
included as part of every immunohistochemistry experiment. Negative control slides (no 
primary antibody) for each type of secondary antibody, were also included as part of 
every experiment; this was used to identify if any non-specific interactions had 
occurred. Example positive and negative control images for immunohistochemistry are 
shown in the Appendix. 
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Table 2.5 Antigen Retrieval Methods used for Immunohistochemistry 
Name Method 
Trypsinization (Tr) 
 
The slides were incubated in 0.1 % (w/v) trypsin 
(Sigma-Aldrich, T7409) at 37 oC for 10 minutes. 
 
Citric Acid (CA) 
 
The slides were placed in a 21 x 21 cm glass 
Pyrex dish, covered with 10 mM citric acid 
buffer, pH 6.0 (Fisher Scientific, c/6200/53), and 
microwaved to boil for 10 minutes. 
 
Trypsin and Citric Acid (Tr/CA) 
 
The slides were incubated in 0.1 % (w/v) trypsin 
at 37 oC for 1 minute, and then washed in 
distilled water. The slides were microwaved in 
10 mM citric acid buffer, pH 6.0 as described 
above in the citric acid antigen retrieval method. 
 
EDTA 
 
The slides were placed in a 21 x 21 cm glass 
Pyrex dish, covered in 1 mM EDTA buffer, 
pH 8.0, and microwaved to boil for 10 minutes 
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2.5.2.3 Standard Immunohistochemistry 
To block any endogenous biotin in the cells, the slides were incubated with avidin 
(Vector, sp-2001) for 10 minutes. The slides were washed twice with TBS to remove 
any excess. The slides were then incubated with biotin (Vector, sp-2001) for 10 minutes 
to bind to any remaining avidin binding sites. Excess biotin was removed by washing 
the slides twice with TBS. To block any non-specific binding of the secondary antibody, 
the slides were incubated with serum derived from the animal in which the secondary 
antibody was raised (Table 2.7), for 5 minutes. The slides were incubated with the 
primary antibody at 4 oC overnight (Table 2.6). Negative control slides were incubated 
with the antibody diluent only. The next day, slides were washed three times with TBS 
to remove excess primary antibody, and an appropriate biotinylated secondary antibody 
was applied for 30 minutes (Table 2.7). The slides were washed twice with TBS, and a 
streptavidin-biotinylated/horseradish peroxidase complex (StrepAB/HRP) (Vector, PK-
6100) was applied for 30 min; this complex binds to the biotin conjugated to the 
secondary antibody, in order to amplify the visible signal. The slides were washed again 
to remove excess StrepAB/HRP, and incubated with diaminobenzidine (DAB) (Sigma-
Aldrich, D4293) for 10 minutes. DAB reacts with the horseradish peroxidase to produce 
a brown precipitate, which identifies the protein of interest. Slides were washed with 
distilled water, and placed into metal slide racks before being counterstained and 
mounted (see section 2.5.2.5). 
 
2.5.2.4 Polymer Staining Kit-based Immunohistochemistry 
The ImmPRESS™ Excel Immunolabelling kit (Vector Laboratories, MP-7601 & MP-
7602) was used as a more sensitive technique for certain primary antibodies which 
failed to work using the standard immunohistochemistry protocol. All reagents 
described in the method below were supplied in the kit. To block any non-specific 
binding, 100 μl of 2.5 % horse serum was applied to each slide, and incubated at 
ambient temperature for 20 minutes. 100 μl of primary antibody (Table 2.8) was applied 
to each slide, and incubated overnight (approximately 16 hours) at 4 oC. Primary 
antibodies were diluted as required in TBS-T (0.05 M Tris-HCl pH 7.6, 0.3 M NaCl and 
0.1 % Tween 20). The slides were washed three times with TBS-T to remove any 
unbound primary antibody. The appropriate ‘amplifier’ (secondary) antibody was 
applied to the slides, and incubated at ambient temperature for 15 minutes. The slides 
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were washed twice with TBS-T to remove excess ‘amplifier’ antibody. Next, 100 μl of a 
third antibody (called the ImmPRESS Excel Reagent in the kit), which is conjugated 
with horseradish peroxidase, was applied to the slides, and incubated for 30 minutes at 
ambient temperature. The slides were washed twice with TBS-T, and once with distilled 
water to remove any excess antibody. 100 μl of 50:50 Immpact DAB reagent 1:reagent 
2 was applied to the slides for 5 minutes at ambient temperature. The slides were 
washed once with distilled water to remove excess DAB, and placed into metal slide 
racks before being counterstained and mounted (see section 2.5.2.5). 
 
Table 2.6 List of Primary Antibodies used for Standard Immunohistochemistry 
Antigen Antibody 
Clone or 
Catalogue # 
Host 
(Production) 
Supplier Dilution* 
(Retrieval 
Method) 
CK5 SP27 Rb (monoclonal) Abcam 1:100 (CA) 
CK7 OV-TL12/30 M (monoclonal) Novocastra 1:400 (CA) 
CK13 1C7 M (monoclonal) abnova 1:500 (Tr/CA) 
CK14 LL002 M (monoclonal) Serotec 1:1200 (Tr/CA) 
CK20.8 Ks20.8 M (monoclonal) Novocastra 1:200 (Tr) 
Claudin 4 3E2C1 M (monoclonal) Zymed 1:500 (CA) 
Claudin 5 4C3C2 M (monoclonal) Invitrogen 1:50 (CA) 
Claudin 7 34-9100 Rb (polyclonal) Zymed 1:200 (CA) 
Occludin 71-1500 Rb (polyclonal) Zymed 1:100 (CA) 
ZO-1 ZO1-1A12 M (monoclonal) Life 
Technologies 
1:100 (CA) 
ZO-2 2847 Rb (polyclonal) Cell Signaling 1:250 (EDTA) 
ZO-3 D57G7 Rb (monoclonal) Cell Signaling 1:200 (Tr/CA) 
HNF-3α/β 
(FOXA1/2) 
C-20 Gt (polyclonal) Santa Cruz 1:150 (CA) 
M – Mouse, Rb- Rabbit, Gt – Goat 
* Dilution previously determined by titration. 
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Table 2.7 List of Sera and Corresponding Secondary Antibodies used for Standard 
Immunohistochemistry 
Serum Company, 
Code 
Dilution 2o Antibody Company, 
Code 
Dilution* 
Rabbit 
Serum 
Dako, 
X0902 
1:10 Biotinylated 
Rabbit anti 
Mouse (Ig) 
 
Dako, 
E0354 
1:200 
Goat Serum Dako, 
X0907 
1:10 Biotinylated 
Goat anti 
Rabbit (Ig) 
Dako, 
E0466 
1:600 
* Dilution previously determined by titration. 
 
Table 2.8 List of Primary Antibodies used for the Polymer Staining Kit-Based 
Immunohistochemistry 
Antigen Antibody 
Clone or 
Catalogue # 
Host 
(Production) 
Supplier Dilution* 
(Retrieval 
Method) 
GATA3 D13C9 Rb (monoclonal) Cell Signalling 1:800 (Mw) 
PPARγ 81B8 Rb (monoclonal) Cell Signalling 1:250 (EDTA) 
RXRα K8508 M (monoclonal) R&D Systems 1:600 (Mw) 
M – Mouse, Rb- Rabbit 
* Dilution previously determined by titration. 
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2.5.2.5 Slide Counterstaining and Mounting 
Slides were incubated in haematoxylin (stains nuclei) (see Appendix) for up to 10 
seconds, and washed in running tap water to remove excess haematoxylin. The slides 
were dehydrated by: 1 x 1 minute wash in 70% ethanol, 3 x 1 minute washes in 100 % 
ethanol, and 2 x 1 minute washes in xylene, and mounted with a coverslip (SLS, 
MIC3104) using DPX (CellPath, SEA-1304-00A). 
 
 
2.5.3 Imaging Immunofluorescence and Immunohistochemistry 
Slides 
Slides generated from immunohistochemistry and immunofluorescence-based 
experiments were imaged using a brightfield/epifluorescence microscope (Olympus, 
BX60) equipped with x10 (dry), x20 (oil) x40 (oil) and x60 (oil) objective lenses and 
emission and excitation filters for DAPI (Hoechst 33258), FITC and Texas Red. Images 
were taken using a digital camera (Olympus, DP50) attached to the microscope, and 
analysed using Image-Pro Plus Software (Media Cybernetics, Image-Pro Plus version 
4.5.1.29). 
 
For immunofluorescence experiments, optimal exposures were chosen for each antibody 
at the time of imaging, in order to best demonstrate the localisation of the protein of 
interest. In cases were protein expression was examined across a treatment time course, 
the optimal exposure for one of the middle time points was picked, and used for all of 
the time points. In cases where absent or very weak expression was observed, the 
optimal exposure of the positive control was used. Negative control wells were imaged 
at the same exposure as the primary antibody labelled wells. Example negative control 
images for IF are shown in Figure 2.4. 
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Figure 2.4 Example Negative Control Images – Indirect Immunofluorescence 
Microscopy 
Example negative control (secondary antibody only) images are shown. The 
corresponding Hoechst 33258 images for each are shown below. Weak background signal 
was observed with all of the secondary antibodies used for IF. 
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2.5.4 Western Blotting 
Western blotting is a process whereby proteins extracted from a population of cells are 
first separated, based on molecular weight, by electrophoresis through a polyacrylamide 
gel. The proteins are then transferred, by electroblotting, onto a Polyvinylidene fluoride 
(PVDF) membrane. The membrane is first blocked, and then probed using antibodies to 
detect the presence of a protein of interest. This technique allows for relative analysis of 
a specific protein between different protein extracts. 
 
2.5.4.1 Protein Lysates 
Prior to taking the lysate, cell cultures were washed twice with cold 1x PBS. Whole 
protein lysates were generated using an SDS lysate buffer (2x sodium dodecyl sulfate 
(SDS) sample buffer (see Appendix) containing 0.013 M DTT (Sigma-Aldrich, D0632) 
and 1 % protease inhibitor (Sigma-Aldrich, P8340)), which were combined at the time 
of taking the lysates. SDS lysate buffer was pipetted onto the cells (100 µl for each well 
of a 6-well plate). Cells were scraped into the lysis buffer using a cell scraper (Sarstedt, 
83.1830), and collected into a 1.5 ml microfuge tube on ice. The lysates were sonicated 
(2.5 W, 40% amplitude) on ice for 10 seconds, followed by a 10 second rest, and then 
another 10 second burst of sonication. Lysates were rested on ice for 30 minutes, and 
centrifuged (Hettich Lab Technologies, MIKRO 200 R) at 18,000 g for 30 minutes at 
4 oC. The supernatant (protein containing portion) was collected, and transferred to a 
fresh 1.5 ml microfuge tube.  Lysates were stored at -20 oC for up to several months, or 
were stored at -80 oC for longer term storage. 
 
2.5.4.2 Coomassie Assay 
A Coomassie assay was used to measure the approximate amount of protein present in 
each protein lysate. This allowed for an equal amount of each protein lysate to be loaded 
for comparison by western blotting. For the Coomassie assay, first a standard curve was 
generated by pipetting equal amounts (10 μl) of bovine serum albumin (BSA) (Thermo 
Scientific, 23209) at the following concentrations, in duplicate, into a 96 well plate: 0 
(dH2O), 25, 125, 250, 500, 750, 1000 μg/ml. 200 μl of Coomassie reagent (Thermo 
Scientific, 23236), warmed to ambient temperature, was added to each well.  
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The absorbance of each sample well was measured at 570 nm using a Multiskan™ 
Ascent™ microplate photometer (Thermo Scientific, 51118300), and a standard curve 
was generated using the accompanying Ascent™ software. 
 
To measure the concentration in each protein lysate, 2 μl of each protein lysate was 
diluted in 23 μl of DEPC-treated water, and pipetted in duplicate into the wells below 
the standards. 200 μl of Coomassie reagent was added to each protein lysate well. The 
absorbance of each well was measured using the microplate photometer, and the 
concentration of each lysate was calculated using the standard curve. The average 
protein concentration of the duplicate sample wells was taken to give the final protein 
concentration for each lysate. 
 
2.5.4.3 SDS-PAGE and Western Blot 
To prepare the protein lysates for SDS-PAGE, each sample (typically 20-25 μg of 
protein) was combined with 4x LDS (Novex®, NP0007) to a final concentration of 1x, 
10x Reducing Agent (Novex®, NP0005) to a final concentration of 1x, and DEPC-
treated water to a final volume of 20 μl. The sample was heated at 70 oC for 10 minutes. 
The combined use of LDS, reducing agent, and near boiling results in denaturation of 
the proteins. The use of LDS also gives the proteins a negative charge, which is 
proportional to the proteins mass; this allows for the linearised proteins to be separated 
based on molecular weight using an electric field. 
 
The samples were loaded into a 4-12% Bis-Tris gel (Novex®, NP0321BOX) or a 3-8% 
Tris-Acetate gel (Novex®, EA0375BOX) set up in an XCell Surelock™ Mini-Cell 
Electrophoresis system (Invitrogen, EI0002). 20x MOPs SDS buffer (Novex®, NP0001) 
or 20x Tris-Acetate SDS buffer (Novex®, LA0041) were diluted to 1x in ELGA-treated 
water, and used as the running buffer. The electrophoresis was performed at 200 V for 
approximately 1 hour, which allowed for the proteins to be sufficiently separated. 
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The proteins were then transferred, by electroblotting, to an Immobilon-FL 0.45 μm 
PVDF membrane (Fisher Scientific, 10113432), which had been activated by incubating 
in methanol briefly prior to its use. The PVDF membrane was placed on top of the gel, 
and between Whatman Grade 1, 150 mM filter paper (Sigma-Aldrich, WHA1001150) 
and blotting pads (Invitrogen, EI9052). The transfer was completed using an XCell II™ 
Blot Module (Invitrogen, EI0002), and 30 V for 2.5 hours in transfer buffer (see 
Appendix), on ice. 
 
The membrane was blocked using 50:50 Odyssey Blocking Buffer (Li-Cor, 927-
40000):TBS or 5% (w/v) milk powder in TBS, for 1 hour, to prevent non-specific 
binding of the antibodies. As a negative control, membranes were incubated with the 
fluorescently-labelled secondary antibody (Table 2.9), which was diluted 50:50 in 
Odyssey Blocking Buffer:TBS-T, for 1 hour at ambient temperature. Membranes were 
washed for 4x five minutes with TBS-T, to remove excess secondary antibody. 
Membranes were then scanned using an Odyssey® infrared imaging system (Li-Cor, 
CLx or Sa), to identify whether any non-specific binding of the secondary antibody had 
occurred. Example negative control western blots are shown in Figure 2.5. 
 
Membranes were incubated with primary antibody (Table 2.10) (diluted 1:1 in Odyssey 
Blocking Buffer:TBS-T pH 7.4 or 5% (w/v) milk powder in TBS-T) overnight 
(approximately 16 hours) at 4 oC. The membranes were washed in TBS-T (see 
Appendix) to remove excess primary antibody, and the secondary antibody was applied 
at ambient temperature for 1 hour. The membrane was washed 4x 5 minutes in TBS-T 
to remove excess secondary antibody, and imaged using the Odyssey® infrared imaging 
system. Membranes were stored in TBS at 4 oC until further use. 
 
If multiple proteins of similar size were being examined on the same membrane, 
antibodies were stripped from the membrane using a 10x antibody stripping solution 
(Source Bioscience, 90100), diluted 1:10 in dH2O, for 20-30 minutes at ambient 
temperature.  To ensure that all of the primary antibody had been removed, appropriate 
secondary antibody was reapplied, washed, and imaged as above. The next primary 
antibody was incubated on the membrane overnight at 4 oC, and the protocol followed 
as above. 
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Figure 2.5 Example Negative Control Western Blots 
Negative control western blots (secondary antibody only) are shown for NHU cells 
(Y938) which were treated with control (CTRL) or GATA3 siRNA as described in 
section 2.10. An RT4 cell lysate was also included on the blots. 30 μg of protein was 
loaded into each well. 
 
 
Western blots were probed with β-actin or histone H3, which were used as loading 
controls for comparison. 
 
Densitometry analysis was completed using the accompanying Li-Cor software (Li-Cor, 
Odyssey version 1.2 or Image Studio Lite version 5.0). Equivalent boxes were drawn 
around each protein band, and the corresponding optical density was calculated. The 
background was measured for each box, as the median intensity above and below each 
box, and subtracted from each densitometry measurement. Densitometry analysis was 
also completed for β-actin expression, and this was used to normalise the amount of 
protein loaded into each lane. 
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Table 2.9 List of Secondary Antibodies used for Western Blotting. 
2o Antibody Conjugated 
Fluorescent Dye 
Company, Code Dilution* 
Goat anti Rabbit Ig IRDye® 800CW Rockland, 611-131-122 1:10,000 
Goat anti Mouse Ig Alexa Fluor® 680 Life Technologies, A21057 1:10,000 
Donkey anti Goat Ig Alexa Fluor® 680 Life Technologies, A21084 1:10,000 
* Dilution determined by titration. 
 
Table 2.10 List of Primary Antibodies used for Western Blotting. 
Antigen Antibody 
Clone or 
Catalogue # 
Host 
(Production) 
Supplier Dilution* 
CK13 1C7 M (monoclonal) abnova 1:1000 
CK14 LL002 M (monoclonal) Serotec 1:1000 
ELF3 EPESER1 Rb (monoclonal) Abcam 1:20,000 
Histone H3 ab1791 Rb (polyclonal) Abcam 1:10,000 
FOXA1 Q-6 M (monoclonal) Santa Cruz 1:500 
GATA3 D13C9 Rb (monoclonal) Cell Signalling 1:1000 
PPARγ E-8 M (monoclonal) Santa Cruz 1:500 
PPARγ 81B8 Rb (monoclonal) Cell Signalling 1:500 
PPARγ D69 Rb (polyclonal) Cell Signalling 1:500 
PPARγ2 N-19 Gt (polyclonal) Santa Cruz 1:500 
β-actin AC-15 M (monoclonal) Sigma-Aldrich 1:250,000 
M – Mouse, Rb- Rabbit, Gt-Goat 
* Dilution determined by titration. 
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 Analysis of Gene Expression 
In order to assess the relative gene (transcript) expression between various cell types or 
treatments, polymerase chain reaction (PCR) was used. To do this, total RNA was 
extracted from the cells, and then treated with DNase to remove any genomic DNA 
contamination of the samples. cDNA was generated using reverse transcriptase, and 
PCR was performed. All steps were performed at ambient temperature unless otherwise 
stated. 
 
For non-quantitative analysis, standard PCR was performed using a thermal cycler 
machine, while for a quantitative analysis of gene expression, quantitative PCR (qPCR) 
was performed using a SYBR® Green-based reporter method. 
 
2.6.1 RNA Extraction 
Total RNA was extracted from cell cultures using TRIzol™ reagent (Fisher Scientific, 
10227212). The medium was removed, and cultures were incubated in 1 ml of TRIzol™ 
(approximately 100 μl/cm2) for 2-5 minutes. The lysate was scraped from the substrate 
using a cell scraper (Sarstedt, 83.1830), and transferred into an RNase/DNase-free 1.5 
mL microfuge tube (Ambion, AM12400). Samples were stored at -80 oC until the RNA 
extraction took place. 
 
For the RNA extraction, samples were thawed to ambient temperature, and 0.2 ml of 
chloroform (VWR, 22711.290) was added. The mixture was vortexed using a Vortex-
Genie® 1 (Scientific Industries, G-560-E) for 15 seconds. The sample was incubated for 
2-3 minutes, followed by centrifugation in a refrigerated centrifuge (Hettich Lab 
Technologies, MIKRO 200 R) at 12500 g for 15 minutes at 4 oC. The centrifugation 
caused the mixture to separate into a lower phenol-chloroform phase (containing DNA 
and protein), a cloudy interphase and a clear upper aqueous phase (containing RNA). 
The upper aqueous phase was carefully pipetted off, and transferred to a new 
RNase/DNase-free 1.5 ml microfuge tube. 0.5 ml of isopropanol (Sigma-Aldrich, 
33539) was added to the aqueous phase solution and the tube was turned end-over-end 
to mix. The samples were incubated for 10 minutes and then centrifuged at 12500 g for 
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20 minutes at 4 oC to pellet the RNA. The sample was washed to remove any excess 
salts by adding 1 ml of 75% (v/v) ethanol to the pellet and centrifuging at 7700 g for 5 
minutes at 4 oC. This wash was repeated once. The final RNA pellet was left to air dry. 
The RNA was resuspended in 30 μl of nuclease-free DEPC-treated water and 
transferred to a 0.5 ml RNase/DNase-free microfuge tube (Ambion, AM12300). 
Samples were stored at -80 oC until DNase treatment. 
 
2.6.2 DNase Treatment 
Any DNA contamination was removed from the RNA samples using the DNA-free™ 
DNA removal kit and accompanying protocol (Ambion®, AM1906). 0.1 volume of 10X 
DNase 1 Buffer and 1 μl of rDNase were added to the 30 μl RNA sample and incubated 
at 37 oC for 30 minutes. 0.1 volume of the DNase Inactivation Reagent was added and 
the RNA was incubated for 2 minutes, with vortexing every 30 seconds. The mixture 
was centrifuged (Sigma-Aldrich, 1-13) at 7000 g for 90 seconds. The aqueous phase 
(which contained the RNA) was collected and transferred to a new 0.5 ml 
RNase/DNase-free microfuge tube. RNA samples were stored at -80 oC. The RNA 
concentration for each sample was determined using a NanoDrop® spectrophotometer 
and its accompanying software (Thermo Scientific, ND-1000). The NanoDrop measures 
the absorbance of the sample at 260 nm to determine the concentration. A260/A280 
ratios were used to assess the RNA sample purity, where values of approximately 2.0 
were accepted as pure. 
 
2.6.3 cDNA Synthesis 
For cDNA synthesis, 1 μg of each RNA sample was used. For each RNA sample, two 
cDNA synthesis reactions were performed: one which contained the reverse 
transcriptase (RT) enzyme to produce the cDNA, and one which did not (RT-negative 
control used to check for genomic DNA contamination). For cDNA synthesis, random 
primers were annealed to the RNA by combining 1 μg of RNA with 1 μl of 50 ng/μl 
random hexamers (Fisher, SO142) and DEPC-treated water, to a final volume of 12 μl. 
The mixture was incubated at 65 oC for 10 minutes, and rested on ice for at least 1 
minute. 4 μl of 5x First Strand Buffer (Invitrogen, Y02321), 2 μl of 0.1 M DTT 
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(Invitrogen, Y00147), and 1 μl of a deoxynucleotide triphosphate (dNTP) (Promega, 
U1240) mix containing 10 mM of each of the four dNTPs (diluted in DEPC-treated 
water) (see Appendix), were added to each of the reaction mixtures and incubated at 
25 oC for 2 minutes. 50 units of the enzyme, Superscript II Reverse Transcriptase 
(Invitrogen, 100004925), was added to only one of the two cDNA synthesis reactions 
(called RT-positive) for each RNA sample. All samples were incubated at 25 oC for a 
further 10 minutes. The reaction tubes were incubated at 42 oC for 50 minutes, where 
cDNA synthesis took place. The enzyme was inactivated by incubating the samples at 
70 oC for 15 minutes. cDNA samples were stored at -20 oC for short term storage (up to 
several months) or -80 oC for longer term storage. 
 
2.6.4 PCR 
Standard PCR is a technique which is used to amplify DNA. It relies on the use of 
forward and reverse primers which allow for amplification of a target sequence. A list 
of the forward and reverse primers used for standard PCR can be found in section 2.6.7. 
 
Standard, non-quantitative PCR was performed using a T100™ Thermal Cycler machine 
(Bio Rad, 186-1096). To make the PCR master mix for 1x  reaction, the following were 
combined: 4 μl of 5x GoTaq® Flexi buffer (Promega, M891A), 0.4 μl of dNTP mix, 2 μl 
of 25 mM MgCl2 (Promega, A351H), 2 μl of the forward primer (10 μM), 2 ul of the 
reverse primer (10 μM), 0.1 μl of 5 U/ul GoTaq® G2 flexi DNA Polymerase (Promega, 
M7808) and 8.5 μl of DEPC-treated water (total volume 19 µl). 19 μl of master mix 
(equivalent to 1x reaction mix) was pipetted into each well of an 8-well PCR tube 
(Starlab, I1400-0800). To this, either 1 μl of test sample cDNA (RT-positive), 1 μl of 
DEPC-treated water (negative control), or 1 μl of genomic/control DNA (Promega, 
G304A) was added. PCR was performed as follows: 95oC for 2 minutes, and then 25-35 
cycles of: 95oC for 30 seconds (denaturation step), annealing temperature (oC) for 30 
seconds (annealing step), and 72oC for 30-90 seconds (extension time: 30 seconds/500 
base pairs) (extension step). The appropriate annealing temperature and extension times 
were determined prior to running the PCR by performing a gradient PCR (see section 
2.6.7.3). Genomic DNA was used as a positive control where possible; otherwise cDNA 
generated from the total RNA of a cell type known to express the target gene was used. 
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GAPDH was used as an internal loading control for all experiments. Samples were 
checked for DNA contamination by running a standard GAPDH PCR on the 
RT-negative samples to ensure that no PCR product was generated. The resulting PCR 
product was resolved on an agarose gel by electrophoresis as described below in section 
2.6.5. An example GAPDH PCR performed on corresponding RT-positive and 
RT-negative samples is shown in Figure 2.6. 
 
 
 
Figure 2.6 Example GAPDH PCR on Reverse Transcriptase Positive and Negative 
cDNA Samples 
The TZ/PD protocol was used to activate PPARγ expression in NHU Cells (Y1281). 
0.1 % DMSO was used as a vehicle control. GAPDH PCR was performed on RT-positive 
and RT-negative samples generated as part of the cDNA synthesis protocol. PCR was 
performed using 25 cycles. H2O (no template) was used as the negative control. Genomic 
DNA was used as a positive control for the PCR. No PCR product could be shown in the 
RT-negative samples, demonstrating that DNA contamination had not occurred during 
the cDNA synthesis. 
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2.6.5 Gel Electrophoresis 
Gel electrophoresis can be used to separate PCR products through an agarose gel. An 
electric field is applied across the gel, causing the negatively charged nucleic acids to 
move towards the cathode. Smaller fragments are able to travel more quickly through 
the gel than larger fragments, which allows for separation based on size (base pairs) 
 
The PCR products were separated in 1-3% (w/v) agarose (Melford, MB1200) gels. The 
agarose gels were created by adding the appropriate amount of agarose to ELGA-treated 
water, and heated (by microwave) until dissolved. 1x SYBER® safe DNA gel stain 
(Invitrogen, S33102) (a DNA intercalating, fluorescent stain) was added to the gels to 
allow for later visualisation of the DNA bands by ultraviolet (UV) detection. The 
agarose was cast into trays, with an appropriate comb, and allowed to solidify. PCR 
products were loaded into the wells of the gel. An appropriate DNA ladder, typically 
Hyperladder IV (Bioline, BIO-33056), was also run on every gel. Gel electrophoresis 
was performed in horizontal gel tanks (SCI-PLAS, HU13 Midi), at approximately 100 
volts using an OmniPAC power supply (Cleaver Scientific Ltd., MP-300V), until the 
DNA had been appropriately separated. DNA bands were visualised, and imaged using 
a Gene Genius Bio imaging System (Syngene, Gene Genius), and accompanying 
software (Syngene, GeneSnap version 7.12). 
 
2.6.6 qPCR 
qPCR allows for a quantitative analysis of gene expression. It relies on the use of 
forward and reverse primers which allow for amplification of a short portion of the 
target gene (up to100 bp). A list of the forward and reverse primers used for qPCR can 
be found in section 2.6.7. qPCR was performed using a SYBR® Green-based detection 
method. For every cycle of the PCR, SYBR® Green dye binds to the double-stranded 
PCR product produced, and fluoresces. The amount of fluorescence detected during 
each cycle is measured, and used to calculate the amount of DNA present in a sample 
relative to a housekeeping gene. GAPDH was used as the housekeeping gene for 
comparison in all qPCR experiments. 
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qPCR was performed using a StepOne™ Real-Time PCR machine (Life Technologies, 
4376357) and accompanying StepOne™ Software (Life Technologies, Version 2.2.2). 
To set up the qPCRs, cDNA (as generated in section 2.6.3) was diluted 1:5 in DEPC-
treated water. qPCR master mix was created by combining: 10 μl of 2x Fast SYBR® 
Green master mix (Applied Biosystems, 4385612), 0.6 μl each of the 10 μM forward 
and reverse primer stocks, and 3.8 μl of DEPC-treated water to a final volume of 15 μl. 
The master mix was pipetted in triplicate into MicroAmp® Fast optical 96-well reaction 
plates (Applied Biosystems, 4346906). 5 μl of cDNA was added to each well in 
triplicate. A single replicate of RT-negative cDNA for each sample was used to ensure 
there was no DNA contamination during the cDNA synthesis reaction. GAPDH was 
used as the internal control for comparison on every plate. To analyse the resulting data, 
cycle threshold (CT) values were extracted, and normalised to GAPDH expression. Fold 
change was calculated relative to a calibrator value (ie. the control sample). 
 
2.6.7 PCR Primer Design and Optimisation 
All PCR primers were ordered from Eurofins Genomics and diluted using DEPC-treated 
water to a working stock of 10 μM. 
 
2.6.7.1 PCR Primers 
Standard PCR primers were designed using NCBI Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast) to be between 19-22 base pairs (bp) 
long and have a GC content of approximately 50%.  The primers were tested prior to 
their use for experiments by running a gradient PCR to determine the appropriate 
annealing temperature for the primers, and to ensure that the correct PCR product size 
was produced (see section 2.6.7.3 for gradient PCR protocol). See Table 2.11 for a list 
of PCR primers used. 
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2.6.7.2 qPCR Primers 
qPCR primers were designed using Primer Express software (Applied Biosciences, 
version 3.0). To test the efficiency of the qPCR primers, qPCR (see section 2.6.6 for 
protocol) was completed using serially diluted (1:5, 1:10, 1:100, 1:1000) genomic DNA 
or cDNA, known to express the target gene, as the template. A standard curve was 
generated using the StepOne™ Software (Life Technologies, Version 2.2.2). Primers 
with an R2 value greater than 0.95, and a single, large peak generated on a melt curve, 
were deemed to be acceptable for use. See for Table 2.12 a list of qPCR primers used. 
 
2.6.7.3 Gradient PCR 
Gradient PCR was used to determine the correct annealing temperature for the primers 
used for standard PCR. A standard PCR master mix was generated using genomic 
DNA, or cDNA generated from the total RNA of cells known to express the target gene, 
as the template. For gradient PCR, the reactions were completed as follows using the 
gradient setting on the PCR machine: 95oC for 2 minutes, and then 30 cycles of: 95oC 
for 10 seconds (denaturation step), 56-66 oC (annealing temperature) for 30 seconds 
(annealing step), and 72oC for 30-90 seconds (extension time: 30 seconds/500 base 
pairs) (extension step). The resulting PCR product was resolved on an agarose gel and 
the PCR product was visualised as described in section 2.6.5. The annealing 
temperature that produced a single band of the correct height PCR product was selected. 
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Table 2.11 List of Primers used for Standard PCR. 
Gene 
Name 
Forward Primer (5’-3’) Reverse Primer (5’-3’) 
CLDN1 TTTACTCCTATGCCGGCGAC ACTTTGCACTGGATCTGCCC 
CLDN10 TTATTGGATGGGCAGGAGCC AGATGTGGCCCCGTTGTATG 
CLDN2 CCTGGGATTCATTCCTGTTG AGTTGGAGCGATTTCTCTGG 
CLDN3 TGGTCGGCCAACACCATTAT CCGTGTACTTCTTCTCGCGT 
CLDN4 CTGGGAAGTGCAGAGTGGAT AAGGAAGAGGAAAAACCCCA 
CLDN5 CTGTTTCCATAGGCAGAGCG AAGCAGATTCTTAGCCTTCC 
CLDN6 CTCTCACTTAGGCTCTGCTG AAATGTGAGTGTAAAGGGGG 
CLDN7 CGAGCCCTAATGGTGGTCTC ACGGGCCTTCTTCACTTTGT 
CLDN8 TCTTCTCCCAGAGGCTTTTT TTTGACTCAGGTACCCACAT 
ELF3 GTTCATCCGGGACATCCTC GCTCAGCTTCTCGTAGGTC 
ESR1 CCATGACCATGACCCTCCAC CCTCGGGGTAGTTGTACACG 
ESR2 CATCTTACCCCTGGAGCACG CATTTGGGCTTGTGGTCTGC 
FOXA1 CAAGAGTTGCTTGACCGAAAGTT TGTTCCCAGGGCCATCTGT 
GATA3 TCCAGACACATGTCCTCCCT TGGTGTGGTCCAAAGGACAG 
GRHL3 GTGACAAGGGAGCTGAGAGG CAGTCTCTGGCCGAAGGTAG 
IRF1 GCTGGGACATCAACAAGGAT GTGGAAGCATCCGGTACACT 
KLF5 GACACCTCAGCTTCCTCCAG ACTCTGGTGGCTGAAAATGG 
LOR GCGAAGGAGTTGGAGGTGTT CTGGGGTTGGGAGGTAGTTG 
PPARA GACACGGAAAGCCCACTCTG TTCCAGAACTATCCTCGCCG 
PPARB GGCTGAGAAGAGGAAGCTGG TGAAGCTGGGGATGCTCTTG 
PPARG* AGACAACCTGCTACAAGCCC GGAAATGTTGGCAGTGGCTC 
PPARG# ACTTTGGGATCAGCTCCGTG GGGCTTGTAGCAGGTTGTCT 
PPARG2~ TCCTTCACTGATACACTGTCTGC GGGCTTGTAGCAGGTTGTCT 
RARA GAAACCTTCCCTGCCCTCTG GGATCAGGATGTCCAGGCAG 
RARB GCCTCCAAGGCAGAAACACT CTTGGCATCAAGAAGGCTGG 
RARG GCAAAGCCCATCAGGAGACT CTGCTCTGGGGTGTACCTTG 
RXRA CTCAATGGCGTCCTCAAGGT TGTTTGCCTCCACGTAGGTC 
RXRB ACTGCCGCTATCAGAAGTGC CCCTGGTCACTCTTCTGTTCC 
RXRG TTCAAGCTCATCGGGGACAC AGCCCTGTAGACAGCAAAGC 
SPRR4 GGCTCACCTGTTCCTAGAGC GTTTACTCTTGGAGGCTTGC 
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Table 2.11 Continued. 
* Both primers are in exon 6. 
# Forward primer is in exon 1 and reverse primer is in exon 6. 
~ PPARG2 specific primers. Forward primer is in exon B and reverse primer is in 
exon 6. 
 
Table 2.12 List of Primers used for qPCR. 
Gene 
Name 
Forward Primer (5’-3’) Reverse Primer (5’-3’) 
ELF3 TCAACGAGGGCCTCATGAA TCGGAGCGCAGGAACTTG 
FOXA1 CAAGAGTTGCTTGACCGAAAGTT TGTTCCCAGGGCCATCTGT 
GAPDH CAAGGTCATCCATGACAACTTTG GGGCCATCCACAGTCTTCTG 
GATA3 TCTATCACAAAATGAACGGACA
GAA 
TGTGGTTGTGGTGGTCTGACA 
PPARG GAACAGATCCAGTGGTTGCAG CAGGCTCCACTTTGATTGCAC 
TGM1 GAGCGGAAGGCAGTAGAGACA CCCCGGTTGGCATACACA 
UPK1A CATTCTTGCTGAACCGTTTGTG GTGACCGTGACAGAACTCTCATG 
UPK1B CGCTTGCCTTCAGCTTGTG GGCCCTGGAAGCAACGA 
UPK2 CAGTGCCTCACCTTCCAACA TGGTAAAATGGGAGGAAAGTCAA 
UPK3A CGGAGGCATGATCGTCATC CAGCAAAACCCACAAGTAGAAAGA 
UPK3B CCTCCTGCTTCACTCTCTCTGTCT GAAACTGACAATCACGGCAGAA 
 
  
Gene 
Name 
Forward Primer (5’-3’) Reverse Primer (5’-3’) 
TGM1 GACCTGTTCCATCTCAGCCC TCTGGAGATGGCGTGGTAGG 
UPK1A GGGGTATCTCGTGGTTTGGG CGTAAGGGCTAGGGACGTTG 
UPK1B TTGAAGCCACCGACAACGAT AACAGACAGGCAGAAGAGGC 
UPK2 CTCCCGCAAGTAAGGAGGT GAAGGATGGGGGAATTGTTA 
UPK3A ATGGGGAGTTCTGATGGGGA TGCTGGAATACACCTCAGCC 
UPK3B CCTCCTGCTTCACTCTCTCTGTCT GAAACTGACAATCACGGCAGAA 
Chapter 2 
 
106 
 Molecular Cloning and Microbiology 
Various molecular cloning and microbiology-based techniques were used to generate a 
retroviral vector, which was used to overexpress one of the human GATA3 coding 
sequences. A plasmid containing the selected GATA3 coding sequence (Ensembl 
Transcript ID – ENST00000379328) was obtained from Mr. Felix Wezel, a previous 
clinical research fellow at the Jack Birch Unit. The coding sequence was amplified from 
this vector using PCR, and ligated into a shuttle vector, pGEM (Promega, A1360). The 
pGEM-GATA3 vector was then transformed into competent bacteria. Colony PCR was 
used to determine the correctly transformed bacteria. A single colony containing the 
pGEM-GATA3 was amplified using liquid culture. Miniprep of the plasmid DNA was 
performed, and the GATA3 coding sequence was checked for its accuracy by 
sequencing. The GATA3 coding sequence was cut from the pGEM vector using 
restriction enzymes, gel purified, and then ligated into the retroviral vector, pLXSN. 
The pLXSN-GATA3 vector was used to transfect retroviral packaging cells (PT67 
cells), for later production of retrovirus. 
 
The techniques used for the generation of the pLXSN-GATA3 vector are outlined 
below. For all molecular cloning experiments, a table top micro centrifuge (Eppendorf, 
5415c) was used for centrifugation steps. 
 
2.7.1 PCR Amplification of a Gene for Cloning 
PCR amplification for gene cloning was used to generate large amounts of the GATA3 
coding sequence from an initial plasmid (plasmid obtained from Felix Wezel). Primers 
were designed to add useful restriction sites, and a Kozak sequence (necessary for 
protein translation in mammalian cells) to either end of the gene sequence (an example 
of PCR primers which were used to amplify the GATA3 gene sequence for cloning can 
be found in Figure 2.7). To ensure accurate amplification of the sequence, a high 
fidelity DNA polymerase, called Q5® (New England BioLabs, M0491S), was used with 
its accompanying protocol.  
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To set up a 25 μl PCR reaction, the following items were combined: 5 μl of 5x Q5 
reaction buffer, 0.5 μl of 10 mM dNTP mix, 1.25 μl of the forward primer (10 μM), 
1.25 μl of the reverse primer (10 μM), 0.1 ng plasmid DNA, 0.25 μl of Q5 high-fidelity 
DNA polymerase and DEPC-treated water to 25 μl. The PCR reaction was run in a 
T100™ Thermal Cycler machine (Bio Rad, 186-1096) with the following conditions: 
98 oC for 30 seconds, and then 30 cycles of: 98 oC for 10 seconds (denaturation step), 
annealing temperature for 30 seconds (annealing step), and 72 oC for 30 seconds/kb 
(extension step). The annealing temperature was determined prior to the PCR by 
running a gradient PCR (see section 2.6.7.3) using cDNA generated from the total RNA 
of a cell type known to express the GATA3 sequence, as the template. 
 
2.7.2 PCR Purification 
PCR purification was performed to purify the GATA3 sequence product from the rest of 
the contents of the PCR master mix, on completion of the PCR reaction. PCR 
purification was completed using a QIAGEN QIAquick® PCR Purification kit, and the 
accompanying protocol (QIAGEN, 28104). 5 volumes of Buffer PB was added for 
every volume of PCR reaction, and the mixture was pipetted into a QIAquick column. 
The column was centrifuged at 13,800 g for 60 seconds. This caused excess liquid to 
pass through the column, while leaving the PCR product bound to the column. The 
flow-through was discarded. The column was washed once by adding 750 μl of Buffer 
PE and centrifuged at 13,800 g for another 60 seconds. The resulting flow-through was 
discarded. To elute the PCR product from the column, the column was placed into a 1.5 
ml microfuge tube, and 30 μl of elution buffer was added to the column. The column 
was left to stand for 1 minute, and centrifuged for 60 seconds. The concentration of the 
resulting PCR product was determined using a NanoDrop® spectrophotometer and its 
accompanying software. 
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Figure 2.7. PCR Primers Used to Generate GATA3 Coding Sequence for Later 
Insertion into the pLXSN Plasmid.  
These primers included a 5’ poly A tail which was used for ligation of the PCR product 
into pGEM. The GATA3 gene was cut from the pGEM plasmid using the added 
restriction sites and ligated to the pLXSN plasmid (cut using the same restriction 
enzymes). The pLXSN-GATA3 construct was later used for transfection into retroviral 
packaging cells (PT67). The pLXSN MSC image was obtained from the pLXSN 
Retroviral Information Sheet (Clontech). 
 
  
pLXSN Multiple Cloning Site (MCS): 
 
Add 5’ EcoR1 = GAATTC and Kozac sequence = ACC 
Add 3’ Xho1= CTCGAG 
GATA3 Forward Primer 5’ - 3’: 
5’ AAAAAAGAATTCACCATGGAGGTGACGGCGGACC 3’  
GATA3 Reverse Primer 5’-3’: 
5’ AAAAAACTCGAGCTAACCCATGGCGGTGACC 3’  
Blue = GATA3 sequence 
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2.7.3 Ligation 
Ligation is the process of joining two DNA segments together (ie. joining an insert and 
vector). To determine the amount of insert DNA necessary for the ligation reaction, the 
following formula was used: 
 
100 ng vector · insert size (kb) · 3 = x ng insert 
  vector size (kb)           1 
 
The following components were combined for the ligation reaction: 1 μl of 10x T4 
DNA ligase buffer (Promega, C126B), 100 ng vector, x ng insert (as calculated above), 
1 μl of T4 DNA Ligase (Promega, M1801) and DEPC-treated water to a final volume of 
10 μl. The ligation mixture was incubated at 4 oC overnight (approx. 16 hours). A 
negative control reaction was carried out, where the insert sequence was omitted, in 
order to account for possible vector re-ligation. 
 
2.7.4 Transformation 
The process whereby bacteria take up plasmid DNA is called transformation. 
Transformations were completed using a strain of competent E. coli called, XL1-Blue 
subcloning-grade competent cells (Agilent Technologies, 200249). For each 
transformation, a positive control transformation, using the plasmid pUC18 (Agilent, 
200231-42), and a negative control transformation, using dH20, were performed. The 
competent cells were thawed on ice, and 50 μl of the competent cells was pipetted into 
chilled Corning® 15 ml centrifuge tubes (Sigma-Aldrich, CLS430791). 0.1-50 ng of 
experimental DNA (5 μl of ligation mix reaction), or 1 μl of pUC18 or 1 μl of dH20 was 
added to the competent cells. The tubes were incubated on ice for 20 minutes. The tubes 
were put into a 42 oC water bath for 45 seconds (where the plasmid DNA enters the 
bacteria cells), and then returned to ice for a further 2 minutes. 900 μl of SOC medium 
(Invitrogen, 15544-034), prewarmed to 37 oC, was added to the cells and they were 
incubated at 37 oC, with shaking, for 30 minutes. 50 – 200 μl was spread onto LB-agar 
(see Appendix) plates (with appropriate antibiotics). The plates were allowed to dry and 
placed inverted at 37 oC overnight (approx. 16 hours). 
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2.7.5 Colony PCR 
To determine which colonies from a ligation, and subsequent transformation were 
successful, colonies grown from the transformation were dabbed into PCR mix 
containing primers for the GATA3 sequence. The PCR was performed as described in 
section 2.6.4, and the products were separated on an agarose gel (see section 2.6.5). 
Based on the size and/or presence of PCR product bands, it was determined which of 
the selected colonies had taken up the plasmid with a successful ligation of the insert 
and plasmid DNA. 
 
 
2.7.6 LB Broth Cultures 
Luria-Bertani (LB) broth cultures were used to generate large amounts of a single 
colony of successfully transformed bacteria; these cultures were used to extract the 
plasmid DNA by miniprep, or to freeze the cells for later use. A single colony grown on 
an LB-agar plate was picked up using a sterile pipette tip and swirled into 6 ml of LB 
broth (with appropriate antibiotics) (see Appendix) in a universal tube. The tubes were 
incubated in a 37 oC incubator, with shaking, overnight (approx. 16 hr). 
 
2.7.7 Miniprep of Plasmid DNA 
The miniprep of plasmid DNA is a process used to extract plasmid DNA from bacterial 
cells. The miniprep of plasmid DNA from liquid LB broth cultures was performed using 
the QIAprep Spin Miniprep Kit (QiaGen, 27104), and its accompanying protocol. The 
bacteria from a 6 ml LB broth culture were pelleted by centrifuging for 15 minutes at 
3000 g at 4 oC. The cells were resuspended in 250 μl of Buffer P1, before being 
transferred to a 1.5 ml microfuge tube. 350 μl of Buffer P2 was added to the tube and 
the contents were mixed by inverting 4-6 times. 350 μl of Buffer N3 was added and 
again, the tubes were inverted 4-6 times to mix. The tubes were centrifuged at 13,800 g. 
The resulting supernatant was put into the QIAprep spin column, and the columns were 
centrifuged at 13,800 g for 1 minute. (At this point, the plasmid DNA binds to the 
column). The resulting flow-through was discarded. The columns were washed once 
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with Buffer PB, and once with Buffer PE, with centrifugation at 13,800 g for 1 minute 
after each wash. The flow-through was discarded, and the tubes were centrifuged once 
more to remove any remaining liquid from the column. To elute the plasmid DNA from 
the column, the column was placed into a new 1.5 ml microfuge tube. 50 μl of elution 
Buffer EB was applied to the column, and it was allowed to stand for 1 minute. The 
tube was centrifuged at 13,800 g for 1 minute. The column was discarded, and the 
concentration of the resulting plasmid DNA was determined by using a NanoDrop® 
spectrophotometer. 
 
2.7.8 Sequencing 
To confirm that the GATA3 sequence was correct, and no errors had been introduced by 
the PCR amplification step, sequencing was performed following miniprep of the 
pGEM-GATA3 vector. All sequencing of DNA was performed using the sequencing 
service provided by the Genomics Department of the Technology Facility in the 
Department of Biology at the University of York, York, UK. Sequencing results were 
analysed using Sequence Scanner v2.0 software (Applied Biosystems). 
 
2.7.9 Restriction Digest of Plasmid DNA 
Restriction digest is a process used to cut double stranded DNA at designated restriction 
cut sites. It relies on the use of restriction enzymes, which are able to recognize specific, 
short sequences of DNA and make a single cut at that site. Restriction digest was used 
to cut the GATA3 sequence out of the shuttle vector (pGEM). It was also used to 
linearise the pLXSN vector, for later ligation of the GATA3 sequence and pLXSN 
vector. 
 
For restriction digests, 1 μg of plasmid DNA was combined with 2 μl of 10x Promega 
Restriction Digest Buffer (used Buffer H) (Promega, R008A), 0.2 μl of 10 mg/ml 
acetylated BSA (Promega, R396D), 1 μl of each the two required restriction enzymes 
(Promega), and DEPC-treated water to 20 μl. The mixture was incubated in a 37 oC 
water bath for 4 hours. To inactivate the enzymes, the mixture was incubated at 65 oC 
for 15 min. 
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2.7.10 Gel Extraction and Purification 
Gel extraction is a method used to purify DNA fragments of varying sizes from a 
mixture (ie. an insert from a plasmid backbone following a restriction digest); the DNA 
fragments are separated by electrophoresis on an agarose gel, then cut out of the gel, 
and purified. Gel extraction was used to separate the GATA3 sequence from the pGEM 
vector backbone after restriction digest. It was also used to resolve the digested pLXSN 
vector backbone. 
 
Gel extraction was used following restriction digest of plasmid DNA. Prior to gel 
electrophoresis, 5x loading buffer (Qiagen, 239901) was added to the restriction digest 
mixture to a final concentration of 1x. Once the DNA bands had been separated on the 
gel by electrophoresis, the required bands (GATA3 sequence and linearised pLXSN 
backbone) were cut out of the gel. To do this, the DNA bands were quickly visualised 
(to prevent UV-induced mutagenesis) using a UV transilluminator, and cut out using a 
scalpel. The gel pieces were put into 1.5 ml microfuge tubes, and the contents of the 
tubes were weighed using a bench top balance. 
 
To purify DNA fragments from agarose gel, a QiaQuick Gel Extraction kit and its 
accompanying protocol (QiaGen, 28704) were used. 3 volumes of Buffer QG was 
added to each volume of gel. The gel mixture was incubated at 50 oC for approximately 
10 minutes, or until the gel had melted. The mixture was vortexed briefly to combine. 
1 volume of isopropanol was added to the tubes and mixed. The mixture was placed 
into a spin column, and the sample was centrifuged at 13,800 g for 1 min (at this point, 
the DNA binds to the column.) The flow-through was discarded and any remaining gel 
mixture was loaded into the column and centrifuged as previous. The column was 
washed using 500 μl of Buffer QG, and centrifuged at 13,800 g for 1 min. The flow 
through was discarded. The column was washed using 750 μl of Buffer PE, and again 
centrifuged for 1 min, and the flow-through discarded. The column was centrifuged 
again, and any remaining flow-through was discarded. The column was placed into a 
1.5 ml microfuge tube, and 30 μl of Buffer EB was applied to the column to elute the 
DNA. The column was allowed to stand for up to 4 minutes before being centrifuged.  
The concentration of the resulting eluted DNA was measured using a NanoDrop® 
spectrophotometer. 
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2.7.11 Plasmid Dephosphorylation 
Plasmid dephosphorylation is used to remove the 5’ phosphate group from the end of a 
restriction digested plasmid DNA segment; this prevents the digested plasmid from 
re-ligating back together during a ligation reaction. Plasmid deposphorylation was 
performed on the gel purified pLXSN vector backbone, prior to ligation with the 
GATA3 coding sequence.  
 
Plasmid dephosphorylation was completed using the FastAP Thermosensitive Alkaline 
Phosphatase kit (Thermo Scientific, EF0651), and accompanying protocol. Up to 1 μg 
of the digested, and purified plasmid back bone was combined with 2 μl of 10x 
Reaction Buffer for AP and 1 μl of FastAP Alkaline Phosphatase. Using a PCR 
machine, the mixture was heated to 37 oC for 10 minutes. It was incubated at 75 oC for 
5 minutes to inactivate the enzyme. 
 
Following, plasmid dephorphorylation, the GATA3 sequence and linearised pLXSN 
vector were ligated together, and then transformed into competent bacteria. Colony PCR 
was performed to confirm successful ligation and transformation. A single, successfully 
transformed colony was expanded by liquid culture, and then the pLXSN-GATA3 
plasmid DNA was extracted by miniprep. This plasmid was used for transfection of 
PT67 cells, as described in below in section 2.8. 
 
2.7.12 Freezing and Thawing Bacteria 
For long term storage of specific bacteria, cells were frozen as glycerol stocks. 750 μl of 
a 6 ml overnight LB broth culture was mixed with 250 μl of sterile 80% (w/v) glycerol 
and put into a 1.5 ml cryo vial (Sarstedt, 73.380.992). The vials were stored at -80 oC 
for future use. 
 
In order to thaw bacteria from a frozen glycerol stock, a sterile pipette tip was used to 
pick up some of the frozen culture, and it was streaked out onto a LB agar plate 
(containing the appropriate antibiotics). The plates were incubated at 37 oC overnight. 
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 Transfection of Retroviral Packaging Cells 
Transfection is the process whereby mammalian cells take up naked DNA. It was used 
to introduce the pLXSN-GATA3 vector into retroviral packaging cells. The pLXSN 
plasmid (see Figure 2.8 for a plasmid diagram) contains a neomycin resistance gene, 
which allows for selection of successfully transfected cells with the antibiotic, G418 
(Sigma-Aldrich, A1720). PT67 retroviral packaging cells were used (Clontech, 
631510), which are a cell line derived from mouse 3T3 cells. The PT67 packaging cells 
contain the necessary GAG, POL and ENV genes, which are required for the production 
of the virus particles. 
 
PT67 cells were grown in T25 flasks, in DMEM with 10% fetal bovine serum (FBS) 
and 1% L-glutamine (LG) (DMEM10%), at 37 oC and 10% CO2 in air until they 
reached approximately 60% confluence. One extra flask of PT67s was used during 
every transfection to act as a ‘mock’ transfection; the exact protocol was followed as 
below, but no plasmid DNA was added. These ‘mock’ transfected cells die under 
antibiotic selection because they do not contain the plasmid. This allowed for an 
approximate determination of the successful selection of the transfected cells. 
 
At the point of transfection, 3 μg of plasmid DNA was mixed, by pipetting, with 90 μl 
of Buffer EC (Qiagen, 301425) and 24 μl of 1 mg/ml Enhancer (Qiagen, 301425) in a 
1.5 ml microfuge tube and incubated at ambient temperature for 5 minutes. 30 μl of 
1 mg/ml Effectene (Qiagen, 301425) (used to aid transfection) was added to the 
mixture, and incubated at ambient temperature for a further 10 minutes. The plasmid 
solution was combined with 5 ml of DMEM10%, and incubated on the PT67 cells for 
approximately 16 hr at 37 oC and 10 % CO2 in air. Following the 16 hour incubation, 
the medium was changed to DMEM10%. 48 hours after transfection, the cells were 
passaged (split at a 1:3 ratio), and grown in DMEM10% with 0.5 mg/ml G418, for 
antibiotic selection of the transfected cells. Flasks were passaged as required if they 
became confluent before all the cells in the ‘mock’ flask had died. The cells were 
medium changed every 2-3 days, and maintained in antibiotic selection as above. Once 
all of the cells in the ‘mock’ flask had died, the remaining flasks were considered as  
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containing only successfully transfected cells. Successful transfection of the 
pLXSN-GATA3 vector was confirmed by PCR and immunofluorescence (data shown 
in Chapter 3). Transfected cells were frozen for future use as described in section 
2.4.11. 
 
The transfection protocol and appropriate antibiotic concentrations required for 
selection, were previously optimised by members of the Jack Birch Unit. 
 
 
Figure 2.8 pLXSN Plasmid Diagram 
The pLXSN plasmid diagram was obtained from the pLXSN retroviral vector 
information sheet (Clontech). The pLXSN plasmid contains the neomycin resistance gene 
for selection of successfully transduced mammalian cells. The 0.5 mg/ml G418 
(antibiotic) was used for selection of the packaging cells. 
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 Transduction of Epithelial Cells using Retrovirus 
Retroviral transduction is the process whereby a retrovirus is used to stably integrate 
genes of interest into the genome of dividing mammalian cells. In order to produce 
retrovirus for transduction of epithelial cells, transfected PT67 cells were used. Upon 
successful retroviral transduction of epithelial cells, the gene of interest, under a 
constitutively active promoter, plus the neomycin resistance gene were incorporated 
into the cells’ genome. The transduction protocol used was previously optimised by 
members of the Jack Birch Unit. 
 
The transfected PT67 cells were grown to over 100% confluence. The medium was 
changed to DMEM:RPMI 1640 (Gibco, 31870-025) (50:50) plus 5% FBS and 1% LG, 
and they were incubated for 16 hours at 37 oC and 10% CO2 in air. The medium 
containing the retrovirus particles was collected from the cells, filtered using a 0.45 μm 
filter (Corning, 431220), to remove any cell debris, and 8 μg/ml Polybrene (Sigma-
Aldrich, H9268) was added to aid in transduction efficiency.  
 
In addition to growing the transfected PT67 cells, equivalently sized flasks of epithelial 
cells were grown so they reached approximately 70% confluence at the time of the 
transduction. An equivalent, extra flask of epithelial cells was grown to act as a ‘mock’ 
transduced flask. The ‘mock’ flask was treated identically to the other flasks, but the 
cells were not incubated with retrovirus. These cells were used to determine successful 
selection of the transduced cells; the mock cells should all die under antibiotic selection. 
 
At the time of transduction, the epithelial cells were incubated in the virus containing 
medium, described above, for 6 hours at 37 oC and 5% CO2. After 6 hours, the medium 
of the epithelial cells was changed to KSFMc, and the cells were incubated for a further 
48 hours. After 48 hours, the cells were passaged and split at a 1:2 ratio. The cells were 
then grown under antibiotic selection (G418). The concentration of antibiotic necessary 
for selection was pre-determined to cause complete death of the mock transduced flask 
within approximately 5 days; in general, buccal epithelial cells required a concentration 
of 0.5 mg/ml G418 for this to occur. Cells were grown using the above antibiotic  
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concentrations until all cells in the mock flask had completely died. The successfully 
transduced cells were then grown in medium containing a maintenance dose of 
antibiotic (0.025 mg/ml G418). 
 
For transduction of the breast carcinoma-derived cell line, MCF-7, the same protocol as 
above was followed, but DMEM10% medium was used in place of KSFMc medium , 
and the cells were grown at 37 oC and 10% CO2 in air. 
 
 Transfection of Urothelial Cells with siRNA 
Transfection of epithelial cells with siRNA is a technique used to transiently knock 
down a gene of interest. It relies on the use of specific siRNA sequences, which are 
short (20-25 bp) RNA sequences designed to a region of a gene of interest. The siRNA 
enters the cell as a double stranded sequence where it binds to the RNA-induced 
silencing complex (RISC). The siRNA sequences are separated, allowing the activated 
RISC, and single siRNA sequence to specifically bind to mRNA of the targeted gene. 
This causes the mRNA sequence to be cleaved, preventing it from carrying on to protein 
translation. 
 
Urothelial cells were seeded into 6-well plates at a density of 4x105 cells/well in 
KSFMc, and incubated at 37oC in 5% CO2 in air overnight. This seeding density 
allowed for the cells to be approximately 80 % confluent at the time of transfection the 
next day. 1.5 μl of Lipofectamine RNAiMAX reagent (used to mediate transfection) 
(Invitrogen, 13778-075) was added to 248.5 μl of KSFM (no supplements) for a final 
volume of 250 μl. The siRNA was added to a final volume of 250 μl of KSFM (no 
supplements) so that the final siRNA concentration would be correct in the 500 μl total 
volume that was added to the cells. The two 250 μl solutions (diluted Lipofectamine and 
siRNA) were combined to a total volume of 500 μl, and incubated at ambient 
temperature for 20 minutes. The cells were washed once with KSFM (no supplements) 
to remove any trace of supplements from the cells, which could affect the transfection 
efficiency. The 500 μl transfection mixture was added to the cells, and they were 
incubated for 4 hr at 37 oC at 5% CO2 in air. 500 μl of KSFM (no supplements) was 
added to each well, as well as 500μl of KSFM containing 0.15 mg/ml bovine pituitary 
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extract (Gibco®, 37000-015), 15 ng/ml epidermal growth factor (Gibco®, 37000-015), 
90 ng/ml cholera toxin, 1 μM PD153035 and 1 μM troglitazone (KSFM with 3x 
supplements plus TZ plus PD). The cells were incubated as such for 24 hours at 37 oC at  
5% CO2 in air. The medium was changed to KSFMc plus 1 μM PD153035 (1.5 ml of 
medium per well) and the cells were incubated at 37 oC at 5% CO2 in air for a further 24 
hours. RNA and protein were harvested. 
 
The siRNA transfection protocol used was generated and optimised by previous 
members of the Jack Birch Unit. 
 
All siRNA was purchased from Thermo Fisher Scientific from their Silencer® Select 
pre-designed and validated siRNA product range. A list of the control and GATA3 
siRNA used can be found in Table 2.13. 
 
Table 2.13. siRNA Information 
siRNA Name (Catalogue #) siRNA Name in Thesis  
Silencer® Select Negative Control #1 siRNA 
(4390843) 
CTRL-siRNA1 
Silencer® Select Negative Control #2 siRNA 
(4390846) 
CTRL-siRNA2 
GATA3 Silencer® Select siRNA  
(S5600) 
GATA3-siRNA1  
GATA3 Silencer® Select siRNA  
(S5601) 
GATA3-siRNA2  
GATA3-siRNA1 (S5600) targeted a sequence in exon 5 of the human GATA3 
transcripts, while GATA3-siRNA2 (S5601) targeted a sequence in exon 6 of the human 
GATA3 transcripts. The negative control siRNAs were predesigned as to not target any 
gene product. 
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 Statistics 
Statistical analysis of the data was performed using GraphPad Prism 6 (GraphPad 
Software Inc.) Where two data sets were being analysed (ie. treatment vs control), for 
three or more independent cell lines, a paired t-test was used. When three for more data 
sets were being compared, a one-way ANOVA test was performed. A Dunnett’s 
multiple comparisons post-hoc test was performed if statistical significance was shown 
by the one-way ANOVA test. The Dunnett’s test was used to compare multiple 
treatments to a single control sample. 
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3 In Vitro Characterisation of Buccal Epithelial 
Cells with Reference to Urothelial Cells 
 Aims and Hypothesis 
The aim of this chapter was to perform an in vitro characterisation of NHB cells with 
reference to NHU cells in terms of the expression of urothelium-associated transcription 
factors and differentiation-associated genes. In doing the characterisation, the goal was 
to: 
1. Identify a set of transcription factors which could be useful for urothelial-type 
cell reprogramming, and in particular, be useful for the transdifferentiation of 
human buccal epithelial cells into urothelial cells. 
2. Determine a set of criteria which could be used to validate successful 
conversion of human buccal epithelial cells into urothelial cells. 
 
The hypothesis was that there exist fundamental differences in the expression of 
transcription factors and differentiation markers between normal human buccal 
epithelial cells and urothelial cells. Further to this, that these differences could be 
identified by comparing the two cell types in three different well characterised urothelial 
cell in vitro model systems. 
 
 Experimental Approach 
NHU cells have been well characterised in vitro. In particular, three cell culture systems 
(termed KSFMc, TZ/PD and ABS/Ca2+ in this thesis) have been previously published, 
and NHU cells characterised for their expression of specific cytokeratin proteins, 
nuclear receptors, transcription factors, uroplakins, and tight junction-associated 
proteins. These three protocols are described in detail in the Introduction and Methods 
chapters of this thesis. Due to their ability to produce highly reproducible, yet varied 
results in NHU cells, the KSFMc, TZ/PD and ABS/Ca2+ protocols were chosen as ideal 
in vitro model systems for comparison of NHB cells to NHU cells to identify 
fundamental differences. 
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NHB cells (from 2-3 independent finite cell lines) were cultured in each of the three 
urothelial cell in vitro systems described above (KSFMc, TZ/PD and ABS/Ca2+) and 
evaluated for their expression of nuclear receptors, cytokeratin proteins, transcription 
factors, and urothelium differentiation-associated genes. The ABS/Ca2+ protocol was 
also used to examine the ability of NHB cells to form a functional barrier epithelium, as 
measured by the TER. In all cases, a single NHU cell line was evaluated, which had 
been treated identically, and was used for comparison and/or as a positive control.  
 
In addition to the three systems described above, examination of NHB cells in response 
to the atRA/PD protocol (see methods section 2.4.10) was also examined to determine 
whether RAR activation could lead to the upregulation of urothelium-associated genes 
in NHB cells. Retinoic acid has been implicated as a key regulator in the maintenance of 
the urothelial cell identity, with a particular role in preventing squamous metaplasia 
(Southgate et al., 1994; Liang et al., 2005; Gandhi et al., 2013). NHB cells were 
evaluated for their expression of urothelial cell-associated transcription factors, as well 
as for their expression of the uroplakin genes, following use of the atRA/PD protocol. 
 
Phase contrast images of buccal epithelial cells and urothelial cells cultured in KSFMc, 
and during treatment with the TZ/PD, ABS/Ca2+ and atRA/PD protocols can be found in 
the Appendix. 
 
3.2.1 Cell Line Nomenclature 
As described in Chapter 2, upon arrival of the human tissue samples to the laboratory, 
each sample was given a unique coded number. Urological tissue specimens were given 
a unique ‘Y’ number (eg. Y1281). Buccal mucosa tissue specimens were given either a 
unique ‘AS’ number (eg. AS001b) or ‘Y’ number (eg. Y1600). When the epithelial cells 
were isolated from these tissue samples they retained their unique identifier, and thus 
were each defined as named, distinct finite cell lines after serial passage. 
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To make the data easier to follow in this chapter, where the two cell types were being 
compared, a specific cell line nomenclature was used for this chapter only. Finite 
normal human buccal epithelial (NHB) cell lines, which were originally identified as 
‘AS’ and ‘Y’ numbers, were renamed to ‘NHB’ numbers. Finite normal human 
urothelial (NHU) cell lines, which were originally identified as ‘Y’ numbers, were 
renamed to ‘NHU’ numbers. A table of the independent finite cell lines used to generate 
results for this chapter, and their corresponding ‘NHB’ and ‘NHU’ numbers can be 
found in Table 3.1. 
 
Table 3.1 List of Independent Finite NHB and NHU Cell Lines, and their 
Corresponding New Identification Numbers used in Chapter 4 
Buccal Epithelial Cell Lines  Urothelial Cell Lines 
Original  
Identifier 
New 
Identifier 
 Original  
Identifier 
New 
Identifier 
AS001b NHB1  Y1281 NHU1 
AS003b NHB2  Y1288 NHU2 
AS005b NHB3  Y1334 NHU3 
AS006b NHB4  Y1358 NHU4 
AS007b NHB5  Y1453 NHU5 
AS010b NHB6  Y1642 NHU6 
AS011b NHB7  Y1677 NHU7 
Y1778 NHB8  Y1691 NHU8 
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3.2.2 Differentiation and Barrier-Associated Gene Expression 
The expression of a panel of genes was used to assess either urothelial-type 
differentiation, stratified squamous-type differentiation, or barrier phenotype in NHB 
cells following use of the KSFMc, TZ/PD, ABS/Ca2+ and/or atRA/PD protocols. 
 
To identify transcription factors which could be useful for transdifferentiation-type 
experiments, a set of transcription factors (ELF3, FOXA1, GATA3, GRHL3, IRF1, 
KLF5, and PPARγ) was chosen for their known importance in regulating urothelial cell 
identity and differentiation, and evaluated for their expression in NHB cells. 
 
To evaluate urothelial-type differentiation capacity of NHB cells, the expression of the 
five uroplakin genes (UPK1A, UPK1B, UPK2, UPK3A and UPK3B) was investigated. 
The uroplakin genes are highly associated with the superficial cells of the urothelium, 
and the formation of AUM plaques. Expression of CK13 was evaluated for its 
association with transitional-type differentiation (Varley et al., 2004b). 
 
For stratified squamous-type differentiation, the expression of genes associated with the 
formation of the cornified cell envelope was investigated in NHB cells and NHU cells. 
These included LOR and SPRR4, which encode for proteins that are crosslinked to form 
the cornfield cell envelope of stratified squamous epithelia. The expression of TGM1 
was also examined, which encodes an enzyme responsible for crosslinking the proteins 
that form the cornified cell envelope. The expression of CK14 was assessed as a 
squamous epithelial cell-associated marker (Harnden and Southgate, 1997). 
 
The expression of a number of claudin genes (CLDN 1-10) was assessed in NHB cells 
as tight junction components associated with paracellular barrier function (Varley et al., 
2006). 
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 Results 
3.3.1 RT-PCR Screen to Determine the Expression of Nuclear 
Receptors in NHB Cells Grown in KSFMc 
Buccal epithelial cells from three independent NHB cell lines (NHB1, NHB3 and 
NHB4) expressed all three retinoic acid receptors (RARA, RARAB and RARG) and all 
three of the peroxisome proliferator-activated receptors (PPARA, PPARD, and PPARG) 
(Figure 3.1). Only two of the retinoid X receptors were expressed, RXRA and RXRB, 
and only ESR1 was expressed of the oestrogen receptors. RT-PCR for a single NHU cell 
line (NHU2) was performed for comparison, and a similar expression profile was 
observed. The main difference in expression was seen with PPARG, where it appeared 
that buccal epithelial cells had potentially lower expression than urothelial cells. 
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Figure 3.1 Nuclear Receptor Gene Expression in NHB Cells and NHU Cells Grown 
in Serum-Free, Low Calcium Medium (KSFMc) by RT-PCR 
Buccal epithelial cells (NHB1, NHB3 and NHB4) and urothelial cells (NHU2) were 
grown in serum-free, low calcium medium (KSFMc) to confluence. PCR was performed 
using 30 cycles for all target genes. GAPDH was used as a loading control (25 cycles). 
H2O (no template) was used as the negative control (-). Genomic DNA or cDNA 
generated from the total RNA of cells known to express the gene of interest was used as a 
positive control for the PCR (+). PPARG PCR was performed using forward and reverse 
primers designed to sequences in exon 6 of the PPARG coding sequence. Note similar 
expression of nearly all of the nuclear receptors assessed between NHU cells and NHB 
cells. A possible difference in expression was observed with PPARG, were NHB cells 
appeared to have weaker expression than NHU cells. 
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3.3.2 Cytokeratin Protein Expression 
3.3.2.1 Expression of Cytokeratin Proteins in NHB Cells Grown in Serum-Free, 
Low Calcium Medium (KSFMc) 
In serum-free, low calcium (0.09 mM) medium (KSFMc), buccal epithelial cells from 
three independent NHB cell lines (NHB2, NHB3 and NHB4) expressed CK5, CK14 
and CK18 in all cells (Figure 3.2). CK7, CK13 and CK19 had mixed expression, with 
some cells positive and other cells negative. Expression of CK20 was absent. In NHU 
cells (NHU4), CK5, CK7, CK18 and CK19 were expressed in all cells. CK13 and CK14 
were expressed in some of the cells and had weak expression in others. CK20 
expression was absent in all cells. 
 
3.3.2.2 Effect of PD and TZ/PD Treatment on the Expression of CK13 in NHB Cells 
CK13 expression was weak to absent in control (0.1 % DMSO) NHB cells (Figure 3.3). 
Upon treatment with either 1 μM PD or combined TZ/PD, CK13 expression noticeably 
increased. Comparable amounts of CK13 expression were observed in both the PD 
only, and TZ/PD treated cells. 
 
3.3.2.3 Expression of Cytokeratin Proteins in NHB Cell Sheets Generated using the 
ABS/Ca2+ Protocol 
Assessment of cell sheets generated from three independent NHB cell lines (NHB1, 
NHB2 and NHB3) using the ABS/Ca2+ protocol, saw cytoplasmic CK5 and CK14 
expression throughout all cell layers of the cell sheets (Figure 3.4). CK7 expression was 
also present throughout the cell sheets, but only in two of the three NHB cell lines 
(NHB1 and NHB3). CK13 expression was specifically restricted to only the upper 
portion of the NHB cell sheets. In NHU cell sheets, CK5, CK7 and CK13 expression 
was observed throughout the entire cell sheet. CK14 expression was absent, as expected 
in NHU cells differentiated with the ABS/Ca2+ protocol. 
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Figure 3.2 Cytokeratin Protein Expression in NHB Cells and NHU Cells Grown in Serum-Free, Low Calcium Medium (KSFMc) by Indirect 
Immunofluorescence Microscopy 
Expression of CK5, CK7, CK13, CK14, CK18, CK19 and CK20 in three independent NHB cell lines (NHB2, NHB3 and NHB4) and a single NHU 
cell line (NHU4). Cells were grown on 12 well glass slides and fixed using 50:50 methanol acetone. Red labelling represents the specified cytokeratin. 
Nuclei were counterstained with Hoechst 33258. NHU cells which had been treated with TZ/PD for 6 days were used as a positive control for CK20 
expression; the positive control image for CK20 can be seen in Appendix 7.4. Note NHB cells express CK5, CK14, and CK18 in all cells. CK7, CK13 
and CK19 expression in NHB cells was mixed, with some cells positive and others negative. CK20 expression was absent. 
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Figure 3.3 CK13 Expression in NHB Cells Following Treatment with DMSO, PD or 
TZ/PD for 72 hours by Western Blotting 
Two independent NHB cell lines A) NHB6 and B) NHB8 were treated with either 
0.1 % DMSO (vehicle control), 1 μM PD or the TZ/PD protocol for 72 hours. CK13 
protein expression was assessed by western blotting. β-actin was used as a loading 
control. 25 μg of protein was loaded into each well. A single NHU cell line (NHU8) 
which had been treated with TZ/PD for 72 hours was included on the blot to act as a 
positive control/for comparison. NHB6 and NHB8 were carried out on the same western 
blot, and therefore have the same NHU positive control. Note increased CK13 
expression in NHB cells as a result of PD treatment and combined TZ/PD treatment. 
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Figure 3.4 Evaluation of Cytokeratin Protein Expression by Immunohistochemistry 
in NHB and NHU Cell Sheets Generated Using the ABS/Ca2+ Protocol  
The expression of cytokeratins 5, 7, 13 and 14 was assessed by immunohistochemistry. 
Cell sheets from a single NHU cell line (NHU3) and three independent NHB cell lines 
(NHB1, NHB2 and NHB3) are shown. Cell sheets were generated on Snapwell 
membranes using the ABS/Ca2+ protocol for seven days. All images are shown with the 
apical surface of the epithelial cell sheet at the top. Positive control and example negative 
control (no primary antibody) images can be found in Appendix 7.4. Note expression of 
CK14 throughout the whole of the NHB cell sheets, and absent in the NHU cell sheet. 
Also note CK13 expression is restricted to only the upper portion of the NHB cell sheets. 
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3.3.3 Assessment of Urothelial Cell Differentiation-Associated 
Transcription Factor Expression 
3.3.3.1 Expression of Urothelium Differentiation-Associated Transcription Factors 
in NHB Cells Treated with TZ/PD 
Buccal epithelial cells from two independent NHB cell lines (NHB4 and NHB5) were 
assessed for their expression of the transcription factors, ELF3, FOXA1, GATA3, 
GRHL3, IRF1, and KLF5 and PPARγ (all transcript variants), by RT-PCR (Figure 3.5). 
GRHL3 and KLF5 displayed high levels of gene expression throughout all of the time 
points (12 hr., 24 hr., and 48 hr.) in both control and TZ/PD treated cells. ELF3 and 
IRF1 gene expression appeared potentially upregulated by TZ/PD, with expression 
being observed at all time points. FOXA1 and GATA3 gene expression was noticeably 
weak to absent at all of the time points. Both of the NHB cell lines investigated showed 
similar results for all genes, at all time points. A single NHU cell line (NHU1), 
evaluated for comparison, displayed clear gene expression for all seven of the 
transcription factors, at all of the control and TZ/PD time points (12 hr., 24 hr., and 48 
hr.), as was expected. 
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Figure 3.5 Evaluation of Transcript Expression of Urothelium-Associated 
Transcription Factors by RT-PCR in NHB Cells and NHU Cells Following TZ/PD 
Treatment 
Buccal epithelial cells A) (NHB4) and urothelial cells B) (NHU1) were treated with 
TZ/PD for 24, 48 and 72 hours. The expression of ELF3, FOXA1, GATA3, GRHL3, 
IRF1, KLF5 and PPARγ (forward and reverse primers designed to sequences in exon 6) 
was assessed by RT-PCR. PCR was performed using 30 cycles. GAPDH was used as a 
loading control (25 cycles). H2O (no template) was used as a negative control (-). 
Genomic DNA was used as the positive control for the PCR (+). A second buccal 
epithelial cell line (NHB5), which showed similar results, was also completed for this 
experiment, and the figure can be found in Appendix 7.4. Note the weak/absent 
expression of FOXA1, GATA3 and PPARγ expression in NHB cells. Also note the 
possible upregulation of ELF3 in NHB cells as a result of TZ/PD. 
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From the original set of seven transcription factors, ELF3, FOXA1, GATA3 and PPARγ 
were chosen to investigate in NHB cells further by RT-qPCR, western blotting and 
immunofluorescence. ELF3 was chosen due to its apparent upregulation as a result of 
the using the TZ/PD protocol. FOXA1, GATA3 and PPARγ were chosen due to their 
apparent weak gene expression in NHB cells in comparison to NHU cells. 
 
Buccal epithelial cells from three independent NBH cell lines (NHB6, NHB7 and 
NHB8) had weak constitutive expression of FOXA1, GATA3 and PPARγ (all transcript 
variants), and there was no significant upregulation of expression as a result of 72 hour 
TZ/PD treatment by RT-qPCR analysis (Figure 3.6). ELF3 expression was significantly 
(P = 0.006) upregulated as a result of using the TZ/PD protocol (72 hour). These results 
confirmed the previous results obtained using RT-PCR. In comparison to a single NHU 
cell line (NHU6), NHB cells had lower transcript abundance of all four of the 
transcription factors (ELF3, FOXA1, GATA3 and PPARγ) in response to TZ/PD. 
 
By western blotting, buccal epithelial cells from three independent NHB cell lines 
(NHB6, NHB7 and NHB8) had weak to absent protein expression of GATA3 and 
PPARγ1 even following use of the TZ/PD protocol for 72 hours (Figure 3.7). ELF3 
protein expression varied between the cell lines; two NHB cell lines (NHB6 and NHB8) 
showed increased ELF3 expression as a result of TZ/PD, while a third cell line (NHB7) 
was negative. FOXA1 expression also varied; one NHB cell line (NHB6) was negative, 
another had expression in control and TZ/PD treated cells (NHB8), and a third cell line 
(NHB7) only showed expression in control cells. 
 
By immunofluorescence, the expression of ELF3 varied among the three NHB cell lines 
(NHB6, NHB7 and NHB8), but in general it was weakly expressed, becoming more 
strongly nuclear at the 144 hr TZ/PD time point (Figure 3.8). FOXA1, GATA3 and 
PPARγ expression was weakly nuclear to absent at all time points (24 hr, 72 hr, and 
144 hr). In NHU cells (NHU6 and NHU7) used for comparison, an obvious 
upregulation of expression, and nuclear localisation was observed as a result of the 
TZ/PD protocol (72 hour), as was expected. 
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Figure 3.6 Assessment of ELF3, FOXA1, GATA3 and PPARγ Transcript Expression 
in NHB Cells and NHU Cells by RT-qPCR Following use of the TZ/PD Protocol for 72 
hour 
RT-qPCR data was generated for A) ELF3, B) FOXA1, C) GATA3 and D) PPARγ 
(forward primer in exon 1 and reverse primer in exon 3) using three independent NHB cell 
lines (NHB6, NHB7 and NHB8), and a single NHU cell line (NHU6) for comparison. 
Cultures were treated with either 0.1% DMSO (vehicle control) or TZ/PD for 72 hours. All 
values are shown relative to the mean of the 0.1% DMSO treated buccal epithelial cells for 
each gene. For NHB cells, error bars represent the standard deviation of the mean of the 
Log(2) fold change of the three independent NHB cell lines (n=3). For NHU cells, error 
bars represent the standard deviation of three technical replicates (n=1). All values were 
first normalised to GAPDH. Statistical analysis was performed using a two-tailed, paired t-
test to determine whether there was a significant change in gene expression as a result of 
using the TZ/PD protocol. ns = non-significant. ** represents P ≤ 0.01. Note the significant 
upregulation of ELF3 expression in NHB cells as a result of TZ/PD treatment. Also note 
weak expression of FOXA1, GATA3 and PPARγ in NHB cells even following the use of 
the TZ/PD protocol. 
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Figure 3.7 Assessment of ELF3, FOXA1, GATA3 and PPARγ Protein Expression by 
Western Blotting in Buccal Epithelial Cells Following 72 hour DMSO, PD and 
TZ/PD Treatment 
Buccal epithelial cells from three independent NHB cell lines, A) NHB6, B) NHB7 and 
C) NBH8 were treated with either 0.1% DMSO (vehicle control), 1 μM PD or TZ/PD for 
72 hours. ELF3, FOXA1 (Santa Cruz, Q-6), GATA3 and PPARγ (Cell Signaling, D69) 
expression was assessed by western blotting. The band corresponding to PPARγ1 
(approximately 52 kDa) is shown. A full length blot showing all PPARγ reactive bands in 
NHB cells can be found in Appendix 7.4. A single NHU cell line (NHU8) which had 
been treated with TZ/PD for 72 hours was included on all blots to act as a positive 
control/for comparison. NHB6 and NHB8 were carried out on the same western blots, 
and therefore have the same NHU positive control. 25 μg of protein was loaded into each 
well and β-actin was used as a loading control. Note weak/absent expression of GATA3 
and PPARγ1 in NHB cells. Expression of ELF3 and FOXA1 protein was variable. 
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Figure 3.8 Evaluation of Transcription Factor Protein Expression in NHB Cells and NHU Cells Following use of the TZ/PD Protocol for 24, 72 
and 144 hours by Indirect Immunofluorescence Microscopy – A) ELF3 
NHB cells (NHB7) were treated with either 0.1% DMSO (vehicle control) or TZ/PD for 24, 72 and 144 hours. A single NHU cell line (NHU7) which 
had been treated with either 0.1% DMSO or TZ/PD for 72 hours was used as a positive control for comparison. A) ELF3, B) FOXA1/2 (Santa Cruz, 
C-20), C) GATA3, and D) PPARγ (Cell Signaling, D69) expression was assessed by immunofluorescence on formalin-fixed slides which had been 
permeabilised using Triton X-100. Inset images show the corresponding Hoechst 33258 staining to demonstrate cell density and nuclei location. All 
antibody-labelled images were taken at the same exposure for both NHB cells and NHU cells. Hoechst 33258 images were taken at optimal exposures. 
Two additional NHB cell lines (NHB6 and NHB8) were evaluated for the purpose of this experiment, and their figures can be found in Appendix 7.4. 
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Figure 3.8 Evaluation of Transcription Factor Protein Expression in NHB Cells and NHU Cells Following use of the TZ/PD Protocol for 24, 72 
and 144 hours by Indirect Immunofluorescence Microscopy – B) FOXA1/2 
See main caption on page 136. Note weak/absent expression of FOXA1/2 in NHB cells even following use of the TZ/PD protocol for up to 144 hours. 
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Figure 3.8 Evaluation of Transcription Factor Protein Expression in NHB Cells and NHU Cells Following use of the TZ/PD Protocol for 24, 72 
and 144 hours by Indirect Immunofluorescence Microscopy – C) GATA3 
See main caption on page 136. Note weak/absent expression of GATA3 in NHB cells even following use of the TZ/PD protocol for up to 144 hours. 
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Figure 3.8 Evaluation of Transcription Factor Protein Expression in NHB Cells and NHU Cells Following use of the TZ/PD Protocol for 24, 72 
and 144 hours by Indirect Immunofluorescence Microscopy – D) PPARγ 
See main caption on page 136. Note weak/absent expression of PPARγ in NHB cells even following use of the TZ/PD protocol for up to 144 hours. 
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3.3.3.2 Expression of FOXA1 and GATA3 Following use of the atRA/PD Protocol 
The effect of RAR activation on the expression of transcription factors FOXA1 and 
GATA3 was assessed by RT-PCR using a single NHB cell line (NHB4) (Figure 3.9). 
FOXA1 gene expression was weak, but appeared induced by the all-trans retinoic acid 
treatment in a dose-dependent manner. GATA3 expression was weak in all of the 
treatments. 
 
Three independent NHB cell lines (NHB8, NHB6 and NHB7) were used to investigate 
the effect of all-trans retinoic acid on the protein expression of FOXA1 and GATA3, by 
western blotting (Figure 3.10). FOXA1 expression was upregulated, but weak in all 
three cell lines, as a result of all-trans retinoic acid treatment. GATA3 expression 
remained absent in all three cell lines. 
 
 
 
Figure 3.9 Evaluation of FOXA1 and GATA3 Transcript Expression by RT-PCR  in 
NHB Cells Following use of the atRA/PD Protocol for 72 hours 
Buccal epithelial cells (NHB4) were treated with 1 μM PD153035 and varying 
concentrations of atRA (10 nM, 100 nM, and 1 μM). Additional cell treatments included 
TZ/PD with and without 100 nM atRA. The treatment time course lasted 72 hours. PCR 
was performed using 30 cycles for all target genes. GAPDH was used as a loading control 
(25 cycles). H2O (no template) was used as the negative control (-). Genomic DNA was 
used as the positive control (+). Note an upregulation of FOXA1 expression as a result of 
increased concentrations of atRA. GATA3 expression appeared weak and unaffected by 
atRA. 
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Figure 3.10 Evaluation of FOXA1 and GATA3 Protein Expression by Western 
Blotting in NHB Cells Following use of the atRA/PD Protocol for 72 hours 
Three independent NHB cell lines (NHB8, NHB6 and NHB7) were treated with either 
1 μM of PD (control) or 1 μM PD with 100 nM atRA for 72 hours. GATA3 and FOXA1 
(Q-6, Santa Cruz) protein expression was assessed by western blotting. β-actin was used 
as a loading control. Protein taken from a single NHU cell line (NHU8), which had been 
treated with TZ/PD for 72 hours, was included on the same blot, and used as a positive 
control for each antibody. 25 μg of protein was loaded into each well. Note increased 
FOXA1 protein expression in all three NHB cell lines as a result of atRA treatment. 
GATA3 expression remained absent in all three of the NHB cell lines. 
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3.3.3.3 Assessment of Urothelial Differentiation-Associated Nuclear Receptor and 
Transcription Factor Expression in NHB and NHU Cell Sheets Generated 
Using the ABS/Ca2+ Protocol 
The expression of transcription factors, FOXA1/2 and GATA3, and nuclear receptors, 
RXRα and PPARγ, was evaluated in NHB cell sheets which had been generated using 
the ABS/Ca2+ protocol (Figure 3.11). In buccal epithelial cell sheets, generated from 
three independent NHB cell lines (NHB1, NHB2 and NHB3), FOXA1/2 expression was 
nuclear, but restricted to only a portion of the nuclei. GATA3 expression was negative 
in all NHB cell lines, while PPARγ expression appeared as both cytoplasmic and 
nuclear. RXRα expression was nuclear in all cells. In the urothelial cell sheets, 
generated using a single NHU cell line (NHU3), clear nuclear expression was observed 
for RXRα, PPARγ, FOXA1 and GATA3. 
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Figure 3.11 Assessment of Transcription Factor and Nuclear Receptor Protein 
Expression in NHB and NHU Cell Sheets Generated Using the ABS/Ca2+ Protocol by 
Immunohistochemistry 
The expression of RXRα, PPARγ (Cell Signaling, 81B8), FOXA1/2 (Santa Cruz, C-20) 
and GATA3 was assessed by immunohistochemistry. Cell sheets from a single NHU cell 
line (NHU3) and three independent buccal epithelial cell lines (NHB1, NHB2 and NHB3) 
are shown. Cell sheets were generated on Snapwell membranes using the ABS/Ca2+ 
protocol for seven days. All images are shown with the apical surface of the epithelial cell 
sheet at the top. Positive control and example negative control (no primary antibody) 
images can be found in Appendix 7.4. Note weak nuclear expression of FOXA1/2 in 
NHB cells. Also note absence of GATA3 expression in NHB cells. PPARγ expression 
appeared both cytoplasmic and nuclear in NHB cell sheets, which differed from the 
strongly nuclear expression observed in NHU cell sheets. 
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3.3.4 Assessment of Urothelium Differentiation-Associated Genes 
3.3.4.1 Uroplakin Gene Expression in NHB Cells Following use of the TZ/PD 
Protocol 
Buccal epithelial cells from two independent NHB cell lines (NHB3 and NHB4) were 
assessed for their expression of the five uroplakin genes following use of the TZ/PD 
protocol for up to 6 days, by RT-PCR (Figure 3.12). UPK1A transcript expression was 
weak/absent in one of the NHB cell lines (NHB3), while in the other (NHB4) it was 
weakly detected at all of the time points. UPK2 transcript was weakly detected at all of 
the TZ/PD time points (0.5, 3 and 6 days). UPK3A expression was absent at all time 
points. UPK1B and UPK3B were expressed at all of the time points assessed. The 
single NHU cell line (NHU5) examined expressed UPK1B and UPK3B at all time 
points. UPK1A, UPK2 and UPK3A expression was most obvious at the 3 and 6 day 
TZ/PD time points in NHU cells. 
 
To determine whether the expression of any of the five uroplakin genes was 
significantly upregulated as a result of using the TZ/PD protocol, RT-qPCR was 
performed for three independent buccal epithelial cell lines (NHB6, NHB7 and NHB8) 
which had been treated with either 0.1% DMSO or the TZ/PD for 72 hours (Figure 
3.13). cDNA generated from a single urothelial cell line (NHU6), which had undergone 
the same TZ/PD protocol for 72 hours, was used for comparison. In NHB cells, the 
expression of UPK1A, UPK1B, UPK2 and UPK3B was detected and upregulated as a 
result of TZ/PD, with UPK2 and UPK3B expression being significantly upregulated. 
Expression of UPK3A was undetectable in all of the NHB cell lines. These results 
agreed with the results observed by RT-PCR. 
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Figure 3.12 Assessment of Uroplakin Gene Expression in Buccal Epithelial Cells and Urothelial Cells by RT-PCR Following TZ/PD Treatment 
A) Buccal epithelial cells (NHB3) and B) urothelial cells (NHU5) were treated with either 0.1% DMSO or TZ/PD for 0.5, 3 or 6 days. The gene 
expression of the five uroplakin genes (UPK1A, UPK1B, UPK2, UPK3A, UPK3B) is shown by RT-PCR. PCR was performed using 30 cycles. 
GAPDH was used as a loading control (25 cycles). H2O (no template) was used as a negative control (-). Genomic DNA was used as the positive 
control for the PCR (+). A second buccal epithelial cell line (NHB4) was also completed for this experiment, and the figure can be found in Appendix 
7.4. Note weak expression of UPK1A, UPK1B and UPK2 in NHB cells. Also note abundant expression of UPK3B in NHB cells. UPK3A was absent in 
both NHB cell lines assessed. 
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Figure 3.13 Evaluation of Uroplakin Gene Expression in Buccal Epithelial Cells and 
Urothelial Cells by RT-qPCR Following 72 hour TZ/PD Treatment 
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Figure 3.13 Evaluation of Uroplakin Gene Expression in Buccal Epithelial Cells and 
Urothelial Cells by RT-qPCR Following 72 hour TZ/PD Treatment 
RT-qPCR data was generated for the five uroplakin genes, A) UPK1A, B) UPK1B, 
C) UPK2, D) UPK3A, and E) UPK3B, using three independent NHB cell lines (NHB6, 
NHB7 and NHB8), and a single NHU cell line (NHU6) for comparison. Cells were 
treated with either 0.1% DMSO (control) or TZ/PD for 72 hours. For NHB cells, error 
bars represent the standard deviation of the mean of the Log(2) fold change of the three 
independent NHB cell lines (n=3). For NHU cells, error bars represent the standard 
deviation of three technical replicates (n=1). Since UPK3A was not detected in NHB 
cells, UPK3A is shown relative to the DMSO treated NHU cells. Gene expression was 
first normalised to GAPDH expression. Statistical analysis was performed using a two-
tailed, paired t-test to assess whether there was any significant change in gene expression 
as a result of TZ/PD. ns = non-significant. * represents P ≤ 0.05. ** represents P ≤ 0.01. 
Note weak expression of UPK1A, UPK1B and UPK2 in NHB cells. Also note the 
significant upregulation of UPK2 and UPK3B expression in NHB cells as a result of 
TZ/PD treatment.  
  
Chapter 3 
 
148 
3.3.4.2 Effect of All-Trans Retinoic Acid on Uroplakin Gene Expression 
The effect of RAR activation on the expression of the five uroplakin genes (UPK1A, 
UPK1B, UPK2, UPK3A, and UPK3B), was assessed by RT-PCR in a single NHB cell 
line (NHB4) (Figure 3.14). UPK1A gene expression appeared possibly downregulated 
as a result of the atRA treatment, while expression of UPK1B, UPK2 and UPK3B was 
maintained. UPK3A expression was absent in all cases. 
 
 
 
Figure 3.14 Evaluation of Uroplakin Gene Expression by RT-PCR Following use of 
the atRA/PD Protocol in NHB Cells 
Buccal epithelial cells (NHB4) were treated with 1 μM PD and varying concentrations of 
atRA (10 nM, 100 nM, and 1 μM). Additional treatments included TZ/PD with and 
without 100 nM atRA. The treatment time course lasted 72 hours. PCR was performed 
using 30 cycles for all target genes. GAPDH was used as a loading control (25 cycles). 
H2O (no template) was used as the negative control (-). Genomic DNA was used as the 
positive control (+). Note no obvious changes in uroplakin gene expression in NHB cells 
following treatment with either PD or atRA/PD. 
 
  
Chapter 3 
 
149 
3.3.4.3 Expression of Selected Claudin Genes in NHB Cells Treated with TZ/PD 
Buccal epithelial cells from two independent NHB cell lines (NHB3 and NHB4) 
displayed expression of claudin 1, 2, 4, and 7 transcript at all of the time points assessed 
during the TZ/PD protocol (12 hr, 72 hr and 144 hr) (Figure 3.15). Claudin 6, 8 and 10 
gene expression was absent at all of the time points. Claudin 3 and 5 gene expression 
was variable between the two cell lines evaluated. In one of the cell lines (NHB4) 
CLDN3 expression was absent at all of the time points, while in the other cell line 
(NHB3) CLDN3 was expressed at all time points. CLDN5 was expressed only at day 
0.5 in one cell line (NHB3) while it was expressed only at day 6 in the other cell line 
(NHB4). In a single NHU cell line (NHU5), assessed for comparison, gene expression 
for claudins 1, 3, 4 and 7 was observed at all of the time points. Claudin 5 expression 
was restricted to only the TZ/PD treated cells at days 3 and 6. Claudin 2 was expressed 
only in the day 6, untreated cells. Expression of claudins 6, 8 and 10 was absent in 
urothelial cells. 
 
3.3.4.4 Assessment of Selected Tight Junction Proteins in NHB and NHU Cell 
Sheets Generated Using the ABS/Ca2+ Protocol 
The expression of several tight junction-associated proteins was assessed in cell sheets 
generated from three independent NHB cell lines (NHB1, NHB2 and NHB3) and a 
single NHU cell line (NHU3) using the ABS/Ca2+ protocol. The expression of claudins 
(CLDNs) -4, -5 and -7 was present at the intercellular borders and restricted to only the 
upper half of the NHB cell sheets (Figure 3.16). This was in contrast to the expression 
observed in the NHU cell sheets, where claudins -4, -5 and -7 were expressed at the 
intercellular borders, but throughout the whole of the cell sheets. Occludin (OCLN) 
expression was observed throughout the entire cell sheet in both the NHB and NHU cell 
sheets. The expression of the claudin proteins was observed at the cell borders/contact 
points in all of the cell lines. Occludin expression was cytoplasmic throughout all of the 
cell sheets, with expression also present at intercellular borders. 
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Figure 3.15 Evaluation of Claudin Gene Expression in NHB Cells and NHU Cells by RT-PCR Following TZ/PD Treatment 
A) NHB cells (NHB3) and B) NHU cells (NHU5) were treated with either 0.1% DMSO or TZ/PD for 0.5, 3 or 6 days. The gene expression of claudins 
(CLDNs) 1-10 is shown by RT-PCR. PCR was performed using either 30 or 35 cycles for a given gene. GAPDH was used as a loading control (25 
cycles). H2O (no template) was used as a negative control (-). Genomic DNA was used as the positive control for the PCR (+). A second buccal 
epithelial cell line (NHB4) was also completed for this experiment, and the figure can be found in Appendix 7.4. Note the similar expression of the 
CLDN genes in NHB cells and NHU cells during use of the TZ/PD protocol. 
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Figure 3.16 Evaluation of Tight Junction Protein Expression in NHB and NHU Cell 
Sheets Generated Using the ABS/Ca2+ Protocol by Immunohistochemistry 
The expression of tight junction-associated proteins, CLDN4, CLDN5, CLDN7 and 
OCLN, was assessed by immunohistochemistry. Cell sheets from a single NHU cell line 
(NHU3) and three independent NHB cell lines (NHB1, NHB2 and NHB3) are shown. 
Cell sheets were generated on Snapwell membranes using the ABS/Ca2+ protocol for 
seven days. All images are shown with the apical surface of the epithelial cell sheet at the 
top. Positive control and example negative control (no primary antibody) images can be 
found in Appendix 7.4. Note expression of CLDN4, CLDN5 and CLDN7 in only the 
upper half of the NHB cell sheets, while NHU cell sheets displayed expression of the 
claudin proteins in all of the cell layers. 
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3.3.5 Assessment of Squamous Differentiation-Associated Genes 
3.3.5.1 Assessment of Stratified Squamous Differentiation-Associated Transcript 
Expression in NHB Cells and NHU Cells Following use of the TZ/PD 
Protocol 
By RT-PCR analysis, NHB cells from two independent cell lines (NHB3 and NHB4) 
showed varied results (Figure 3.17). One NHB cell line (NHB3) had negative 
expression of LOR and SPRR4. The other cell line (NHB4) had weak transcript 
expression of LOR and SPRR4 at the 3 and 6 day TZ/PD treated time points. TGM1 
was expressed at all of the time points assessed in both NHB cell lines, with a possible 
upregulation of expression at the 3 and 6 day TZ/PD time points. The single NHU cell 
line, evaluated for comparison, showed weak expression of LOR in the control cells at 
day 6. Expression of SPRR4 and TGM1 was absent at all of the time points. 
 
The expression of TGM1 was further assessed by RT-qPCR in three independent NHB 
cell lines (NHB6, NHB7 and NHB8), and demonstrated a significant upregulation in 
expression as a result of TZ/PD treatment at 72 hours (Figure 3.18). The single NHU 
cell line (NHU6) assessed for comparison, demonstrated weak expression, which was 
downregulated as a result of using the TZ/PD protocol. 
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Figure 3.17 Assessment of Stratified Squamous-Associated Gene Expression in NHB 
Cells and NHU Cells by RT-PCR Following TZ/PD Treatment 
Buccal epithelial cells A) (NHB3) and urothelial cells B) (NHU5) were treated with either 
0.1 % DMSO (vehicle control) or TZ/PD for 0.5, 3 or 6 days. The transcript expression of 
several stratified sqaumous differentiation-associated genes (LOR, SPRR4 and TGM1) is 
shown by RT-PCR. PCR was performed using either 25 or 30 cycles for a given gene. 
GAPDH was used as a loading control (25 cycles). H2O was used as a negative control 
(-). Genomic DNA was used as the positive control for the PCR (+). A second buccal 
epithelial cell line (NHB4), was also completed for this experiment and the figure can be 
found in Appendix 7.4. Note strong expression of TGM1 in NHB cells, and an absence of 
expression in NHU cells. 
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Figure 3.18 RT-qPCR Analysis of TGM1 Gene Expression in NHB Cells Following 
72 hour TZ/PD Treatment 
RT-qPCR data was generated for TGM1 expression in three independent NHB cell lines 
(NHB6, NHB7 and NHB8), and a single NHU cell line (NHU6) for comparison. Cultures 
were treated with either 0.1% DMSO (vehicle control) or TZ/PD for 72 hours. Values are 
shown relative to the mean of the 0.1% DMSO treated NHB cells for each gene. All 
values were first normalised to GAPDH. For NHB cells, error bars represent the standard 
deviation of the mean of the Log(2) fold change of the three independent NHB cell lines 
(n=3). For NHU cells, error bars represent the standard deviation of three technical 
replicates (n=1). Statistical analysis was performed using a two-tailed, paired t-test to 
assess whether there was a significant change in gene expression as a result of TZ/PD. * 
represents P ≤ 0.05. Note significantly upregulated expression of TGM1 in NHB cells as 
a result of TZ/PD treatment. In NHU cells TGM1 expression is weak and downregulated 
as a result of TZ/PD. 
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3.3.6 Assessment of Barrier Function During use of the ABS/Ca2+ 
Protocol 
Buccal epithelial cells from three independent cell lines (NHB1, NHB2 and NHB3) 
were unable to form a functional barrier at any time during the seven day ABS/Ca2+ 
differentiation protocol on Snapwell inserts (Figure 3.19). The TER values were 
maintained below 200 Ω·cm2 in all three of the cell lines at all of the time points 
assessed. An NHU cell line (NHU3), used for comparison, displayed characteristic 
barrier formation, surpassing a TER of 1000 Ω·cm2 two days after the calcium 
concentration was increased to 2 mM. This barrier function was maintained throughout 
the rest of the time course, with a maximum TER achieved on day 7. 
 
 
 
Figure 3.19 Measurement of Barrier Function for NHB Cells and NHU Cells During 
the ABS/Ca2+ Protocol - TER 
NHB cells and NHU cells were pre-treated with 5% ABS for 5 days and then passaged 
and seeded onto Snapwell inserts. The calcium concentration was increased to 2 mM after 
24 hours. The TER was measured every day for seven days. Three independent NHB cell 
lines (NHB1, NHB2, and NHB3) and a single NHU cell line (NHU3) were evaluated. 
Error bars represent the standard deviation of the mean of n=3 replicates of each cell line. 
Note NHB cells did not gain barrier function during use of the ABS/Ca2+ protocol, 
something that is reproducibly observed in NHU cells. 
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 Summary of Results 
 NHB cells expressed cytokeratin proteins, CK5, CK7, CK13, CK14, CK18 and 
CK19 when grown in KSFMc. Expression of CK13 could be upregulated in 
NHB cells by treatment with either PD or TZ/PD, suggesting that CK13 
expression may not be mediated by PPARγ in NHB cells. Use of the ABS/Ca2+ 
protocol maintained expression of the squamous epithelial cell-associated 
protein, CK14, in NHB cell sheets. In urothelial cells sheets, CK14 expression 
was absent as a result of ABS/Ca2+ differentiation. 
 
 NHB cells had weak to absent expression of the urothelial differentiation-
associated transcription factors, ELF3, FOXA1, GATA3, and PPARγ1. This was 
observed at both the transcript and protein levels, and there was no significant 
upregulation or increased nuclear localisation as a result of using the TZ/PD 
protocol. ELF3 was significantly upregulated at the transcript level as a result of 
TZ/PD in NHB cells. NHB cell sheets generated using the ABS/Ca2+ protocol, 
were absent for GATA3 expression. FOXA1/2 and PPARγ showed weak 
nuclear expression in the NHB cell sheets. 
 
 NHB cells expressed three of the five uroplakin genes (UPK1A, UPK1B, and 
UPK2) at low transcript abundance, and their expression was upregulated as a 
result of TZ/PD. UPK3B expression in NHB cells was comparable to that of 
NHU cells. Expression of UPK2 and UPK3B was significantly upregulated as a 
result of using the TZ/PD protocol in NHB cells. 
 
 In NHB cell sheets, expression of the claudin proteins assessed was restricted to 
only the upper half of the cell sheets. This differed from urothelial cells sheets 
which expressed CLDN4, -5 and -7 throughout the whole of the cell sheet. 
 
 All-trans retinoic acid treatment of NHB cells caused an upregulation of both 
FOXA1 transcript and protein expression, but did not obviously affect GATA3 
expression, or the expression of the five uroplakin genes. 
 
 In vitro maintained NHB cells were unable to form a functional barrier using the 
ABS/Ca2+ protocol, which differed from what is consistently observed with 
NHU cells. 
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 Summary Table of Key Differences Between NHB Cells 
and NHU Cells 
Table 3.2 Summary Table of Results Comparing the Expression of Markers Genes 
Assessed in Chapter 4 Between NHB Cells and NHU Cells in Vitro 
Protocol Makers Assessed NHB Cells NHU Cells 
KSFMc 
Cytokeratins 
CK7 
CK13 
CK14 
CK20 
Some cells 
Some cells 
All cells 
Absent 
All cells 
Some cells 
Some cells 
Absent 
Transcription 
Factors 
ELF3 
FOXA1 
GATA3 
PPARγ 
Weak/Absent 
Weak/Absent 
Weak/Absent 
Weak/Absent 
Weak 
Weak 
Weak 
Weak 
TZ/PD 
Transcription 
Factors 
ELF3 
FOXA1 
GATA3 
PPARγ 
Weak 
Weak 
Weak/Absent 
Weak/Absent 
Strong 
Strong 
Strong 
Strong 
Uroplakin 
Genes 
UPK1A 
UPK1B 
UPK2 
UPK3A 
UPK3B 
Weak 
Weak 
Weak 
Absent 
Strong 
Strong 
Strong 
Strong 
Strong 
Strong 
atRA/PD 
Transcription 
Factors 
FOXA1 
GATA3 
Weak 
Weak/Absent 
Not assessed 
Not assessed 
ABS/Ca2+ 
Transcription 
Factors 
GATA3 
FOXA1 
PPARγ 
Weak/Absent 
Weak Nuclear 
Weak Nuclear 
Strong Nuclear 
Strong Nuclear 
Strong Nuclear 
Tight 
Junction 
Proteins 
CLDN4 
CLDN5 
CLDN7 
Upper half of sheet 
Upper half of sheet 
Upper half of sheet 
All layers of sheet 
All layers of sheet 
All layers of sheet 
Cytokeratins 
CK7 
CK14 
Weak/Absent 
All layers of sheet 
All layers of sheet 
Absent 
Barrier 
Function 
TER No:  < 200 Ω·cm2 Yes:  > 1000 Ω·cm2 
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4 Expression of PPARγ and GATA3 in 
Urothelial Cell Differentiation 
 Background 
4.1.1 PPARγ Expression in Urothelial Cells 
PPARγ has been identified as a key regulator of normal human urothelial cell 
differentiation, although the specific PPARγ isoform which most contributes to the 
differentiation has yet to be elucidated. Of the few reports of PPARγ protein expression 
in urothelial cells grown in vitro, none have identified which of the two isoforms is 
involved. Two groups have demonstrated the expression of PPARγ in NHU cells grown 
in KSFMc by western blotting (Kawakami et al., 2002; Varley et al., 2004a); both 
groups used the E-8 antibody clone produced by Santa Cruz Biotechnology Inc., and 
demonstrated the expression of a single PPARγ band. Georgopolous et al. later 
demonstrated the expression of three E-8 reactive bands by western blotting, in NHU 
cells which had been transduced to overexpress human telomerase reverse transcriptase 
(hTERT). The authors also showed that there were changes in the expression of the 
three bands following PPARγ activation using the TZ/PD protocol (Georgopoulos et al., 
2011). The corresponding molecular weight of the protein bands observed was not 
reported in any of the three papers described above, making it difficult to infer which of 
the PPARγ isoforms was being recognised.  
 
More recently, Strand et al. investigated the expression of PPARγ in human prostate 
epithelial cells. The authors demonstrated that the prostate epithelial cells expressed 
both the PPARγ1 and PPARγ2 isoforms by western blotting, and showed that when 
PPARγ2 was knocked down using shRNA, the cells upregulated the expression of 
CK20, a urothelial superficial cell-associated marker (Strand et al., 2013). This work 
suggested that it was the expression of PPARγ1, and not PPARγ2 which was important 
for urothelial-type differentiation, although the work was completed using prostate 
epithelial cells. 
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Another important aspect of PPARγ expression in urothelial cells in vitro is defining the 
localisation of the protein in the cells, which has only minimally been investigated 
(Varley et al., 2004a; Varley et al., 2004b). Varley et al. demonstrated that at low 
density, when NHU cells were grown in KSFMc, they displayed primarily cytoplasmic 
PPARγ expression. This was also shown to be the case when cells were treated with the 
PPARγ agonist, troglitazone (TZ). The localisation of PPARγ changed when the cells 
were treated with PD153035 (PD), where the expression became nuclear. When the 
cells were treated with both TZ and PD, PPARγ expression was also nuclear. The E-8 
antibody from Santa Cruz Biotechnology Inc. was used for the immunofluorescence in 
this instance. This work suggested that when the proliferative phenotype of NHU cells 
was blocked, by using an EGFR tyrosine kinase inhibitor, PPARγ translocates to the 
nucleus. The authors further showed that use of PD153035 resulted in a reduction of 
phosphorylated PPARγ, and suggested that dephosphorylation of PPARγ was associated 
with its subsequent translocation to the nucleus (Varley et al., 2004a). 
 
4.1.2 Role and Expression of GATA3 in Urothelial Cells 
The transcription factor, GATA3, has been identified as an important diagnostic and 
prognostic marker of bladder cancer (Miyamoto et al., 2012), but its role in normal 
healthy human urothelial cells has not yet been investigated. Other potentially related 
transcription factors like PPARγ, FOXA1 and ELF3, have been shown to have key roles 
in both bladder cancer (Biton et al., 2014; Cancer Genome Atlas Research, 2014; 
Eriksson et al., 2015), as well as important roles in the differentiation of normal human 
urothelial cells (Varley et al., 2004a; Varley et al., 2009; Böck et al., 2014). Questions 
have arisen as to whether GATA3 may also hold a regulatory role in the differentiation 
of normal urothelial cells given that it has been shown to be expressed in urothelial cells 
(Böck et al., 2014; Li et al., 2014b), and its noted role in bladder cancer. 
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 Aim 
Based on the results presented in Chapter 3, were GATA3 and PPARγ expression was 
shown to be weak/absent in NHB cells in comparison to NHU cells, the aim of this 
chapter was to: 
 Investigate the expression and role of the transcription factors, PPARγ and 
GATA3, in normal human urothelial cell identity and differentiation. 
 
 
 Experimental Objectives 
The objectives of this chapter were to: 
 Assess GATA3 transcript expression following PPARγ activation using the 
TZ/PD protocol. 
 Examine the expression of the PPARγ1 and PPARγ2 transcript variants in 
urothelial cells. 
 Determine which of the two PPARγ protein isoforms is important for normal 
human urothelial cell differentiation. 
 Examine the protein expression of GATA3, PPARγ, FOXA1 and ELF3 in 
urothelial cells following PPARγ activation by using the TZ/PD protocol. 
 Investigate the effect of GATA3 knockdown on the expression of urothelial 
differentiation-associated genes. 
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 Experimental Approach 
4.4.1 PPARγ Transcript Variants and Protein Isoforms 
Gene expression of PPARγ was evaluated by RT-PCR in NHU cells to assess which of 
the PPARγ transcript variants was expressed. PCR was performed using two sets of 
primers, which used the same reverse primer (Table 4.1). Since all four of the main 
PPARγ transcript variants contain exons 1-6 (Figure 4.1), ‘total PPARγ’ gene 
expression was evaluated using a forward PCR primer designed to a sequence in exon 1, 
and reverse PCR primer designed to a sequence in exon 6. The full length PCR product 
size generated using the exon 1 and exon 6 primers was 1209 bp. To evaluate PPARγ2-
specific expression, a forward PCR primer was designed to a sequence in exon B, and 
the same reverse primer as above, designed to a sequence in exon 6, was used; exon B is 
specific to the PPARγ2 protein coding transcript variant. The full length PCR product 
size generated using the exon B and exon 6 primers was 1288 bp. 
 
NHU cells used for this experiment were grown and differentiated by Mrs. Ros Duke, a 
research technician at the Jack Birch Unit. The subsequent RNA extraction, cDNA 
synthesis, and PCR was performed by Dr. Joanna Pearson, who is also a research 
technician at the Jack Birch Unit. 
 
Table 4.1 PPARG-Specific Primer Sequences 
Target Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Total PPARG ACTTTGGGATCAGCTCCGTG GGGCTTGTAGCAGGTTGTCT 
PPARG2 TCCTTCACTGATACACTGTCTGC GGGCTTGTAGCAGGTTGTCT 
The forward ‘total PPARG’ primer is designed to sequence in exon 1. The forward 
PPARG2 primer is designed to a sequence in exon B. Both primer sets have the same 
reverse primer which is designed to a sequence in exon 6. 
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Figure 4.1 PPARγ Gene Structure and Main Protein Isoforms 
A) The most recent description of the human PPARG gene structure defines ten exons: 
A1.1, A1.2, A2, B and 1-6 (Aprile et al., 2014). Alternative splicing of these exons 
results in the production of four main protein coding transcript variants, which are 
used to produce the PPARγ1 and PPARγ2 proteins. 
B) The PPARγ1 protein is produced from the translation of exons 1-6. The PPARγ2 
protein is produced from the translation of a portion of exon B plus exons 1-6, which 
results in the human PPARγ2 protein having the same amino acid sequence as 
PPARγ1, with an additional 28 amino acids at the N terminus (Fajas et al., 1997). 
This figure is adapted from (Aprile et al., 2014). 
 
To investigate which of the two PPARγ protein isoforms was expressed in NHU cells, 
whole protein lysates were generated from NHU cells following growth in KSFMc, and 
following use of the TZ/PD and ABS/Ca2+ protocols. Protein expression was assessed 
by western blotting using the ‘total PPARγ’ antibodies E-8 (Santa Cruz), 81B8 (Cell 
Signaling), D69 (Cell Signaling), and the PPARγ2-specific antibody, N-19 (Santa 
Cruz). 
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4.4.2 Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) 
Activation and Inhibition 
The TZ/PD protocol was used throughout this chapter as a means of activating PPARγ 
in NHU cells. Use of the TZ/PD protocol with NHU cells has been previously shown to 
cause upregulation of the transcription factors, ELF3, FOXA1 and IRF1 (Varley et al., 
2009; Böck et al., 2014), as well as upregulation of urothelial differentiation-associated 
genes like CK20, the uroplakins, and several claudins (Varley et al., 2004a; Varley et 
al., 2006). In all of the cases, the upregulation was demonstrated to be specifically as a 
result of PPARγ activation by use of the PPARγ-specific antagonists, GW9662 or 
T0070907, which abrogated the upregulation. 
 
To determine whether PPARγ activation had any effect on GATA3 or PPARγ gene 
expression, NHU cells were subjected to the TZ/PD protocol. In one set of experiments, 
the protein expression of transcription factors, PPARγ, GATA3, FOXA1 and ELF3 was 
evaluated in NHU cells treated with TZ/PD for 12, 24, 48, 72 or 166 hours. All cultures, 
including controls, contained 0.1 % DMSO as the vehicle. Protein expression was 
investigated by western blotting and immunofluorescence. FOXA1 and ELF3 were 
investigated due to their known upregulation as a result of PPARγ activation in NHU 
cells, as verification of successful use of the TZ/PD protocol. The expression of the 
nuclear receptor, RXRα, was also investigated by western blotting due to its known role 
as a dimerization partner required for PPARγ function. To demonstrate successful 
transitional-type differentiation of the NHU cells using TZ/PD, CK13 expression was 
assessed in immunoblotting experiments, and CK20 expression was assessed in 
immunofluorescence experiments. 
 
To investigate whether gene upregulation caused in response to TZ/PD was specifically 
as a result of PPARγ activation, NHU cells (Y1153) were pretreated with 1 μM of the 
non-competitive PPARγ antagonist, T0070907 (IC50 = 1 nM) (Cambridge Bioscience, 
CAY10026), for 3 hours prior to the start of the TZ/PD protocol. The use of the 
inhibitor prior to TZ/PD treatment was based on previously published work (Varley et 
al., 2006). Total RNA was isolated following subsequent use of the TZ/PD protocol for 
6, 24, 48 and 72 hours. Control cells were treated with 0.1 % DMSO (vehicle control). 
Cell culture, cell treatment, and RNA extraction for this experiment was carried out by 
Chapter 4 
165 
Tom Wahlicht as part of an undergraduate research project at the Jack Birch Unit. The 
RNA generated from this experiment was used to produce cDNA, and perform the 
subsequent PCR shown in this chapter. 
 
4.4.3 Urothelial Carcinoma-Derived Cell Lines 
The expression of PPARγ was investigated in various human bladder carcinoma-derived 
cell lines by western blotting. The protein lysates used to generate the western blot were 
originally produced by either Shu Guo (MPhil student in the Jack Birch Unit) or Ros 
Duke (research technician at the Jack Birch Unit). All cell lines were previously 
genotyped and mycoplasma tested upon arrival to the Jack Birch Unit. A list of the cell 
lines investigated with relevant information pertaining to their derivation and culture 
conditions can be found below in Table 4.2: 
 
Table 4.2 Bladder Carcinoma-Derived Cell Lines 
Cell Line Derivation Growth Medium (% Serum) 
5637 Grade II carcinoma RPMI (5% FBS) (Standard) or 
KSFM (Adapted)* 
UMUC9 Grade III carcinoma DMEM (10% FBS) 
RT4 Grade I carcinoma DMEM:RPMI (50:50) (5% FBS) 
EJ Grade III carcinoma DMEM:RPMI (50:50) (5% FBS) 
RT112 Grade II carcinoma DMEM:RPMI (50:50) (5% FBS) 
* The standard growth medium for 5637 cells is Roswell Park Memorial Institute 
(RPMI) medium - 1640 with 5% FBS. The cells were adapted for growth in KSFM with 
no serum by Shu Guo as part of her MPhil project. 
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4.4.4 Proteasome Inhibition 
MG132 (Sigma, C2211) is a potent proteasome inhibitor. Previous work in adipocyte-
cells (murine fibroblasts differentiated to adipocytes) revealed that treatment of the cells 
with MG132 resulted in an upregulation of PPARγ protein expression, suggesting that 
PPARγ was being degraded by the proteasome (Hauser et al., 2000). 
 
The use of MG132 was employed to investigate whether PPARγ protein was being 
degraded by the proteasome in NHU cells. PPARγ activation was induced in NHU cells 
by using the TZ/PD protocol for 72 hours. Control cells were treated with 0.1 % DMSO 
(vehicle control). The medium was then changed, and the cells were either treated with 
0.1 % DMSO (vehicle control) or 12.5 μM MG132 for 6 hours. The concentration of 
MG132 used was based on previously published work in NHU cells (Varley et al., 
2006). 
 
4.4.5 GATA3 Knockdown Using siRNA 
Transfection of NHU cells with GATA3 siRNA was used to investigate the effect of 
GATA3 knockdown on the expression of urothelium-associated transcription factors 
and differentiation-associated genes. 
 
GATA3 siRNA was titrated before use to determine an optimal concentration which 
provided knockdown of GATA3 expression, with minimal associated cell death. NHU 
cells (Y1752) were transfected with either 50 nM or 100 nM of each of the GATA3 
siRNAs, and then PPARγ was activated using the TZ/PD protocol for 48 hours to 
induce differentiation-associated genes. Control cells were treated with the transfection 
reagent only, followed by use of the TZ/PD protocol for 48 hours. 
 
Using the optimal siRNA concentration determined, two independent NHU cell lines, 
(Y1356 and Y938) were transfected with either CTRL-siRNA1, CTRL-siRNA2, 
GATA3-siRNA1 or GATA3-siRNA2 for 4 hours, and then PPARγ was activated using 
the TZ/PD protocol for 48 hours. A third NHU cell line (Y1815) was transfected with 
either CTRL-siRNA1, GATA3-siRNA1 or GATA3-siRNA2, and the protocol was 
followed as above.  
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 Results 
4.5.1 GATA3 Transcript Expression in NHU Cells Following PPARγ 
Activation and Inhibition 
GATA3 transcript expression could be shown in NHU cells (Y1153) by RT-PCR 
(Figure 4.2). Treatment of the cells with TZ/PD upregulated GATA3 expression after 
48 and 72 hours. Use of the PPARγ antagonist, T0070907, abrogated the upregulation 
caused by TZ/PD. 
 
Using RT-qPCR, some of the results obtained using RT-PCR were confirmed. GATA3 
transcript expression was upregulated upon treatment of NHU cells (Y1281) with 
TZ/PD at the 12, 24 and 48 hour time points, in comparison to control cells (Figure 4.3 
A). GATA3 expression also increased in control cells as time progressed. FOXA1 
expression was evaluated as a control for comparison, due to its known upregulation in 
NHU cells in response to TZ/PD (Figure 4.3).  
 
 
 
Figure 4.2. Evaluation of GATA3 Transcript Expression by RT-PCR in Urothelial 
Cells Following PPARγ Activation and Inhibition 
NHU cells (Y1153) were treated with either the vehicle control (0.1 % DMSO), TZ/PD or 
1 μM T0070907 plus TZ/PD for either 6, 24, 48 or 72 hours. Total RNA was extracted 
and cDNA produced. GATA3 expression was assessed by PCR (27 cycles). GAPDH was 
used as a loading control (25 cycles). H2O (no template) was used as a negative control 
(-). Genomic DNA was used as the positive control for the PCR (+). Note upregulation of 
GATA3 transcript expression as a result of TZ/PD at 48 and 72 hours. Treatment with the 
PPARγ antagonist, T0070907, appears to abrogate this upregulation. 
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Figure 4.3. RT-qPCR analysis of GATA3 and FOXA1 Transcript Expression in 
NHU Cells Following PPARγ Activation using the TZ/PD Protocol 
NHU cells (Y1281) were treated with either 0.1% DMSO (vehicle control) or TZ/PD 
for 12, 24 or 48 hours. Total RNA was extracted and cDNA produced. The expression 
of A) GATA3 and B) FOXA1 was evaluated by qPCR. All values were normalised to 
GAPDH expression, and are shown relative to the 12 hour DMSO time point. Error 
bars represent the standard deviation of the three technical replicates. Note upregulation 
of GATA3 transcript expression as a result of TZ/PD treatment at all time points 
assessed in NHU cells. 
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4.5.2 PPARγ Transcript Expression in NHU Cells 
The expression of PPARγ transcript in NHU cells was assessed by RT-PCR. In three 
independent NHU cell lines (Y1361, Y1393 and Y1289) PPARγ expression was 
observed in both control cells (0.1 % DMSO), and in cells where PPARγ had been 
activated using the TZ/PD protocol. Using the ‘total PPARγ’ primers (primers designed 
to sequences in exon 1 and exon 6) a large band corresponding to the full length PCR 
product could be observed at approximately 1200 bp in all of the samples (Figure 4.4). 
A number of smaller PCR products were also produced using these primers, which 
could possibly correspond to alternate splice variants that are missing internal exons. 
PPARγ expression could also be shown in UMUC9 cells, which acted as a positive 
control due to their known PPARγ expression. 
 
The expression of PPARγ2 was also evaluated in NHU cells at the transcript level by 
RT-PCR using the PPARγ2-specific primers (primers designed to sequences in exon B 
and exon 6) (Figure 4.5 A). PPARγ2 expression was weak/absent in the single NHU 
cell line (Y939) assessed, under all conditions (0.1 % DMSO, TZ/PD and ABS/Ca2+). 
PPARγ2 expression was also evaluated in UMUC9 cells, and an obvious PCR product 
was observed. The expression of UPK2 was evaluated for this experiment to 
demonstrate successful differentiation of the NHU cells using both the TZ/PD and 
ABS/Ca2+ protocols; a clear upregulation of UPK2 expression could be observed using 
both protocols (Figure 4.5 B). 
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Figure 4.4 Analysis of PPARγ Transcript Expression by RT-PCR in Three 
Independent NHU Cell Lines Following PPARγ Activation Using the TZ/PD Protocol  
Three independent NHU cell lines (Y1361, Y1393, Y1289) were treated with either the 
vehicle control (0.1% DMSO), or TZ/PD for either 4 or 7 Days. Total RNA was extracted 
and cDNA produced. Total PPARγ (forward primer in exon 1 and reverse primer in exon 
6) expression was assessed by PCR (35 cycles). H2O (no template) was used as a negative 
control (-). Expression of PPARγ in UMUC9 cells, was used as a positive control (+). 
The full length PCR product size produced using these primers should be 1209 bp. Note 
the clear full length PPARγ PCR product in all samples except for the negative control 
(-). Possible alternate PPARγ splice variants, missing internal exons, were also observed 
as distinct smaller PCR products. 
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Figure 4.5 Analysis of PPARγ2 Transcript Expression in NHU Cells by RT-PCR 
NHU cells (Y939) were treated with either the vehicle control (0.1% DMSO), or TZ/PD, 
or ABS/Ca2+ for 3 or 7 Days. Total RNA was extracted and cDNA produced.  
A) PPARγ2 (forward primer in exon B and reverse primer in exon 6) expression was 
assessed by RT-PCR (35 cycles). 
B) UPK2 expression was evaluated to demonstrate differentiation of the cells. 
H2O (no template) was used as a negative control (-). cDNA generated from the total 
RNA of UMUC9 cells, was used as a positive control (+). The full length PCR product 
size produced using these primers should be 1288 bp. Note the absence of PPARγ2 PCR 
product in all NHU samples. 
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4.5.3 PPARγ Protein Expression in NHU Cells Evaluated Using 
Different PPARγ Antibodies 
PPARγ protein expression was assessed in NHU cells using the four different PPARγ 
antibodies (antibodies outlined in detail in the Appendix) (E-8, 81B8, D69 and N-19) 
(Figure 4.6). Using the three ‘total PPARγ’ antibodies (E-8, 81B8 and D69), PPARγ1 
expression was shown to be weak/absent in the control cells (0.1% DMSO). When 
PPARγ was activated using the TZ/PD protocol, a band corresponding to PPARγ1 
expression (approximately 52 kDa) was observed. NHU cells treated with the ABS/Ca2+ 
protocol for 12 days also displayed PPARγ1 protein expression. 
 
As was observed with the MCF-7 cells (see Appendix), use of the E-8 antibody 
identified a number of additional protein bands, including a band directly below the 
PPARγ1-associated band (Figure 4.6 A). In NHU cells, a band corresponding to the 
approximate size of the PPARγ2 protein (57 kDa) was also observed using the E-8 
antibody, but was not observed using either the 81B8 or D69 antibodies. 
 
The PPARγ2-specific antibody (N-19) was used to determine if PPARγ2 protein was 
expressed in NHU cells (Y1390 and Y1230) (Figure 4.6 D). No band corresponding to 
PPARγ2 could be observed in any of the NHU cell samples, although a number of 
additional bands were observed in the ABS/Ca2+ differentiated cells, including a doublet 
of bands at approximately (52-54 kDa). These bands were not observed using any of the 
‘total PPARγ’ antibodies, and are therefore unlikely to be associated with PPARγ2 
protein. 
 
PPARγ2 protein expression was further examined in another NHU cell line (Y1691), 
following PPARγ activation using the TZ/PD protocol for 72 or 144 hours (Figure 4.7). 
No obvious PPARγ2 protein expression could be observed in the control or TZ/PD 
treated cells at either of the time points assessed. 
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Figure 4.6 Assessment of PPARγ Protein Expression in NHU Cells Evaluated Using 
Several Different PPARγ Antibodies by Western Blotting 
NHU cells (Y1390) were treated with either 0.1% DMSO or TZ/PD for 72 hours. A 
further NHU cell line, Y1230, was differentiated using ABS/Ca2+ for 12 days. Total 
PPARγ expression was assessed, by western blotting, using the (A) E-8 (Santa Cruz), (B) 
81B8 (Cell Signaling), and (C) D69 (Cell Signaling) antibodies. PPARγ2 expression was 
assessed using the (D) N-19 (Santa Cruz) antibody. MCF-7 cells overexpressing either 
PPARγ1 or PPARγ2 were included as positive controls. 25 μg of protein was loaded into 
each well. Arrows indicate the positions of the PPARγ1 and PPARγ2 bands. Note clear 
PPARγ1 protein expression in the TZ/PD and ABS/Ca2+ samples using the E-8, 81B8 and 
D69 antibodies. 
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Figure 4.7 Examination of PPARγ2 Expression by Western Blotting in NHU Cells 
Following PPARγ Activation using the TZ/PD Protocol  
NHU cells (Y1691) were treated with either 0.1% DMSO or TZ/PD for 72 and 144 hours. 
PPARγ2 expression was assessed by western blotting using the N-19 (Santa Cruz) 
antibody. MCF-7 cells overexpressing PPARγ2 were included as positive control. 20 μg 
of protein was loaded into each well. Note absent PPARγ2 expression in the NHU cells. 
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4.5.4 Expression of ELF3, FOXA1, GATA3 and PPARγ in NHU 
Cells Following PPARγ Activation using the TZ/PD Protocol 
The expression of PPARγ and GATA3 was evaluated in NHU cells following PPARγ 
activation (by use of the TZ/PD protocol) for 24, 48, 72 and 144 hours. Transcription 
factors, ELF3 and FOXA1, were also evaluated as controls due to their known role 
downstream of PPARγ in urothelial cell differentiation. CK13 expression was evaluated 
as an internal control to demonstrate successful induction of differentiation using 
TZ/PD. CK13 expression became noticeably upregulated starting at the 48 hour TZ/PD 
time point. 
 
By western blotting, NHU cells from two independent cell lines (Y1642 and Y1677) 
displayed considerable upregulation of ELF3 and FOXA1 expression as a result of 
PPARγ activation, as would be expected (Figure 4.8). PPARγ1 was weakly expressed at 
all of the time points assessed, but became upregulated starting at the 48 hour TZ/PD 
time point. GATA3 expression was very weak at all of the time points, although there 
was an obvious upregulation following 72 and 144 hours of TZ/PD treatment. RXRα 
expression was also evaluated, and was expressed at all of the time points in both 
control and treated cells.  
 
By indirect immunofluorescence, NHU cells from three independent cell lines (Y1642, 
Y1677, and Y1541) displayed nuclear expression of ELF3 which appeared upregulated 
as a result of PPARγ activation at all of the time points assessed (Figure 4.9 A). 
FOXA1/2 expression was clearly nuclear in both control and TZ/PD treated cells, but a 
noticeable upregulation was observed as a result of PPARγ activation (Figure 4.9 B). 
GATA3 expression was nuclear in all cases, with a clear upregulation in control cells at 
the 144 hour time point (Figure 4.9 C). GATA3 expression also appeared upregulated as 
a result of PPARγ activation at all of the time points assessed. PPARγ expression was 
nuclear in control and TZ/PD treated cells (Figure 4.9 D). A clear upregulation of 
expression could be observed starting at the 48 hour TZ/PD time point. 
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Figure 4.8. Evaluation of Transcription Factor, and Other Urothelial 
Cell-Associated Protein Expression by Western Blotting in NHU Cells Following 
PPARγ Activation 
NHU cells (Y1677) were treated with either 0.1% DMSO (vehicle control) or TZ/PD 
for 24, 48, 72 or 144 hours. ELF3, FOXA1 (Santa Cruz, Q-6), GATA3, PPARγ (Cell 
Signaling, D69), and RXRα protein expression was assessed by western blotting. For 
PPARγ expression, the band corresponding to PPARγ1 (approximately 52 kDa) is 
shown. β-actin was used as a loading control. CK13 expression was evaluated to 
demonstrate induction of transitional-type differentiation. An additional NHU cell line 
(Y1642) was also evaluated for this experiment, and its figure can be found in 
Appendix 7.6. 25 μg of protein was loaded into each well. Note the clear upregulation 
of ELF3, FOXA1, GATA3 and PPARγ expression following use of the TZ/PD 
protocol. 
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Figure 4.9. Evaluation of Transcription Factor Protein Expression in NHU Cells Following PPARγ Activation using the TZ/PD Protocol for 12, 
24, 48, 72 and 144 hours by Indirect Immunofluorescence Microscopy – A) ELF3 
NHU cells (Y1677) were treated with either 0.1% DMSO (vehicle control) or TZ/PD for 12, 24, 48, 72 and 144 hours. Immunofluorescence labelling 
for (A) ELF3, (B) FOXA1/2 (Santa Cruz, C-20), (C) GATA3 and (D) PPARγ (Cell Signaling, D69) was performed on formalin-fixed slides which had 
been permeabilised with Triton X-100. Inset images represent the corresponding Hoechst 33258 staining to demonstrate cell density and nuclei 
location. All antibody labelled images were taken at the same exposure to enable for comparison of expression between the untreated and treated cells, 
and between the different time points. Hoechst 33258 images were taken at optimal exposures. Two additional NHU cell lines (Y1642 and Y1541) 
were evaluated for the purpose of this experiment, and their figures can be found in Appendix 7.6. CK20 expression was assessed to demonstrate 
successful TZ/PD differentiation at the 144 hour time point; an example of this can be found in Appendix 7.6. 
A 
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Figure 4.9. Evaluation of Transcription Factor Protein Expression in NHU Cells Following PPARγ Activation using the TZ/PD Protocol for 12, 
24, 48, 72 and 144 hours by Indirect Immunofluorescence Microscopy – A) FOXA1/2 
See main caption on page 177. Note nuclear expression of FOXA1/2 in NHU cells, with upregulated expression associated with PPARγ activation. 
 
 
 
 
B 
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Figure 4.9. Evaluation of Transcription Factor Protein Expression in NHU Cells Following PPARγ Activation using the TZ/PD Protocol for 12, 
24, 48, 72 and 144 hours by Indirect Immunofluorescence Microscopy – C) GATA3 
See main caption on page 177. Note nuclear expression of GATA3 in NHU cells, with clear upregulated expression associated with PPARγ activation. 
 
 
 
 
C 
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Figure 4.9. Evaluation of Transcription Factor Protein Expression in NHU Cells Following PPARγ Activation using the TZ/PD Protocol for 12, 
24, 48, 72 and 144 hours by Indirect Immunofluorescence Microscopy – D) PPARγ 
See main caption on page 177. Note nuclear expression of PPARγ in NHU cells, with upregulated expression associated with PPARγ activation. 
 
D 
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4.5.5 PPARγ Protein Expression in Native Human Urothelium 
By western blotting, freshly isolated urothelium from three independent human donor 
tissue samples (Urothelium-1, Y1772, Ureter; Urothelium-2, Y1773, Ureter; 
Urothelium-3, Y1774, Renal Pelvis) displayed abundant expression of PPARγ1 (Figure 
4.10 A). Using the D69 antibody (Cell Signaling) a possible PPARγ2 band could be 
observed in each of the samples at approximately 57 kDa. Using the PPARγ2-specific 
antibody, N-19 (Santa Cruz), it was shown that this band was not PPARγ2, and that no 
PPARγ2 expression could be observed in any of the urothelium protein lysates (Figure 
4.10 B & C). 
 
 
4.5.6 PPARγ Protein Expression in Urothelial Carcinoma-Derived 
Cell Lines 
The expression of PPARγ1 protein could be observed in UMUC9 cells, RT4 cells, 
RT112 cells, and 5637 cells grown in RPMI plus 5 % FBS, by western blotting (Figure 
4.11). PPARγ1 protein expression was absent in EJ cells, as well as in 5637 cells that 
were grown in KSFM. Using the D69 antibody (Cell Signaling), a band corresponding 
to the appropriate height for PPARγ2 (approximately 57 kDa) could be observed in the 
5637 cells grown in KSFM. Further assessment of PPARγ2 protein expression, using 
the N-19 antibody (Santa Cruz), revealed that this band in the 5637 cells was not 
PPARγ2. None of the urothelial carcinoma-derived cell lines evaluated displayed any 
detectable PPARγ2 protein. 
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Figure 4.10 Evaluation of PPARγ Protein Expression in Native Urothelium by 
Western Blotting 
The urothelium from three independent human donor tissue samples (Urothelium-1, 
Y1772, Ureter; Urothelium-2, Y1773, Ureter; Urothelium-3, Y1774, Renal Pelvis) was 
isolated; after removing the urothelium using forceps, the urothelium cell sheets were 
pelleted by centrifugation, and whole protein lysates were generated. Expression of (A) 
total PPARγ (Cell signaling, D69) and (B) PPARγ2 (Santa Cruz, N-19) was assessed by 
western blotting. The corresponding color images were overlaid for the two antibodies in 
(C). Histone 3 (H3) expression was used as a loading control. MCF-7 cells 
overexpressing either PPARγ1 or PPARγ2 were included as positive controls for each 
antibody. 20 μg of protein was loaded into each well. Note clear PPARγ1 protein 
expression and an absence of PPARγ2 protein expression in native urothelium. 
Chapter 4 
183 
 
Figure 4.11 Assessment of PPARγ Protein Expression in Urothelial Carcinoma-Derived Cell Lines by Western Blotting 
The expression of (A) total PPARγ (Cell Signaling, D69) and (B) PPARγ2 (Santa Cruz, N-19) was assessed in several urothelial carcinoma-derived 
cell lines by western blotting. The corresponding colour images were overlaid for the two antibodies in (C). Histone 3 (H3) expression was used as a 
loading control. MCF-7 cells overexpressing either PPARγ1 or PPARγ2 were included as positive controls for each antibody. 20 μg of protein was 
loaded into each well. Note PPARγ1 protein expression in 5637 cells grown in RPMI plus 5 % FBS, UMUC9 cells, RT4 cells and RT112 cells. 
PPARγ2 expression was absent in all of the urothelial carcinoma-derived cell lines. 
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4.5.7 Expression of PPARγ Protein in NHU Cells Following 
Proteasome Inhibition 
Since PPARγ1 protein expression appeared fairly weak in NHU cells, even following 
activation of PPARγ using TZ/PD, the proteasome inhibitor, MG132, was used to 
determine if PPARγ protein was being degraded by the proteasome.  
 
By western blotting, it was shown that the addition of the proteasome inhibitor to NHU 
cells caused a dramatic increase in PPARγ1 expression in both control (0.1% DMSO) 
and TZ/PD treated cells (Figure 4.12). NHU cells from two independent cell lines 
(Y1390 and Y1691) were assessed for the purpose of this experiment, with both cell 
lines showing a similar trend in expression. 
 
Treatment of UMUC9 cells with MG132 was also evaluated, for comparison. UMUC9 
cells expressed high levels of PPARγ1 under normal growth conditions. After treatment 
with MG132, a slight increase in PPARγ1 expression was observed (Figure 4.12 B). 
 
Proteasome inhibition did not result in any gain of PPARγ2 protein expression in either 
NHU cells or UMUC9 cells. 
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Figure 4.12 Evaluation of PPARγ Protein Expression by Western Blotting in NHU 
Cells and UMUC9 Cells Following Proteasome Inhibition 
A) Western blot showing PPARγ protein expression (Cell Signaling, D69) in NHU cells 
(Y1390) treated with the proteasome inhibitor, MG132 (MG). NHU cells were first 
treated with either 0.1% DMSO (vehicle control) or TZ/PD for 72 hours. The 
medium was then changed, and the cells were either treated with 0.1% DMSO 
(vehicle control) or 12.5 μM MG132 for 6 hours. 
B) Western blot showing PPARγ protein expression (Cell Signaling, D69) in UMUC9 
cells treated with either 0.1% DMSO (vehicle control) or 12.5 μM MG132 for 6 
hours. 
The band corresponding to PPARγ1 (approximately 52 kDa) is indicated. β-actin was 
used as a loading control. 20 μg of protein was loaded into each well. The graphs shown 
represent densitometry analysis for the respective PPARγ1 protein expression. Data is 
shown relative to the DMSO treated cells. All values were first normalised to β-actin 
expression. An additional NHU cell line (Y1691) was completed for this experiment (see 
Appendix 7.6), which showed similar results to the NHU cell line shown above. Note 
clear upregulation of PPARγ1 protein expression in NHU cells following treatment with 
MG132. PPARγ2 expression was absent and not affected by proteasome inhibition in 
NHU cells or UMUC9 cells. 
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4.5.8 GATA3 Knockdown Using siRNA Prior to PPARγ Activation  
4.5.8.1 GATA3 siRNA Titration 
NHU cells (Y1752) displayed knockdown of GATA3 protein expression following 
transfection with either GATA3-siRNA1 or GATA3-siRNA2 at both the 50 nM and 
100 nM concentrations (Figure 4.13 A). Densitometry analysis of the corresponding 
western blot revealed that GATA3-siRNA2 was more effective at GATA3 knockdown 
than GATA3-siRNA1 (Figure 4.13 B). At the 100 nM concentration both GATA3 
siRNAs were able to reduce GATA3 protein expression by greater than 55%. 100 nM 
was chosen as the concentration to proceed with for the following experiments. At both 
siRNA concentrations, the cells survived and looked typical of being treated with 
TZ/PD alone. 
 
4.5.8.2 Effect of GATA3 Knockdown on the Expression of Urothelial 
Differentiation-Associated Transcription Factors 
GATA3 knockdown was shown to be significant using both of the GATA3 siRNAs 
relative to control siRNA, by RT-qPCR (P ≤ 0.001) (Figure 4.14 A). By western 
blotting, GATA3-siRNA1 did not result in a significant knockdown of GATA3 protein, 
while GATA3-siRNA2 did cause a significant (P ≤ 0.01) knockdown of GATA3 protein 
in NHU cells (Figure 4.15). There was no significant change (P > 0.05) in FOXA1 
transcript (Figure 4.14 B) or protein expression (Figure 4.15), as a result of GATA3 
knockdown. PPARγ expression was significantly (P ≤ 0.05) downregulated at the 
transcript level (Figure 4.14 C), but this was not observed at the protein level (Figure 
4.15); PPARγ protein expression appeared very weak in all of the NHU cell lines at the 
time point investigated (48 hr TZ/PD). 
 
4.5.8.3 Effect of GATA3 Knockdown on the Expression of Urothelial 
Differentiation-Associated Genes 
Knockdown of GATA3 resulted in a significant (P ≤ 0.01) downregulation of CK13 
protein expression by GATA3-siRNA2 (Figure 4.16 A & B). It also caused a significant 
(P ≤ 0.001) downregulation of UPK2 gene expression, which was demonstrated by 
RT-qPCR analysis (Figure 4.16 C). 
Chapter 4 
187 
 
Figure 4.13. Effectiveness of GATA3 siRNA Evaluated by Western Blotting 
NHU cells (Y1752) were transfected with 50 nM and 100 nM of either GATA3-siRNA1 
or GATA3-siRNA2 for 4 hours, and then PPARγ was activated using the TZ/PD protocol 
for 48 hours. Control cells were treated with the transfection reagent only, followed by 
TZ/PD for 48 hours (denoted as 0 nM siRNA in the figures). 
A) Western blot demonstrating GATA3 knockdown using both of the GATA3 siRNAs 
at 50 and 100 nM. RT4 cells were used as a positive control for GATA3 protein 
expression. β-actin was used as a loading control. 25 μg of protein was loaded into 
each well. 
B) Densitometry analysis of the GATA3 protein expression (bands designated by arrow 
in A) shown relative to β-actin expression. 
Note knockdown of GATA3 protein expression by both GATA3-siRNA1 and 
GATA3-siRNA2 at both the 50 nM and 100 nM concentrations. 
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Figure 4.14. Effect of GATA3 Knockdown on Urothelial Differentiation-Associated 
Transcription Factor Expression Evaluated by RT-qPCR 
RT-qPCR data was generated for (A) GATA3, (B) FOXA1, and (C) PPARγ gene 
expression using three independent NHU cell lines (Y1356, Y938, and Y1815) 
transfected with siRNA. Cultures were transfected with 100 nM of either CTRL-siRNA1, 
GATA3-siRNA1 or GATA3-siRNA2 for 4 hours, and then PPARγ was activated using 
TZ/PD for 48 hours. Values are shown as the mean of the three independent cell lines 
relative to CTRL-siRNA1. Error bars represent the standard deviation of the mean of the 
three independent NHU cell lines. All values were first normalised to GAPDH 
expression. Statistical analysis was performed using a one-way ANOVA test with a 
Dunnett’s multiple comparisons post-hoc test. * represents P ≤ 0.05. ** represents P ≤ 
0.01. *** represents P ≤ 0.001. ns = not significant, P > 0.05. Note significant knockdown 
of GATA3 in NHU cells as a result of transfection with GATA3 siRNA. There was no 
effect on FOXA1 transcript expression. PPARγ transcript was significantly 
downregulated as a result of GATA3 knockdown. 
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Figure 4.15. Effect of GATA3 Knockdown on Urothelial Cell Differentiation-
Associated Transcription Factor Protein Expression Evaluated by Western Blotting 
NHU cells from three independent cell lines (Y1356, Y938, and Y1815) were transfected 
with 100 nM of either CTRL-siRNA1, CTRL-siRNA2, GATA3-siRNA1 or 
GATA3-siRNA2 for 4 hours, and then PPARγ was activated using the TZ/PD protocol 
for 48 hours.  
A) GATA3, FOXA1 (Santa Cruz, Q-6), and PPARγ (Cell Signaling, D69) expression 
was assessed by western blotting. β-actin was used as a loading control. RT4 cells 
were used as a positive control for each antibody. Western blots for the cell line 
Y1356 are shown. Western blots for the two additional NHU cell lines (Y938 and 
Y1815) can be found in Appendix 7.6. 30 μg of protein was loaded into each well. 
B) Densitometry analysis of GATA3 and FOXA1 protein expression shown relative to 
CTRL-siRNA1. All values were first normalised to β-actin expression. Data is 
represented as the mean of the three independent transfected NHU cell lines (Y1356, 
Y938, and Y1815). Error bars represent the standard deviation of the mean of the 
three independent cell lines. Statistical analysis was performed using a one-way 
ANOVA test with a Dunnett’s multiple comparisons post-hoc test. ** represents 
P ≤ 0.01. ns = not significant, P > 0.05. 
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Figure 4.16. Effect of GATA3 Knockdown on the Expression of Urothelial 
Differentiation-Associated Genes Evaluated by Western Blotting and RT-qPCR 
NHU cells from three independent cell lines (Y1356, Y938, and Y1815) were transfected 
with 100 nM of either CTRL-siRNA1, CTRL-siRNA2, GATA3-siRNA1 or GATA3-
siRNA2 for 4 hours, and then PPARγ was activated using the TZ/PD protocol for 48 
hours. 
A) Representative western blot showing CK13 expression in NHU cells (Y1356) 
following GATA3 knockdown. β-actin was used as a loading control. 20 μg of 
protein was loaded into each well. 
B) Densitometry analysis of CK13 protein expression in the three independent NHU cell 
lines (Y1356, Y938, and Y1815). All values were first normalised to β-actin. 
C) RT-qPCR data generated for UPK2 gene expression using the three independent 
NHU cell lines (Y1356, Y938, and Y1815). All values were first normalised to 
GAPDH. 
Data is shown as the mean of the three independent cell lines (Y1356, Y938, and Y1815) 
relative to CTRL-siRNA1. Error bars represent the standard deviation of the mean of the 
three independent NHU cell lines. Statistical analysis was performed using a one-way 
ANOVA test with a Dunnett’s multiple comparisons post-hoc test. ** represents P ≤ 0.01 
*** represents P ≤ 0.001. ns = not significant, P > 0.05. 
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 Summary of Results 
 GATA3 transcript and protein expression was upregulated in NHU cells as a result 
of TZ/PD treatment. This upregulation was likely attributed to PPARγ activation, as 
use of the PPARγ antagonist, T0070907, appeared to abrogate the upregulation. 
 
 PPARγ expression could be shown at the transcript level by RT-PCR in NHU cells. 
Use of PPARγ2-specific PCR primers revealed weak/absent PPARγ2 expression 
even following activation of PPARγ using the TZ/PD protocol. This suggested that 
the PPARγ expression shown using the PCR primers that amplify ‘total PPARγ’ was 
almost entirely attributable to transcript variants encoding for the PPARγ1 protein. 
The potential for the expression of novel alternate transcript variants was also 
revealed using the ‘total PPARγ’ PCR primers. 
 
 The primary PPARγ protein isoform detected in native human urothelium, cultured 
NHU cells, and several urothelial carcinoma-derived cell lines was PPARγ1. 
PPARγ2 protein expression could not be obviously detected in any of the cell types. 
 
 Significant knockdown of GATA3 expression could be successfully demonstrated at 
both the transcript and protein levels in NHU cells following transfection with 
GATA3-targeted siRNAs. 
 
 GATA3 was shown to have a potentially important regulatory role in the 
differentiation of urothelial cells. Knockdown of GATA3 expression by siRNA 
revealed a significant downregulation of both CK13 and UPK2 expression. 
 
 GATA3 also appears to contribute to the regulation of key transcription factors 
involved in urothelial differentiation, as GATA3 knockdown also resulted in the 
significant downregulation of PPARγ transcript expression. 
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5 Overexpression of GATA3 and PPARγ1 in 
Buccal Epithelial Cells 
 
 Rationale and Aims 
Results presented in Chapter 3, comparing transcription factor expression between 
buccal epithelial cells and urothelial cells, saw noticeably weak expression of GATA3 
and PPARγ. Use of the TZ/PD, atRA/PD or ABS/Ca2+ protocols with NHB cells did not 
cause any obvious upregulation of GATA3 or PPARγ expression. These observations 
suggested not only that abundant expression of GATA3 and PPARγ may be critical for 
maintaining the urothelial cell identity, but also that low expression of GATA3 and 
PPARγ expression may be important for maintaining a squamous epithelial cell 
phenotype. In Chapter 4, PPARγ1 was identified as the primary PPARγ protein isoform 
involved in urothelial cell differentiation. In addition to this, GATA3 was shown to 
have a potential role in regulating the differentiation of urothelial cells. As a result, 
GATA3 and PPARγ1 were chosen to overexpress in NHB cells in an initial attempt to 
transdifferentiate NHB cells into NHU cells. 
 
The aim of this chapter was to assess the ability of individual GATA3 overexpression 
and PPARγ1 overexpression to cause urothelial-type transdifferentiation of NHB cells. 
 
 Hypothesis 
The hypothesis was that individual overexpression of GATA3 or PPARγ1 in NHB cells 
would have the ability to upregulate urothelium-associated genes and downregulate 
squamous epithelial cell-associated genes. 
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 Experimental Approach 
The results portion of this chapter is separated into two sections (Chapter 5A and 
Chapter 5B), where Chapter 5A corresponds to results pertaining to GATA3 
overexpression in NHB cells, and Chapter 5B corresponds to PPARγ1 overexpression 
in NHB cells. 
 
To assess the propensity for either GATA3 overexpression or PPARγ1 overexpression 
to cause urothelial-type transdifferentiation of NHB cells, transduced NHB cells were 
assessed for their expression of urothelium-associated transcription factors, urothelium-
associated differentiation markers, the squamous epithelial cell-associated protein 
(CK14), and barrier function, following use of the TZ/PD, atRA/PD and/or ABS/Ca2+ 
protocols. For urothelial-type transdifferentiation, the ultimate goal would be to 
upregulate urothelium-associated transcription factors and differentiation-associated 
genes, and promote barrier function. The expectation would also be to downregulate 
squamous epithelial cell-associated genes. A table outlining experiments which were 
performed on GATA3 overexpressing and PPARγ1 overexpressing cells, and the 
markers assessed can be found in Table 5.1. Based on the results presented in Chapter 3 
and Chapter 4, the work in this chapter aimed to assess whether individual GATA3 
overexpression or PPARγ1 overexpression in NHB cells could: 
1. Upregulate and cause nuclear localisation of key urothelial differentiation-
associated transcription factors, ELF3, FOXA1, GATA3 and PPARγ1. 
2. Cause upregulation of the urothelium differentiation-associated uroplakin genes. 
3. Cause downregulation of CK14 expression, a squamous epithelial cell-
associated cytokeratin. 
4. Cause an increase in barrier function, as measured by the TER. Various tight 
junction-associated proteins were also assessed to evaluate whether any changes 
in their expression had occurred. 
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Table 5.1 Summary of Experiments Performed to Assess the Transdifferentiation 
Potential of GATA3 Overexpression and PPARγ1 Overexpression in NHB Cells 
Protocol Makers Assessed Technique Used 
TZ/PD 
Transcription Factors 
ELF3 
FOXA1 
GATA3 
PPARγ 
RT-qPCR 
Western Blotting 
Immunofluorescence 
Uroplakin Genes 
UPK1A 
UPK1B 
UPK2 
UPK3A 
UPK3B 
RT-qPCR 
 
atRA/PD 
Transcription Factors 
ELF3 
FOXA1 
GATA3 
IRF1 
PPARγ 
RT-PCR 
Immunofluorescence 
Western Blotting 
Cytokeratins 
CK13 
CK14 
Immunofluorescence 
ABS/Ca2+ 
Transcription Factors 
GATA3 
PPARγ 
FOXA1 
Western Blotting 
Tight Junction 
Proteins 
CLDN3 
CLDN4 
CLDN5 
CLDN7 
ZO-1 
ZO-3 
Western Blotting 
Cytokeratins 
CK13 
CK14 
Western Blotting 
Barrier Function  TER 
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5.3.1 GATA3 Overexpression and PPARγ1 Overexpression 
NHB cells were transduced with retroviruses generated from PT67 cells transfected 
with either the empty pLXSN vector (control), the pLXSN vector containing the eGFP 
coding sequence (control), the pLXSN vector containing the GATA3 coding sequence, 
or the pLXSN vector containing the PPARγ1 coding sequence. Successfully transduced 
cells were maintained under antibiotic (0.025 mg/ml G418) selection. Details of the 
generation of the pLXSN-GATA3 vector and its subsequent transfection into PT67 cells 
can be found in Chapter 2 of this thesis. 
 
The pLXSN-eGFP vector was previously generated, transfected into PT67 cells, and 
verified for use by Dr. Joanna Pearson, a research technician at the Jack Birch Unit. The 
PPARγ1 overexpression vector was previously generated, and transfected into PT67 
cells by Ms. Jenny Hinley, a research technician at the Jack Birch Unit. 
 
5.3.2 FOXA1 Antibodies for Immunofluorescence Microscopy 
Two different antibodies were used to assess FOXA1 expression by 
immunofluorescence microscopy in this chapter, the C-20 antibody (Santa Cruz), which 
detects both FOXA1 and FOXA2 expression, and the Q-6 antibody (Santa Cruz), which 
is specific for FOXA1 expression. The C-20 antibody was used for 
immunofluorescence in the two previous chapters. The Q-6 antibody was used for 
FOXA1 detection by western blotting in all of the chapters. Its use for 
immunofluorescence was introduced in this chapter as a potentially more specific 
antibody for detecting FOXA1 expression than the C-20 antibody. The antibody used 
for each experiment is identified in the figure legends. Overall, both antibodies gave 
similar results. 
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 Results – Part A (GATA3 Overexpression)  
5.4.1 GATA3 Overexpression in NHB Cells 
Forced overexpression of GATA3 in NHB cells resulted in no obvious changes to cell 
morphology by phase contrast microscopy (Figure 5.1 A). GATA3 overexpression 
could be successfully demonstrated in NHB cells by RT-PCR and immunofluorescence 
microscopy (Figure 5.1 B & C). GATA3 expression was nuclear in the GATA3 
overexpressing cells. In control transduced cells (eGFP/Empty), GATA3 expression 
was weak/absent. 
 
5.4.2 Evaluation of Transcription Factor Expression in Control and 
GATA3 Overexpressing NHB Cells Following TZ/PD 
Treatment 
Forced overexpression of GATA3 in NHB cells resulted in an upregulation of ELF3 and 
FOXA1 transcript in two independent transduced NHB cell lines (AS008b and Y1590) 
following use of the TZ/PD protocol for 72 hours (Figure 5.2). PPARγ transcript 
expression was variable in the two cell lines assessed; one transduced cell line 
(AS008b) demonstrated an upregulation of PPARγ expression, while the other cell line 
(Y1590) showed a slight decrease in PPARγ expression as a result of GATA3 
overexpression. 
 
By western blotting, no obvious change in FOXA1 protein expression was observed as 
a result of GATA3 overexpression in two independent cell lines (Y1590 and Y1595) 
which had been treated with either 0.1 % DMSO or TZ/PD for 72 hours (Figure 5.3). 
PPARγ protein expression was absent in both control and GATA3 overexpressing cells 
even after use of the TZ/PD protocol. Clear GATA3 overexpression could be shown by 
western blotting in both DMSO and TZ/PD treated GATA3 overexpressing NHB cells. 
 
By immunofluorescence, ELF3 expression appeared to have increased nuclear 
localisation as a result of GATA3 overexpression when the cells were treated with 
TZ/PD (Figure 5.4). There was no obvious change in localisation of FOXA1. PPARγ 
expression was weak/absent in all cases. GATA3 expression was clearly nuclear in the 
GATA3 overexpressing cells, and absent in control (Empty) cells. 
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Figure 5.1 Demonstration of GATA3 Overexpression in NHB Cells (AS008b) 
A) Phase contrast images of control (eGFP) and GATA3 overexpressing NHB cells 
(AS008b). Scale bar = 200 μm. 
B) RT-PCR analysis of GATA3 gene expression in control (eGFP) and GATA3 
overexpressing NHB cells (AS008b). GATA3 PCR was performed using 30 cycles. 
GAPDH was used as a loading control (25 cycles). H2O (no template) was used as the 
negative control (-). Genomic DNA was used as a positive control for the PCR (+). 
C) Immunofluorescence labelling for GATA3 was performed on formalin-fixed slides 
permeabilised with Triton X-100. Inset images represent the corresponding Hoechst 
33258 staining to demonstrate cell density and nuclei location. Antibody labelled 
images were taken at the same exposure. Hoechst 33258 images were taken at 
optimal exposures. Note there was no obvious change in cell morphology as result of 
GATA3 overexpression. GATA3 overexpression could be clearly demonstrated by 
both RT-PCR and immunofluorescence microscopy. 
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Figure 5.2 Analysis of ELF3, FOXA1, GATA3 and PPARG Transcript Expression by RT-qPCR in Control and GATA3 Overexpressing 
NHB Cells Following TZ/PD Treatment for 72 hours 
Control (eGFP or Empty) and GATA3 overexpressing NHB cells A) AS008b and B) Y1590 were treated with TZ/PD for 72 hr. RNA was extracted 
and cDNA generated. qPCR data is shown for GATA3, ELF3, FOXA1, and PPARG gene expression. All values were normalised to GAPDH and are 
shown relative to the control (eGFP or Empty) cells for each gene. Data is shown as the mean of three technical replicates. Error bars represent the 
standard deviation of the three technical replicates. Note clear overexpression of GATA3 transcript. Also note upregulation of ELF3 and FOXA1 in 
two independent transduced NHB cell lines. PPARγ expression was variable between the two independent NHB cell lines. 
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Figure 5.3 Evaluation of GATA3, FOXA1 and PPARγ Protein Expression by 
Western Blotting in Control and GATA3 Overexpressing NHB Cells Following 
Treatment with 0.1 % DMSO or TZ/PD for 72 hour 
Control (Empty) and GATA3 overexpressing NHB cells A) Y1595 and B) Y1590, were 
treated with either 0.1% DMSO (vehicle control) or TZ/PD for 72 hr. Whole protein 
lysates were generated. GATA3, FOXA1 (Santa Cruz, Q-6), and PPARγ (Cell 
Signalling, D69) expression was assessed by western blotting. The band corresponding 
to PPARγ1 (approximately 52 kDa) is shown. NHU cells (Y1282 and Y1691 
respectively), which were treated with TZ/PD for 72 hours, were included on each of the 
blots to act as positive controls. β-actin was used as a loading control. 25 μg of protein 
was loaded into each well. Note clear overexpression of GATA3 protein. Also note there 
was no obvious change in FOXA1 or PPARγ protein expression as a result of GATA3 
overexpression in NHB cells even following use of the TZ/PD protocol. 
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Figure 5.4 Evaluation of ELF3, FOXA1, GATA3, and PPARγ Expression by Indirect Immunofluorescence Microscopy in Control and 
GATA3 Overexpressing NHB Cells Treated with 0.1 % DMSO or TZ/PD for 72 Hours 
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Figure 5.4 Evaluation of ELF3, FOXA1, GATA3, and PPARγ Expression by Indirect 
Immunofluorescence Microscopy in Control and GATA3 Overexpressing NHB Cells 
Treated with 0.1 % DMSO or TZ/PD for 72 Hours 
Control (Empty) and GATA3 overexpressing NHB cells (Y1595) were treated with either 
0.1 % DMSO (vehicle control) or TZ/PD for 72 hours. Immunofluorescence labelling for 
ELF3, FOXA1 (Santa Cruz, Q-6), GATA3 and PPARγ (Cell Signaling, D69) was 
performed on formalin-fixed slides which had been permeabilised with Triton X-100. 
Inset images represent the corresponding Hoechst 33258 staining to demonstrate cell 
density and nuclei location. Antibody labelled images were taken at the same exposure 
for each antibody. Hoechst 33258 images were taken at optimal exposures. NHU cells 
(Y1752) which had been treated with TZ/PD for 48 hours were used as positive controls. 
An additional transduced cell line (Y1590) was also evaluated for the purpose of this 
experiment, and its figure can be found in Appendix 7.7. Note clear nuclear localisation 
of GATA3 in the GATA3 overexpressing cells, and absent GATA3 expression in control 
(Empty) cells. Also note possible increased nuclear localisation of ELF3 in the GATA3 
overexpressing NHB cells following use of the TZ/PD protocol. FOXA1 and PPARγ 
expression were unchanged by GATA3 overexpression. 
 
 
 
5.4.3 Evaluation of Uroplakin Gene Expression in Control and 
GATA3 Overexpressing NHB Cells Following use of the TZ/PD 
Protocol for 72 Hours 
The expression of the five uroplakin genes was assessed by RT-qPCR in two 
independent transduced NHB cell lines (AS008b and Y1590) following use of the 
TZ/PD protocol for 72 hours (Figure 5.5). UPK1A and UPK3A gene expression was not 
detectable in either cell line. UPK1B expression was slightly increased in one of the 
NHB cell lines (AS008b), but had no obvious change in expression in the other cell line 
(Y1590), as a result of GATA3 overexpression. UPK2 and UPK3B expression was 
increased in both cell lines as a result of GATA3 overexpression following use of the 
TZ/PD protocol. 
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Figure 5.5 RT-qPCR analysis of Uroplakin Gene Expression in Control and GATA3 Overexpressing NHB Cells (AS008b) Following 
Treatment with TZ/PD for 72 Hours 
Control (eGFP or Empty) and GATA3 overexpressing NHB cells, A) AS008b and B) Y1590, were treated with TZ/PD for 72 hr. RNA was extracted 
and cDNA generated. qPCR data was generated for UPK1A, UPK1B, UPK2, UPK3A, and UPK3B gene expression. UPK1A and UPK3A expression 
was absent in both cell lines and is therefore not shown. All values were normalised to GAPDH expression, and are shown relative to the control 
(eGFP or Empty) cells for each gene. Data is shown as the mean of three technical replicates. Error bars represent the standard deviation of the three 
technical replicates. Note increased UPK2 andUPK3B expression in the two independent NHB cells lines as a result of GATA3 overexpression. 
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5.4.4 Evaluation of Transcription Factor and Cytokeratin Protein 
Expression in Control and GATA3 Overexpressing NHB Cells 
Treated with the atRA/PD Protocol for 72 hours 
Treatment of control (eGFP) and GATA3 overexpressing NHB cells with the atRA/PD 
protocol for 72 hours resulted in no obvious change in ELF3, FOXA1, IRF1 or PPARG 
transcript expression, as a result of GATA3 overxpression. An upregulation of FOXA1 
expression was found in both the control (eGFP) and GATA3 overexpressing cells by 
both RT-PCR (Figure 5.6) and immunofluorescence microscopy (Figure 5.7). 
 
No obvious change in CK13 or CK14 expression was observed in atRA/PD treated 
GATA3 overexpressing cells in comparison to control (eGFP) cells by 
immunofluorescence (Figure 5.7). 
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Figure 5.6 Analysis of Transcription Factor Expression by RT-PCR in Control and 
GATA3 Overexpressing NHB Cells Following use of the atRA/PD Protocol for 72 
Hours 
Control (eGFP) and GATA3 overexpressing NHB cells (AS008b) were treated with 
either 1 μM PD or 1 μM PD plus 100 nM atRA for 72 hours. RT-PCR was performed 
using 30 cycles for all target genes. GAPDH was used as a loading control (25 cycles). 
H2O (no template) was used as the negative control (-). Genomic DNA was used as a 
positive control for the PCR (+). Note clear GATA3 overexpression. Also note no 
obvious change in ELF3, FOXA1, IRF1 or PPARG expression as a result of GATA3 
overexpression even following treatment with atRA. 
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Figure 5.7 Evaluation of Transcription Factor and Cytokeratin Protein Expression by Indirect Immunofluorescence Microscopy in Control 
and GATA3 Overexpressing NHB Cells Following use of the atRA/PD Protocol for 72 Hours 
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Figure 5.7 Evaluation of Transcription Factor and Cytokeratin Protein Expression 
by Indirect Immunofluorescence Microscopy in Control and GATA3 Overexpressing 
NHB Cells Following use of the atRA/PD Protocol for 72 Hours 
Control (Empty) and GATA3 overexpressing NHB cells (AS008b) were treated with 
either 1 μM PD or 1 μM PD plus 100 nM atRA for 72 hours. Immunofluorescence 
labelling for A) FOXA1 (Santa Cruz, Q-6), and GATA3, and B) CK13 and CK14, was 
performed on formalin-fixed slides which had been permeabilised with Triton X-100. 
Inset images represent the corresponding Hoechst 33258 staining to demonstrate cell 
density and nuclei location. Antibody labelled images were taken at the same exposure 
for each antibody. Hoechst 33258 images were taken at optimal exposures. NHU cells 
(Y1156) which had been treated with TZ/PD for 72 hours were used as positive controls 
for FOXA1, GATA3 and CK13 expression. Scale bar = 50 μm. Note no obvious change 
in FOXA1, CK13, or CK14 protein expression as a result of GATA3 overexpression and 
subsequent PD or atRA/PD treatment. 
 
5.4.5 Assessment of Tight Junction-Associated Protein Expression in 
Control and GATA3 Overexpressing NHB Cells During use of 
the ABS/Ca2+ Protocol 
The expression of several tight junction-associated proteins was assessed during use of 
the ABS/Ca2+ protocol in two independent transduced NHB cell lines (Y1595 and 
AS011b) by western blotting (Figure 5.8). A clear upregulation of CLDN3 protein 
expression was observed as a result of GATA3 overexpression at all of the time points. 
No obvious change in CLDN4, CLDN5 or CLDN7 protein expression was observed as 
a result of GATA3 overexpression; they were expressed at all of the time points in both 
cell types. ZO-1 expression varied between the two cell lines, but there was no clear 
trend in expression as a result of GATA3 overexpression. Overexpression of GATA3 
was observed at all of the time points assessed in the GATA3 overexpressing cells. 
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5.4.6 Evaluation of CK14 Expression in Control and GATA3 
Overexpressing NHB Cells During use of the ABS/Ca2+ 
Protocol 
CK14 was strongly expressed at all of the time points assessed during use of the 
ABS/Ca2+ protocol, in both control and GATA3 overexpressing NHB cells (Y1595 and 
AS011b) (Figure 5.9). NHU cells (Y1336) which had been differentiated with 
ABS/Ca2+, and included on the same western blots for comparison, showed a 
characteristic lack of CK14 expression. 
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Figure 5.8 Assessment of Tight Junction-Associated Protein Expression by Western 
Blotting in Control and GATA3 Overexpressing NHB Cells During use of the 
ABS/Ca2+ Protocol 
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Figure 5.8 Evaluation of Tight Junction-Associated Protein Expression by Western 
Blotting in Control and GATA3 Overexpressing NHB Cells During use of the 
ABS/Ca2+ Protocol 
Control (Empty) and GATA3 overexpressing NHB cells from two independent NHB cell 
lines (Y1595 and AS011b) were subjected to the ABS/Ca2+protocol for up to 7 days. 
Whole protein lysates were generated on the days indicated. 
A) CLDN3, CLDN4, CLDN5, CLDN7, and ZO-1 protein expression was assessed by 
western blotting. Evaluation of GATA3 expression demonstrated successful GATA3 
overexpression at all of the time points. Western blots for the transduced NHB cell 
line, Y1595, are shown. β-actin was used as a loading control. Protein extracted from 
NHU cells (Y1336), which had been differentiated with ABS/Ca2+ for 5 days, was 
included on the same western blots, and used as a positive control. 25 μg of protein 
was loaded into each well. 
B) Densitometry analysis of CLDN3 protein expression at each of the time points during 
use of the ABS/Ca2+ protocol. Data is shown for the western blot above, 
corresponding to Y1595. All values were normalised to β-actin expression. 
The western blot figures for the additional cell line (AS011b), which showed similar 
results, can be found in Appendix 7.7. 
Note clear upregulation of CLDN3 expression as a result of GATA3 overexpression in 
NHB cells at all time points during use of the ABS/Ca2+ protocol. The other tight 
junction-associated proteins examined were not obviously affected by GATA3 
overexpression. 
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Figure 5.9 Analysis of CK14 Expression by Western Blotting in Control and GATA3 
Overexpressing NHB Cells During use of the ABS/Ca2+ Protocol 
Control (Empty) and GATA3 overexpressing NHB cells from two independent cell lines 
A) Y1595 and B) AS011b were subjected to the ABS/Ca2+protocol for up to 7 days. 
Whole protein lysates were generated on the days indicated. CK14 expression was 
assessed by western blotting. β-actin was used as a loading control. A whole protein 
lystate from NHU cells (Y1336), which had been differentiated with ABS/Ca2+ for 5 
days, was included on the same western blots for comparison. 25 μg of protein was 
loaded into each well. Note no reduction in CK14 expression (a squamous epithelial cell-
associated protein) as a result of GATA3 overexpression in NHB cells during use of the 
ABS/Ca2+ protocol. The NHU cells showed a characteristic lack of CK14 expression. 
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5.4.7 Assessment of Barrier Function in Control and GATA3 
Overexpressing NHB Cells During use of the ABS/Ca2+ 
Protocol 
GATA3 overexpression had no obvious effect on the barrier function of NHB cells 
in vitro (Figure 5.10). Using a single transduced NHB cell line (AS011b), the TER was 
measured for seven days during use of the ABS/Ca2+ protocol. Control (eGFP) and 
GATA3 overexpressing cells maintained a TER below 150 Ω·cm2 at all of the time 
points assessed. 
 
 
Figure 5.10 Transepithelial Electrical Resistance Measurement Time Course for 
Control and GATA3 Overexpressing NHB Cells During use of the ABS/Ca2+ Protocol 
Control (eGFP) and GATA3 overexpressing NHB cells (AS011b) were pre-treated with 
5% ABS for 5 days, and then passaged and seeded onto Greiner Bio-One 12-well 
ThinCert™ cell culture inserts. The calcium concentration was increased to 2 mM after 
24 hours. The TER was measured every day for eight days. Data is shown as the mean of 
three technical replicates. Error bars represent the standard deviation from the mean of 
n = 3 technical replicates. Note there was no gain in barrier function as a result of 
GATA3 overexpression during use of the ABS/Ca2+ protocol. 
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 Summary of Results (Chapter 5A) 
 NHB cells were successfully transduced, using retrovirus, to overexpress 
GATA3. Successful GATA3 overexpression could be shown at both the 
transcript and protein levels. 
 
 GATA3 overexpression resulted in an upregulation of ELF3 and FOXA1 
(urothelium-associated transcription factors) transcript expression following 
treatment with TZ/PD for 72 hours. By western blotting, no obvious changes in 
ELF3, FOXA1 or PPARγ expression could be observed, but by 
immunofluorescence there appeared to be increased nuclear localisation of ELF3 
as result of TZ/PD treatment in GATA3 overexpressing NHB cells. 
 
 The expression of the urothelium-associated differentiation markers, UPK2 and 
UPK3B, was upregulated as a result of GATA3 overexpression, when the 
TZ/PD protocol was followed. 
 
 Use of the atRA/PD protocol resulted in an increase in FOXA1 expression in 
both control (eGFP) and GATA3 overexpressing cells. There was no 
downregulation of CK14 expression as a result of GATA3 expression even 
when the atRA/PD protocol was followed. 
 
 During use of the ABS/Ca2+ protocol, the expression of urothelial barrier 
function-associated tight junction protein, CLDN3, was upregulated as a result 
of GATA3 overexpression. The expression of other constitutively expressed 
tight junction proteins (CLDN4, CLDN5, CLDN7 and ZO-1) was not affected 
by GATA3 overexpression. 
 
 GATA3 overexpression did not result in any gain of barrier function, as 
measured by TER, when the ABS/Ca2+ protocol was applied. 
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 Results – Part B (PPARγ1 Overexpression) 
5.6.1 PPARγ1 Overexpression in Human Buccal Epithelial Cells 
NHB cells transduced to overexpress PPARγ1 had no obvious change in cell 
morphology in comparison to control cells (Empty) (Figure 5.11 A). Cultures grew as 
usual. Successful overexpression of PPARγ gene expression was demonstrated by RT-
PCR (Figure 5.11 B) and RT-qPCR (Figure 5.12).  
 
 
Figure 5.11 Phase Contrast Images and Analysis of PPARγ Expression by RT-PCR 
in Control and PPARγ1 Overexpressing NHB Cells 
A) Phase contrast images of control (Empty) and PPARγ1 overexpressing NHB cells 
(AS011b). Scale bar = 200 μm 
B) RT-PCR analysis of PPARγ gene expression in control (Empty) and PPARγ1 
overexpressing NHB cells (AS011b). PPARγ PCR (primers in exon 1 and exon 6) 
was completed using 35 cycles. GAPDH was used as a loading control (25 cycles). 
Note overexpression of PPARγ transcript expression shown by RT-PCR. 
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5.6.2  Assessment of ELF3, FOXA1, GATA3 and PPARγ Expression 
after use of the TZ/PD Protocol for 72 Hours in Control and 
PPARγ1 Overexpressing NHB Cells 
FOXA1 and GATA3 transcript expression was upregulated as a result applying the 
TZ/PD protocol in PPARγ1 overexpressing cells in three independent transduced cell 
lines (AS021b, Y1721 and AS011b) (Figure 5.12). ELF3 expression was assessed in 
two of the cell lines (AS021b and Y1721), and a clear upregulation of expression could 
be observed as a result of PPARγ1 overexpression. Overexpression of PPARγ transcript 
was evident in all three of the transduced NHB cell lines. 
 
By western blotting, FOXA1 protein expression showed a dramatic, but not significant 
(P > 0.05), increase in expression in both DMSO and TZ/PD treated PPARγ1 
overexpressing cells, from four independent transduced NHB cell lines (Y1600, 
AS027b, AS021b and AS011b) (Figure 5.13). GATA3 protein expression was weak to 
absent in all of the cell lines. There was no obvious change in ELF3 protein expression 
as a result of PPARγ1 overexpression even following use of the TZ/PD protocol. 
 
By immunofluorescence, ELF3 expression appeared more intensely nuclear in the 
TZ/PD treated PPARγ1 overexpressing cells, in comparison to control (Empty) cells, in 
three independent transduced NHB cell lines (AS027b, Y1600, Y1656) (Figure 5.14). 
FOXA1 expression appeared nuclear, and a possible upregulation of expression was 
observed in the TZ/PD treated PPARγ1 overexpressing cells. Nuclear GATA3 
expression was observed in the TZ/PD treated PPARγ1 overexpressing cells in two of 
the transduced cell lines (AS027b and Y1600); GATA3 expression was otherwise 
negative. Clear nuclear expression of PPARγ could be observed in both the DMSO and 
TZ/PD treated PPARγ1 overexpressing cells. 
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Figure 5.12 RT-qPCR Analysis of PPARG, ELF3, FOXA1 and GATA3 Transcript 
Expression in Control and PPARγ1 Overexpressing NHB Cells Treated with TZ/PD 
for 72 Hours 
Control (Empty) and PPARγ1 overexpressing NHB cells (AS021b) were treated with 
TZ/PD for 72 hr. RNA was extracted and cDNA produced. qPCR data was generated to 
evaluate A) PPARγ, B) ELF3, C) FOXA1 and D) GATA3 expression. Values are shown 
relative to the control (Empty) cells. Gene expression was first normalised to GAPDH 
expression. Error bars represent the standard deviation of three technical replicates. Two 
additional transduced NHB cell lines (Y1721 and AS011b) were also evaluated for this 
experiment, and showed similar results. The figures can be found in Appendix 7.8. Note 
clear upregulation of ELF3, FOXA1, and GATA3 transcript expression as a result of 
PPARγ1 overexpression in NHB cells following use of the TZ/PD protocol. 
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Figure 5.13 Analysis of ELF3, FOXA1, GATA3 and PPARγ Protein Expression by 
Western Blotting in Control and PPARγ1 Overexpressing NHB Cells Treated with 
either 0.1 % DMSO or TZ/PD for 72 Hours 
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Figure 5.13 Analysis of ELF3, FOXA1, GATA3 and PPARγ Protein Expression by 
Western Blotting in Control and PPARγ1 Overexpressing NHB Cells Treated with 
either 0.1 % DMSO or TZ/PD for 72 Hours 
Control (Empty) and PPARγ1 overexpressing NHB cells, A) Y1600, B) AS027b, C) 
AS021b, D) AS011b, were treated with either 0.1% DMSO (vehicle control) or TZ/PD 
for 72 hr. Whole protein lysates were generated. ELF3, FOXA1 (Santa Cruz, Q-6), 
GATA3 and PPARγ (D69 for A, B and C; E-8 for D) expression was assessed by western 
blotting. The band corresponding to PPARγ1 (approximately 52 kDa) is shown. Various 
protein lysates were included on each of the blots to act as positive controls (CTRL) 
including RT4 cells, UMUC9 cells, and NHU cells treated with TZ/PD for 72 hours. 
β-actin was used as a loading control. Note clear PPARγ1 overexpression in all of the 
NHB cell lines. Also note the upregulation of FOXA1 expression as a result of PPARγ1 
overexpression in NHB cells. ELF3 and GATA3 expression were not obviously affected 
by the PPARγ1 overexpression in DMSO or TZ/PD treated transduced NHB cells. 
E) Densitometry analysis of FOXA1 protein expression shown relative to control cells 
(Empty-DMSO). All values were first normalised to β-actin. Data is shown as the mean 
of the four independent NHB cell lines shown above (Y1600, AS027b, AS021b, 
AS011b). Error bars represent the standard deviation of the mean of the four independent 
cell lines. Statistical analysis was completed using a one-way ANOVA test, but found no 
statistical difference (P > 0.05). 
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Figure 5.14 Evaluation of ELF3, FOXA1, GATA3 and PPARγ Protein Expression by Immunofluorescence Microscopy in Control and 
PPARγ1 Overexpressing NHB Cells Treated with 0.1 % DMSO or TZ/PD for 72 hours 
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Figure 5.14 Evaluation of ELF3, FOXA1, GATA3 and PPARγ Protein Expression by 
Immunofluorescence Microscopy in Control and PPARγ1 Overexpressing NHB Cells 
Treated with 0.1 % DMSO or TZ/PD for 72 hours 
Control (Empty) and PPARγ1 overexpressing NHB cells (AS027b) were treated with 
either TZ/PD for 72 hours or 0.1% DMSO (vehicle control). Immunofluorescence 
labelling for ELF3, FOXA1/2 (Santa Cruz, C-20), GATA3, and PPARγ (Cell Signaling, 
D69) was performed on formalin-fixed slides which had been permeabilised with Triton 
X-100. Inset images represent the corresponding Hoechst 33258 staining to demonstrate 
cell density and nuclei location. Antibody labelled images were taken at the same 
exposure for each antibody. Hoechst 33258 images were taken at optimal exposures. 
NHU cells (Y1541) which had been treated with TZ/PD for 72 hours were used as a 
positive controls. Two additional transduced NHB cell lines (Y1600 and Y1656) were 
also evaluated for this experiment, and showed similar results; the figures can be found in 
Appendix 7.8. Note possible increased nuclear localisation of ELF3, FOXA1 and GATA3 
as a result of TZ/PD treatment in PPARγ1 overexpressing cells. 
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5.6.3 Evaluation of Uroplakin Gene Expression in Control and 
PPARγ1 Overexpressing NHB Cells Treated with TZ/PD for 72 
Hours 
The expression of the five uroplakin genes was assessed by RT-qPCR in two 
independent transduced NHB cell lines (Y1721 and AS021b) following 72 hour TZ/PD 
treatment (Figure 5.15). The expression of UPK1A, UPK2 and UPK3B varied between 
the two cell lines. In one transduced cell line (Y1721), the expression of UPK1A, UPK2 
and UPK3B was increased as a result of PPARγ1 overexpression, while in the other cell 
line (AS021b), the expression was decreased as a result of PPARγ1 overexpression. 
UPK1B was upregulated in both transduced cell lines as a result of PPARγ1 
overexpression. UPK3A gene expression was not detectable in either cell line. 
 
5.6.4 Evaluation of FOXA1, GATA3 and PPARγ1 Gene Expression 
in Control and PPARγ1 Overexpressing NHB Cells after using 
the atRA/PD Protocol for 72 Hours 
Use of the atRA/PD protocol caused no obvious change in PPARγ1 protein expression in 
control or PPARγ1 overexpressing NHB cells (AS027b) (Figure 5.16). GATA3 expression 
appeared weak in all cases. FOXA1 expression was upregulated in PPARγ1 overexpressing 
cells which had been treated with either 1 μM PD153035 or 1 μM PD153035 plus 100 nM 
atRA. 
 
Chapter 5B 
 
222 
 
Figure 5.15 RT-qPCR Analysis of Uroplakin Gene Expression in Control and PPARγ1 Overexpressing NHB Cells treated with TZ/PD for 72 
Hours 
Control (Empty) and PPARγ1 overexpressing NHB cells, A) Y1721 and B) AS021b, were treated with TZ/PD for 72 hr. RNA was extracted and 
cDNA produced. qPCR data was generated to evaluate UPK1A, UPK1B, UPK2 and UPK3B expression. UPK3A was also evaluated but it was not 
expressed. Values are shown relative to the control (Empty) cells. Gene expression was first normalised to GAPDH expression. Error bars represent 
the standard deviation of three technical replicates. Note increased UPK1B expression in two independent transduced NHB cell lines as a result of 
PPARγ1 overexpression. Expression of UPK1A, UPK2 and UPK3B was variable between the two NHB cell lines. 
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Figure 5.16 Evaluation of PPARγ, FOXA1, and GATA3 Protein Expression by 
Western Blotting in Control and PPARγ1 Overexpressing NHB Cells Treated with 
PD or atRA/PD for 72 hours 
Control (Empty) and PPARγ1 overexpressing NHB cells (AS027b) were treated with 
either1 μM PD153035 (control) or 100 nM atRA plus 1 μM PD153035 for 72 hours. 
A) PPARγ (Cell Signaling, D69), FOXA1 (Santa Cruz, Q-6), and GATA3 expression was 
assessed by western blotting. The band corresponding to PPARγ1 (approximately 52 
kDa) is shown. β-actin was used as a loading control. NHU cells (Y1691) which had been 
treated with TZ/PD for 72 hours, were included on each of the western blots to act as a 
positive controls. 
B) Densitometry analysis of FOXA1 protein expression shown relative to control cells 
(Empty-PD). All values were first normalised to β-actin expression. 
Note upregulation of FOXA1 expression as a result of PPARγ1 overexpression in both 
PD and atRA/PD treated NHB cells. GATA3 expression was weak/absent in all cases. 
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5.6.5 Evaluation of Tight Junction Protein Expression in Control 
and PPARγ1 Overexpressing NHB Cells During use of the 
ABS/Ca2+ Protocol 
Assessment of the expression of several tight junction proteins revealed that CLDN3 
was significantly upregulated as a result of PPARγ1 overexpression during use of the 
ABS/Ca2+ protocol (Figure 5.17). CLDN4, CLDN5, CLDN7, ZO-1 and ZO-3 were all 
expressed in both control and PPARγ1 overexpressing cells; no obvious changes in 
expression were observed. 
 
5.6.6 Evaluation FOXA1 Protein Expression in Control and PPARγ1 
Overexpressing NHB Cells During use of the ABS/Ca2+ 
Protocol 
Since FOXA1 expression was increased in PPARγ overexpressing cells following use 
of the TZ/PD and atRA/PD protocols, its expression was also assessed during use of the 
ABS/Ca2+ protocol. FOXA1 expression was also upregulated as a result of PPARγ1 
overexpression during use of the ABS/Ca2+ protocol, although not significantly 
(P > 0.05) (Figure 5.18). 
 
5.6.7 Assessment of CK13 and CK14 Protein Expression in Control 
and PPARγ1 Overexpressing NHB Cells During use of the 
ABS/Ca2+ Protocol 
CK14 expression was assessed in control (Empty) and PPARγ1 overexpressing NHB 
cells by western blotting in three independent cell lines (AS027b, Y1721 and Y1600) 
differentiated with ABS/Ca2+ (Figure 5.19). PPARγ1 overexpression had no obvious 
effect on CK14 expression. Similarly, CK13 expression was assessed in two of the 
transduced cell lines (AS027b and Y1721) and showed no obvious change in expression 
as a result of PPARγ1 overexpression. NHU cells (Y1336) which had been 
differentiated with ABS/Ca2+ for 5 days were evaluated for comparison, and showed 
characteristic expression of CK13, and absent expression of CK14. 
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Figure 5.17 Evaluation of Tight Junction-Associated Protein Expression in Control 
and PPARγ1 Overexpressing NHB Cells by Western Blotting During use of the 
ABS/Ca2+ Protocol 
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Figure 5.17 Evaluation of Tight Junction-Associated Protein Expression in Control 
and PPARγ1 Overexpressing NHB Cells by Western Blotting During use of the 
ABS/Ca2+ Protocol 
Control (Empty) and PPARγ1 overexpressing NHB cells from three independent cell 
lines (AS027b, Y1721 and Y1600) were subjected to the ABS/Ca2+ protocol for up to 
eight days. Whole protein lysates were generated on the days indicated. 
A) CLDN3, CLDN4, CLDN5, CLDN7, ZO-1 and ZO-3 expression was assessed by 
western blotting. Western blots for the transduced NHB cell line, AS027b, are shown. 
β-actin was used as a loading control. Protein extracted from NHU cells (Y1336), 
which had been differentiated with ABS/Ca2+ for 5 days, was included on all of the 
western blots to act as a positive control/for comparison. 25 μg of protein was loaded 
into each well. 
B) Densitometry analysis of CLDN3 protein expression at the Day 7 time point. All 
values were normalised to β-actin. Expression is shown relative to control (Empty) 
cells. Data is shown as the mean of three independent transduced cell lines (AS027b, 
Y1721 and Y1600). Error bars represent the standard deviation of the mean of the 
three independent cell lines. Statistical analysis was performed using a two-tailed, 
paired t-test.  * represents P ≤ 0.05. 
The western blot figures for the two additional cell lines can be found in Appendix 7.8. 
Note upregulation of CLDN3 protein expression at Day 4 and 7 in PPARγ1 
overexpressing cells. All other tight junction-associated proteins assessed were unaffected 
by PPARγ1 overexpression in NHB cells during use of the ABS/Ca2+ protocol. 
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Figure 5.18 Evaluation of FOXA1 Expression in Control and PPARγ1 
Overexpressing NHB Cells by Western Blotting During use of the ABS/Ca2+ 
Protocol 
Control (Empty) and PPARγ1 overexpressing NHB cells from three independent cell 
lines (AS027b, Y1721 and Y1600) were subjected to the ABS/Ca2+ protocol for up to 
7 days. Whole protein lysates were generated on the days indicated. 
A) FOXA1 expression was assessed by western blotting. Western blots for the 
transduced NHB cell line, AS027b, are shown. β-actin was used as a loading control. 
Protein extracted from NHU cells (Y1336) which had been differentiated with 
ABS/Ca2+ for 5 days was included on all of the western blots, and used as a positive 
control. 25 μg of protein was loaded into each well. 
B) Densitometry analysis of FOXA1 protein expression at the Day 7 time point. All 
values were normalised to β-actin. Expression is shown relative to control (Empty) 
cells. Data is shown as the mean of three independent transduced cell lines (AS027b, 
Y1721 and Y1600). Error bars represent the standard deviation of the mean of the 
three independent transduced NHB cell lines. Statistical analysis was performed using 
a two-tailed, paired t-test. ns = not significant, P > 0.05. The western blot figures for 
the two additional cell lines can be found in Appendix 7.8. 
Note upregulation of FOXA1 expression as a result of PPARγ1 overexpression during 
use of the ABS/Ca2+ protocol. 
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Figure 5.19 Analysis of CK13 and CK14 Expression in Control and PPARγ1 
Overexpressing NHB Cells by Western Blotting During use of the ABS/Ca2+ Protocol 
Control (Empty) and PPARγ1 overexpressing NHB cells from three independent NHB 
cell lines, A) AS027b, B) Y1721 and C) Y1600, were subjected to the ABS/Ca2+ protocol 
for up to eight days. Whole protein lysates were generated on the days indicated. CK13 
and CK14 expression was assessed by western blotting. β-actin was used as a loading 
control. Protein extracted from NHU cells (Y1336) which had been differentiated with 
ABS/Ca2+ for 5 days were included on all of the western blots to act as a positive 
control/for comparison. 25 μg of protein was loaded into each well. Note there was no 
obvious change in CK13 or CK14 expression as a result of PPARγ1 overexpression. 
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5.6.8 Assessment of Barrier Function in Control and PPARγ1 
Overexpressing NHB Cells 
PPARγ1 overexpression had no obvious effect on the barrier function of NHB cells in 
vitro (Figure 5.20). Using a single transduced NHB cell line (Y1600), the TER was 
measured over seven days of the ABS/Ca2+ protocol. Control (Empty) and PPARγ1 
overexpressing cells maintained TER measurements below 100 Ω·cm2 at all of the time 
points assessed.  
 
 
 
Figure 5.20 Transepithelial Electrical Resistance Measurement Time Course for 
Control and PPARγ1 Overexpressing NHB Cells During use of the ABS/Ca2+ 
Protocol 
Control (Empty) and PPARγ1 overexpressing NHB cells (Y1600) were pre-treated with 
5% ABS for 5 days, and then passaged and seeded onto Greiner Bio-One 12-well 
ThinCert™ cell culture inserts. The calcium concentration was increased to 2 mM 
following 24 hours. The TER was measured every day for eight days. Data is shown as 
the mean of n = 3 technical replicates. Error bars represent the standard deviation of the 
mean of the three technical replicates. Note no gain in barrier function as a result of 
PPARγ1 overexpression while using the ABS/Ca2+ protocol. 
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 Summary of Results (Chapter 5B) 
 NHB cells were successfully transduced, using retrovirus, to overexpress 
PPARγ1. Successful PPARγ1 overexpression could be shown at both the 
transcript and protein levels. 
 
 PPARγ1 overexpression resulted in an upregulation of FOXA1 expression when 
the cells were treated with TZ/PD protocol, atRA/PD protocol, and during use of 
the ABS/Ca2+ protocol. This work suggested that when abundant PPARγ1 
expression is present it acts upstream of FOXA1 expression in NHB cells. 
 
 PPARγ1 overexpression resulted in an upregulation of ELF3 and GATA3 
transcript expression in cultures treated with TZ/PD for 72 hours. By western 
blotting, GATA3 and ELF3 expression showed no increase in expression, but by 
immunofluorescence, some increased nuclear localisation was observed in the 
TZ/PD treated PPARγ1 overexpressing cells. 
 
 UPK1B expression was upregulated as a result of PPARγ1 overexpression in the 
two transduced cell lines assessed. 
 
 CLDN3 expression was significantly upregulated as a result of PPARγ1 
overexpression during use of the ABS/Ca2+ protocol. The expression of other 
tight junction proteins (CLDN4, CLDN5, CLDN7, ZO-1 and ZO-3) was not 
affected. 
 
 PPARγ1 overexpression had no effect on the squamous epithelial cell-associated 
protein, CK14, during use of the ABS/Ca2+ protocol. 
 
 PPARγ1 overexpression did not result in any gain of barrier function, as 
measured by the TER, during use of the ABS/Ca2+ protocol. 
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6 Discussion 
 Thesis Overview 
The aim in this thesis was to investigate transcription factors involved in urothelial cell 
differentiation for the potential use of transdifferentiating human buccal epithelial cells 
into urothelial cells. To do this, first a set of transcription factors was identified which 
were differentially expressed between buccal epithelial cells and urothelial cells: ELF3, 
FOXA1, GATA3 and PPARγ. Since ELF3 and FOXA1 have been previously shown to 
act downstream of PPARγ in urothelial cells (Varley et al., 2009; Böck et al., 2014), 
PPARγ and GATA3 were identified as key upstream transcription factors to 
overexpress in buccal epithelial cells. The determined transcription factors (PPARγ and 
GATA3) were then investigated of their expression and/or role in urothelial cells to gain 
a better understanding of their importance to urothelial cell identity and differentiation. 
This work revealed that PPARγ1 was the primary PPARγ protein isoform involved in 
urothelial cell differentiation. Use of GATA3 knockdown in urothelial cells revealed 
that GATA3 likely has important regulatory roles in urothelial cell differentiation. In the 
final results chapter, the transcription factors GATA3 and PPARγ1 were individually 
overexpressed in human buccal epithelial cells, and evaluated for their ability to cause 
urothelial-type transdifferentiation. Although individual overexpression of the two 
transcription factors was unable to cause complete transdifferentiation, each were able 
to cause the upregulation of genes associated with urothelial cell differentiation and 
barrier formation. 
 
This work has provided further evidence of the importance of ELF3, FOXA1 and 
PPARγ in maintaining the urothelial cell identity and promoting differentiation. It has 
also provided preliminary evidence in support of GATA3 as a key transcription factor in 
urothelial cell differentiation. Further to this, the work has provided evidence that 
buccal epithelial cells are likely capable of being transdifferentiated into urothelial cells, 
although this will probably require the combined overexpression of several of the 
identified transcription factors.  
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 PPARγ Antibody Specificity  
6.2.1 Western Blotting 
An issue that arose with the use of the PPARγ antibodies tested in this thesis, was the 
presence of a number of additional proteins detected by western blotting, whether 
PPARγ-specific or not. Using the E-8 antibody (Santa Cruz) an obvious band could be 
observed directly below the PPARγ1-specific band at approximately 48 kDa in MCF-7 
cells (see Appendix) and NHU cells (Chapter 4). Without appropriate positive controls, 
this band could easily be confused for PPARγ1 if no true PPARγ1 band was present. In 
addition to this lower 48 kDa band, the E-8 antibody also detected a band at 
approximately 58 kDa in NHU cells, which could be shown in control, TZ/PD and 
ABS/Ca2+ treated NHU cells (Figure 4.6). Georgopoulos et al. demonstrated the 
presence of these two additional bands, using the E-8 antibody, in control NHU cells 
and NHU cells which had been immortalised by the overexpression of hTERT. The 
authors did not draw any conclusions as to which of the protein bands corresponded to 
which of the PPARγ isoforms, due to lack of appropriate positive controls, and simply 
reported the presence of three PPARγ bands (Georgopoulos et al., 2011). The presence 
of this 58 kDa band detected by the E-8 antibody is very similar in height to that of 
anticipated full length PPARγ2. Work completed in Chapter 4 of this thesis using the 
PPARγ2-specific antibody (Santa Cruz, N-19) revealed that this 58 kDa band detected 
in NHU cells by the E-8 antibody did not correspond to PPARγ2 expression (Figure 
4.7). The presence of additional bands detected by the E-8 antibody allows for possible 
misinterpretation of results, making it a poor choice of antibody to use in future for the 
detection of PPARγ expression by western blotting. 
 
Although the D69 antibody (Cell Signaling) specifically identified both PPARγ1 and 
PPARγ2 in MCF-7 cells (see Appendix), with very minimal extra bands detected, when 
it was used on whole protein extracts from native urothelium and urothelial carcinoma-
derived cell lines, several other protein bands could be detected (Figure 4.10 and Figure 
4.11). Similar to the E-8 antibody, a band at approximately 58 kDa could be observed in 
some cell types. Use of the PPARγ2-specific antibody (Santa Cruz, N-19) again 
revealed that this band was not PPARγ2 protein. 
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The E-8 antibody is one of the most widely used antibodies for detecting PPARγ protein 
expression by western blotting, with data published in hundreds of papers. Its ability to 
detect additional protein bands at such similar heights to that of true PPARγ1 and 
PPARγ2 makes the ability to trust this antibody to convincingly detect PPARγ 
expression difficult. Similarly, the presence of this additional 58 kDa band, which could 
also be detected using the D69 antibody, proved that care must be taken in the 
interpretation of results. It became clear that in order to make use of the E-8, or D69 
antibodies for detecting PPARγ by western blotting, two key additional conditions must 
be met: the use of rigorous positive controls for full length PPARγ1 and PPARγ2 
expression, as well as the added use of a PPARγ2-specific antibody to confirm any 
PPARγ2 expression detected. 
 
Interesting questions arise from this work as to the identity of these many additional 
bands detected by these PPARγ antibodies. Are these post-translationally modified 
versions of PPARγ? Are they alternative splice variants of PPARγ? Or, are they simply 
non-specific binding of the antibodies? A much more sophisticated analysis would need 
to be undertaken to answer these questions, but it is likely worth spending the time. 
 
6.2.2 Immunofluorescence 
Of the two reports demonstrating detection of PPARγ by immunofluorescence 
microscopy in NHU cells, both used methanol:acetone fixation and the E-8 antibody 
(Varley et al., 2004a; Varley et al., 2004b). Both reports demonstrated primarily 
cytoplasmic localisation of PPARγ in NHU cells grown at low confluence in KSFMc. 
When NHU cells were treated with 1 μM troglitazone, the localisation was also 
primarily cytoplasmic, but when the cells were treated with either 1 μM PD153035, or 
TZ/PD, PPARγ expression became nuclear (Varley et al., 2004a).  
 
Work shown in the Appendix, suggested that the E-8 antibody may not be specific at 
detecting PPARγ expression by immunofluorescence. Using PT67 cells, a clear 
overexpression of PPARγ could be observed above control levels, but this could not be 
shown using the MCF-7 cells (see Appendix), where a similar nuclear and cytoplasmic 
expression was observed in all of the cell types. In addition to this, it was also shown, 
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using the PT67 cells, that formalin fixation of the cells was required to best observe 
PPARγ expression using the E-8 antibody (see Appendix). This work calls into question 
the observations previously made by Varley et al, and suggests that these experiments 
warrant being repeated using either the 81B8 or D69 antibodies, which did appear more 
specific to detecting PPARγ. 
 
 PPARγ Transcript Expression in Urothelial Cells 
Evaluation of PPARγ expression at the transcript level in NHU cells revealed abundant 
expression (Figure 4.4). Use of the PPARγ2-specific PCR primers revealed very 
weak/absent expression (Figure 4.5), suggesting that the transcript identified using the 
‘total PPARγ’ primers primarily contributes to PPARγ1 protein production. Of 
particular interest was the number of additional, smaller PCR products generated using 
the ‘PPARγ total’ primers. Since the forward primer was designed to a sequence in exon 
1 and the reverse primer to a sequence in exon 6, it is possible that these smaller PCR 
products correspond to novel PPARγ transcript variants missing one or more internal 
exons. A more thorough investigation, which involves sequencing of these PCR 
products, would need to be undertaken to support this idea. 
 
Several alternate PPARγ splice variants have been described in other cell types. 
Sabatino et al. described novel PPARγ transcript variants which were produced as the 
result of a read-through into intron 4. Due to an in-frame stop codon, the protein 
produced from the variants was missing the ligand binding domain (coded by exon 5 
and 6). The authors determined that the protein acted as a dominant negative to wild-
type PPARγ, and also showed that it was unable to elicit transcription using a PPRE-
luciferase reporter assay (Sabatino et al., 2005). In a subsequent publication by the same 
group, the authors showed that expression of these novel transcript variants varied in a 
time-specific manner throughout human adipogenesis in vitro (Aprile et al., 2014). They 
suggested that PPARγ expression is likely heavily regulated through the expression of 
these alternate variants, but more work is needed to investigate this idea further. 
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Another truncated PPARγ variant has also been described, which is produced from the 
insertion of a novel exon 3’ (Kim et al., 2006). Due to an in-frame stop codon, this 
results in the protein product missing the protein segment corresponding to exons 4, 5 
and 6. The authors determined that the variant acted in a dominant negative fashion, and 
also showed that when it was overexpressed in Chinese hamster ovary (CHO) cells, it 
caused both an increase in proliferation and colony formation (Kim et al., 2006). 
 
 PPARγ Protein Expression in Urothelial Cells  
Using the PPARγ total antibody, D69 (Cell Signaling), and the PPARγ2-specific 
antibody, N-19 (Santa Cruz), it was shown in this thesis that PPARγ1 was the most 
abundant PPARγ isoform present in native urothelium, cultured NHU cells, and several 
urothelial carcinoma-derived cell lines (Chapter 4). PPARγ2 protein expression could 
not be detected in any of these cell types. 
 
In NHU cells grown in KSFMc, PPARγ1 expression was very weak, and could be 
difficult to detect by western blotting unless sufficient protein was loaded (typically a 
minimum of 25 μg) (Chapter 4). Expression was also weakly nuclear by 
immunofluorescence microscopy (Figure 4.9). Following induction to differentiate 
using TZ/PD (a PPARγ agonist and EGFR-TK inhibitor), PPARγ1 expression increased 
with a noticeable upregulation starting at 48 hours, and carrying on at the 72 and 144 
hour TZ/PD time points, by western blotting (Figure 4.8). By immunofluorescence 
microscopy, treatment of the cells with TZ/PD increased the nuclear expression, with 
maximal expression observed at both the 72 and 144 hour time points. Treatment of 
NHU cells with the proteasome inhibitor, MG132, caused a striking upregulation of 
PPARγ1 protein expression (Figure 4.12). 
 
The current prevailing view presented in the literature, suggests that PPARγ is highly 
expressed in NHU cells grown in KSFMc; two groups have previously demonstrated 
that NHU cells grown in KSFMc have clear and obvious PPARγ expression by western 
blotting (Kawakami et al., 2002; Varley et al., 2004a). As discussed in the previous 
section, it was also demonstrated that PPARγ expression in NHU cells grown at low 
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confluence in KSFMc is primarily cytoplasmic, and upon activation of PPARγ using 
TZ/PD, PPARγ translocates to the nucleus (Varley et al., 2004a). 
 
Data presented in Chapter 4 supports an alternate theory, where PPARγ expression is 
largely labile, and is weakly nuclear in NHU cells grown to confluence in KSFMc. 
Following PPARγ activation using the TZ/PD protocol, PPARγ1 expression is 
strikingly upregulated, but due to a rapid turnover rate, caused by degradation by the 
proteasome, this is observed as only a slight upregulation in expression. 
 
Georgopoulos et al. appear to have unknowingly demonstrated the upregulation of 
PPARγ1 protein expression in NHU cells treated with TZ/PD several years ago. Using 
the E-8 antibody for western blotting, the authors demonstrated the presence of three 
PPARγ protein bands, but did not identify which of the bands corresponded to which 
PPARγ isoform. Based on the results shown in this chapter, it is likely that the ‘middle’ 
band shown by Georgopoulos et al. correlates to PPARγ1 expression. If this is the case, 
the authors also demonstrated weak PPARγ1 expression in undifferentiated NHU cells, 
and showed that use of the TZ/PD protocol causes a 1.4-fold increase in expression. 
Their data would also suggest that in late passage NHU cells immortalised using 
hTERT overexpression, the upregulation of PPARγ1 as a result of TZ/PD treatment 
fails to occur. 
 
Strand et al. have also published evidence which would support this alternative model 
of PPARγ expression in NHU cells. Using prostate epithelial cells, the authors showed 
that knockdown of PPARγ2 expression results in the de novo expression of CK20, a 
protein expressed only in the superficial cells of the urothelium, which suggested that 
the presence of PPARγ2 expression was inhibitory to urothelial-type differentiation 
(Strand et al., 2013). This result agrees with the observations shown in Chapter 4 which 
demonstrate a lack of PPARγ2 expression in native urothelium, in NHU cells grown in 
KSFMc, and in NHU cells induced to differentiate using the TZ/PD protocol. Strand et 
al. also demonstrated that the knockdown of both PPARγ1 and PPARγ2 resulted in the 
loss of differentiation-associated genes, and caused an increase in CK14 expression. 
This result also supports the work presented in Chapter 4, where it was shown that 
PPARγ expression is weak in NHU cells grown in KSFMc. It is well established that 
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NHU cells grown in KSFMc express CK14, are highly proliferative, and fail to express 
genes associated with urothelial differentiation (Varley et al., 2004a; Varley et al., 
2004b; Varley et al., 2006). 
 
 The Involvement of GATA3 in Urothelial Cell 
Differentiation 
GATA3 expression was upregulated upon activation of PPARγ in NHU cells using the 
TZ/PD protocol; this could be observed at the transcript level as early as 12 hours 
following the start of TZ/PD treatment (Figure 4.3). By western blotting, GATA3 
expression was noticeably upregulated at the 72 and 144 hour TZ/PD time points 
(Figure 4.8). The PPARγ antagonist, T0070907, prior to TZ/PD, resulted in an 
inhibition of GATA3 upregulation, which was shown by RT-PCR (Figure 4.2). 
Together these results begin to suggest that GATA3 may act downstream of PPARγ in 
the transcription factor cascade that regulates urothelial differentiation; these results 
need further investigation in additional cell lines and using additional experimental 
methods (western blotting, RT-qPCR) to provide convincing evidence. In contrast to 
this, knockdown of GATA3 expression, prior to PPARγ activation, resulted in a 
significant downregulation of PPARγ transcript expression (Figure 4.14). This result 
suggested the opposite notion, where GATA3 acts upstream of PPARγ. GATA3 was  
also shown to have key roles in the differentiation of urothelial cells; both CK13 and 
UPK2 expression were significantly downregulated as a result of GATA3 knockdown 
(Figure 4.16). 
 
Tong et al. have shown that during adipocyte differentiation, GATA3 is highly 
expressed in preadipocytes, but as the cells are induced to differentiate into mature 
adipocytes, GATA3 expression is lost while PPARγ expression is upregulated. Forced 
expression of GATA3 in murine adipocyte precursor cells prevented their ability to 
undergo adipocyte differentiation. In addition to this, the authors also demonstrated that 
embryonic stem (ES) cells, which were deficient in GATA3, had a greater propensity 
for adipocyte differentiation than control ES cells (Tong et al., 2000). This work 
suggested an inhibitory role for GATA3 in adipogenesis. The authors further 
demonstrated that this inhibitory role was, in part, due to direct binding of GATA3 to 
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the PPARγ2 promoter, preventing transcription (Tong et al., 2000). GATA3 has also 
been shown to have a positive regulatory role on PPARγ expression; work completed in 
murine T helper 2 (Th2) cells has shown that GATA3 was able to both bind to and 
positively regulate PPARγ gene expression, with expression of both genes being 
important for Th2 cell differentiation (Wei et al., 2011). 
 
Work presented in this chapter provides evidence suggesting that neither PPARγ nor 
GATA3 is truly upstream of the other in urothelial cell differentiation, and that both 
PPARγ and GATA3 may be important for positively regulating each others expression. 
 
 Use of Buccal Epithelial Cells for Bladder Tissue 
Engineering 
One of the possible methods that has been suggested for obtaining surrogate epithelial 
cells for bladder tissue engineering was to simply use another known barrier forming 
epithelial cell type. The main epithelial cell type suggested for this in the literature has 
been buccal epithelial cells (Lu et al., 2010; Watanabe et al., 2011), since buccal 
mucosa is already used as a grafted tissue for urology-based applications (reviewed in 
Markiewicz et al., 2007). The use of buccal epithelial cells for bladder tissue 
engineering has already been investigated by Watanabe et al., with some mixed results. 
The authors applied a composite cystoplasty approach, where autologous buccal 
epithelial cell sheets were produced, and then transplanted into the bladder of dogs. The 
authors found that direct transplant of the buccal epithelial cell sheets into the bladder 
resulted in loss of the cell sheets, with much of the grafts containing no epithelium after 
three weeks. This work suggested that direct use of buccal epithelial cell sheets in the 
bladder is not sufficient for bladder tissue-engineering. In order for the cell sheets to 
survive in the bladder, the authors demonstrated that the cell sheets must first be 
implanted in a latex poach in the abdomen for five days, before implantation in the 
bladder. This resulted in successful production of a stratified squamous epithelium in 
the bladder after three weeks. 
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Work presented in this thesis does not support or refute the use of buccal epithelial cells 
for bladder tissue engineering. What became clear throughout the work, was that major 
differences between buccal epithelial cells and urothelial cells exist. The most striking 
difference, which is likely most relevant for bladder tissue-engineering, was the 
inability of buccal epithelial cell sheets to form a functional barrier, as measured by 
TER (Figure 3.19). The work raises questions as to whether in vitro generated buccal 
epithelial cell sheets have the long term capacity to sustain barrier function and survive 
in the bladder. The result may provide a possible reason why the cell sheets produced 
by Watanabe et al. failed to survive in the bladder following direct implantation. Long 
term studies assessing the capacity for direct buccal mucosa grafts to survive in the 
bladder have shown relatively positive results, with no major adverse effects to the 
epithelium; this work suggested that the cells can survive in the bladder long term. It is 
therefore possible that the alternate approach taken by Watanabe et al., which relied on  
pre-implantation of the cell sheets in the abdomen, away from the bladder 
microenvironment, may be a key necessary step in preparing the cells for use, allowing 
them to develop a more mature barrier function. Long term studies using this alternate 
method of implantation are necessary to ascertain whether buccal epithelial cells on 
their own could be used for bladder tissue-engineering. 
 
One of the groups studying the effect of the bladder microenvironment on direct buccal 
mucosa grafts, provided evidence of UPK2 expression in transplanted buccal mucosa 
following 6 and 12 months in the bladder of pigs. The authors suggested that this 
demonstrated the transdifferentiation potential of buccal epithelial cells. Work presented 
in this thesis demonstrated that human buccal epithelial cells in vitro are capable of 
expressing UPK2 (Figure 3.13), which suggested that UPK2 gene expression alone may 
not be an appropriate predictor of urothelial-type differentiation. It is probably unlikely 
that the bladder microenvironment itself would be capable of transdifferentiating buccal 
epithelial cells into urothelial cells, as urine has been shown to have no urothelial 
differentiation-associated signalling capacity (Stahlschmidt et al., 2005). Whether 
signalling from the underlying stroma and/or adjacent urothelial cells could have the 
capacity to cause urothelial-type transdifferentiation is not yet known. Based on the 
results shown by Lu et al. it appears most likely that the UPK2 expression observed is 
attributed to ingrowth of adjacent urothelium. 
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 Identification of Differentially Expressed Transcription 
Factors Between Buccal Epithelial Cells and Urothelial 
Cells 
The differentiation of urothelial cells is thought to be controlled by a tightly regulated 
cascade of transcription factor expression. In this thesis, the expression of seven 
transcription factors known to be important for urothelial cell differentiation (ELF3, 
FOXA1, GATA3, GRHL3, IRF1, KLF5 and PPARγ) was investigated in buccal 
epithelial cells (Figure 3.5). Of these transcription factors, PPARγ has been previously 
implicated as a key upstream transcription factor in human urothelial cell differentiation 
(Varley et al., 2004a; Varley et al., 2004b; Varley et al., 2006). Other key transcription 
factors, ELF3 and FOXA1, have been shown to act directly downstream of PPARγ in 
urothelial cell differentiation (Varley et al., 2009; Böck et al., 2014). Further to this, 
work presented in this thesis demonstrated that GATA3 may also act downstream of 
PPARγ, but that it is also capable of regulating PPARγ expression, suggesting that a 
feedback loop exists between PPARγ and GATA3 in urothelial cell differentiation. In 
addition to human in vitro work, previous work using mouse models identified GRHL3 
and KLF5 as key transcription factors involved in urothelial cell differentiation and 
barrier function (Yu et al., 2009; Bell et al., 2011). 
 
The work in this thesis evaluating the expression of transcription factors known to be 
important for urothelial cell identity and differentiation, revealed noticeably weak 
expression of ELF3, FOXA1, GATA3 and PPARγ in buccal epithelial cells. In addition 
to this, the expression of FOXA1, GATA3 and PPARγ could not be significantly 
upregulated as a result of using the TZ/PD protocol (Figure 3.6), suggesting that 
activation of PPARγ does not occur in human buccal epithelial cells. FOXA1 
expression was able to be upregulated by other methods (atRA treatment) (Figure 3.10), 
indicating that at least FOXA1 is capable of being upregulated in buccal epithelial cells. 
These results highlighted key differences in the expression of transcription factors that 
play important roles in the differentiation of urothelial cells. 
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Previous work investigating the effect of PPARγ agonists on the differentiation of 
squamous epithelial cells from skin has shown that they are able to cause some 
upregulation of the squamous terminal differentiation-associated genes involucrin and 
transglutaminase-1 (Westergaard et al., 2001; Mao-Qiang et al., 2004). Neither of the 
groups investigated whether this was specifically as a result of PPARγ activation or due 
to off-target effects of the drugs. Westergaard et al. also investigated the expression of 
the three PPAR nuclear receptors (α, γ, δ) in normal human keratinocytes in vitro, when 
the cells were grown in KSFM with added bovine pituitary extract and epidermal 
growth factor. The authors found absent expression of PPARγ2, weak expression of 
PPARα and PPARγ1, and abundant expression of PPARδ (40 μg of protein was 
loaded). The work identified PPARδ as the predominant PPAR isoform in 
keratinocytes. Mao-Qiang demonstrated that knockout of PPARγ in the skin of mice did 
not result in any obvious changes to the epithelium. These results altogether suggesting 
that PPARγ likely does not play an essential role in squamous epithelial cell 
differentiation. 
 
The results presented in this thesis also suggest that the combined weak expression of 
FOXA1, GATA3 and PPARγ may be a key indicator of the basal, squamous cell state. 
This is in agreement with the work presented in Chapter 4, which demonstrated that low 
expression of FOXA1, GATA3 and PPARγ was associated with urothelial cells in their 
undifferentiated, basal state (grown in KSFMc). This line of thinking is in further 
agreement with bladder cancer research, where low expression of FOXA1, GATA3 and 
PPARγ is associated with basal muscle invasive bladder cancers, as well as with 
squamous cell carcinoma of the bladder (Biton et al., 2014; Damrauer et al., 2014; 
Eriksson et al., 2015). 
 
When GATA3 and PPARγ1 were individually overexpressed in human buccal epithelial 
cells, neither factor was able to cause significant upregulation of the other even when 
subjected to the TZ/PD or ABS/Ca2+ protocols. This work suggested that in buccal 
epithelial cells, either that GATA3 and PPARγ1 act independently of one another, or 
that both factors are heavily repressed and inaccessible to the other factor. 
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6.7.1 FOXA1 Expression 
There were several interesting observations pertaining to FOXA1 expression observed 
in the results shown in this thesis, which are discussed below. 
 
6.7.1.1 PPARγ1 and FOXA1 
PPARγ has been shown to act directly upstream of FOXA1 in the regulation urothelial 
cell differentiation (Varley et al., 2009). Results from this thesis identified PPARγ1 as 
the primary PPARγ protein isoform involved in urothelial cell differentiation, which 
suggests that it is PPARγ1 which acts directly upstream of FOXA1. 
 
Overexpression of PPARγ1 in buccal epithelial cells resulted in the upregulation of 
FOXA1 expression in both control (0.1 % DMSO) and TZ/PD treated cells (Figure 
5.13). This work suggested that simply the presence of PPARγ1 expression (ie. without 
exogenous ligand activation) is able to transactivate FOXA1 expression in buccal 
epithelial cells. Upon attempts to activate PPARγ using the TZ/PD protocol, FOXA1 
expression was further upregulated. This work demonstrated that when abundant 
PPARγ1 protein is present, it can transactivate the FOXA1 transcription factor pathway 
in human buccal epithelial cells. 
 
6.7.1.2 GATA3 and FOXA1 
Investigation into the effect of GATA3 knockdown on urothelial cell differentiation 
revealed that knockdown of GATA3 expression had no significant effect on FOXA1 
transcript or protein expression (Figure 4.15). This was true even though knockdown of 
GATA3 appeared to downregulate PPARγ gene expression (Figure 4.14). These results 
indicated that in urothelial cell differentiation, GATA3 appears to act independently of 
FOXA1 expression. This was further shown in human buccal epithelial cells where 
overexpression of GATA3 failed to cause any upregulation of FOXA1 protein 
expression in any of the cell culture systems examined. 
 
In breast epithelial cell differentiation and cancer progression, GATA3 has been shown 
to act directly upstream of FOXA1, and this interaction has been shown to be 
particularly important for mediating ESRα expression (Kouros-Mehr et al., 2006; 
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Theodorou et al., 2013). GATA3, FOXA1 and ESRα have also been shown to act as an 
‘enhanceosome’ in order to elicit maximal expression from estrogen-responsive genes 
in ESRα-positive breast cancers (Kong et al., 2011). These results altogether indicate an 
essential role for the interaction of GATA3 and FOXA1 in breast epithelial cells. 
 
The results presented in this thesis identify a striking difference between FOXA1 and 
GATA3 regulation in human buccal epithelial cells, urothelial cells, and those 
previously published in breast epithelial cells. These differences appear to be related to 
distinct differences in nuclear receptor signaling, since the estrogen receptors are not 
readily associated with squamous or urothelial-type differentiation. These differences in 
nuclear receptor usage appear to lead to major differences in transcription factor 
regulation. 
 
6.7.1.3 Retinoic Acid and FOXA1 
The retinoic acid receptors have been implicated as key upstream regulators of 
urothelium development, differentiation, and in particular in inhibiting squamous 
epithelial cell gene expression (Southgate et al., 1994; Mauney et al., 2010; Gandhi et 
al., 2013; Kang et al., 2014b). Results in this thesis demonstrated that FOXA1 transcript 
and protein expression could be upregulated in human buccal epithelial cells as a result 
of treatment with all-trans retinoic acid (Figure 3.9 and Figure 3.10). Previous work in 
murine embryonic carcinoma cell lines has shown the presence of a RARE in the 
FOXA1 promoter (Jacob et al., 1999). The authors also demonstrated that the RARs 
interact directly with the FOXA1 promoter to elicit gene expression. 
 
Although this phenomenon was not investigated in urothelial cells in this thesis, 
questions arise as to whether retinoic acid could also be a key regulator of FOXA1 
expression in urothelial cell differentiation, and in turn be a key transcription factor 
involved in preventing squamous-type differentiation. FOXA1 has previously been 
indicated as having a role in preventing squamous differentiation in a mouse model 
(Reddy et al., 2015), although a link to retinoic acid signalling was not discussed. 
Investigation into a link between retinoic acid signalling, FOXA1, and preventing 
squamous differentiation in human urothelial cells would be very interesting. 
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 Uroplakins as Markers of Urothelial Cell Differentiation 
The expression of the uroplakin genes has been primarily associated with urothelial 
cells, and they are known to be key protein components of the urothelium-specific 
asymmetric unit membrane (Sun et al., 1996; Deng et al., 2002). While the expression 
of UPK1B and UPK3B has been previously described in other cell types including 
corneal epithelium and mesothelium (Adachi et al., 2000; Kanamori-Katayama et al., 
2011; Rudat et al., 2014), respectively, the prevailing view in the literature has been that 
expression of the uroplakin genes is the ultimate urothelium-specific marker. This is 
particularly true in studies which have aimed to convert multipotent or pluripotent stem 
cells into urothelial cells (Tian et al., 2010; Wu et al., 2013; Osborn et al., 2014). 
 
The work presented in this thesis demonstrated low abundance transcript expression of 
UPK1A, UPK1B, and UPK2 in human buccal epithelial cells, along with considerable 
expression of UPK3B (Figure 3.13). Use of the TZ/PD protocol resulted in the 
upregulation of UPK1A, UPK1B, UPK2 and UPK3B gene expression in buccal 
epithelial cells, with UPK2 and UPK3B expression being significantly upregulated. 
Further to this, overexpression of GATA3 and PPARγ1 in human buccal epithelial cells 
resulted in additional upregulation of several of the uroplakin genes when the cells were 
treated with TZ/PD (Figure 5.5 and Figure 5.15). The ability to detect any uroplakin 
gene expression in buccal epithelial cells was a surprising and unexpected result, as 
there have only been a few reports of uroplakin gene expression in other cell types 
(Adachi et al., 2000; Kanamori-Katayama et al., 2011; Rudat et al., 2014). These results 
indicate that in addition to UPK1B and UPK3B expression being non-specific to 
urothelial cells, UPK1A and UPK2 are also able to be expressed in other cell types. 
 
These results have particular implications for reprogramming and transdifferentiation-
type experiments, when attempting to convert any cell type into urothelial cells. In 
recent years, many attempts have been made to convert various types of multipotent and 
pluripotent stem cells into urothelial cells. Of these attempts, the primary evidence used 
to demonstrate successful conversion to urothelial cells, as opposed to other epithelial 
cell types, has been to show upregulated expression of one or more of the uroplakin 
genes. The work presented in this thesis suggests that demonstrating upregulated 
expression of the uroplakin genes is not enough to distinguish urothelial cells from other 
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epithelial cell types. In particular, demonstrating the upregulation as relative fold-
change RT-qPCR data, where low abundance expression can be made to look more 
impressive than it actually is. Since UPK3A expression could never be shown in buccal 
epithelial cells, the ability to demonstrate considerable UPK3A expression may be the 
most appropriate marker of urothelial cell specificity and differentiation. 
 
One interesting question that arose from the work in this thesis, investigating uroplakin 
gene expression, was which aspect of the TZ/PD protocol was able to cause the 
upregulation of the uroplakin genes in buccal epithelial cells. In urothelial cells, 
uroplakin gene expression appears to be regulated specifically by PPARγ expression 
(Varley et al., 2004a), but work in this thesis suggested that PPARγ activation did not 
occur in buccal epithelial cells treated with TZ/PD. It is therefore plausible that the 
upregulation of the uroplakin genes may have been due to off-target effects of the drugs, 
or due to the effects of the PD153035, indicating that other transcription factors, in 
addition to those downstream of PPARγ, may be able to regulate uroplakin gene 
expression. 
 
 Barrier Function and Tight Junction-Associated Gene 
Expression 
The urothelium is known to be one of the tightest barrier epithelia in the human body, 
with its primary function to act as a barrier to urine. The barrier function of the 
urothelium is attributed to two main features: highly specialised tight junctions and the 
presence of the AUM (reviewed in Khandelwal et al., 2009). The barrier function of 
buccal epithelium in contrast, is considered to be similar to that of skin, relying on the 
terminal differentiation of the epithelial cells, and the formation of a complex matrix of 
intracellular proteins and extracellular lipids (reviewed in Kalinin et al., 2002). 
 
Cross et al. originally demonstrated that when NHU cells were induced to differentiate 
using the ABS/Ca2+ protocol, they were able to form a functional barrier epithelium as 
measured by TER and permeability assays. Barrier function in human urothelial cells  
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does not occur when the cells are grown in KSFMc (Cross et al., 2005) or during use of 
the TZ/PD protocol (Fleming, 2008), even though the TZ/PD protocol is able to 
upregulate key tight junction-associated proteins (Varley et al., 2006).  
 
Work presented in this thesis demonstrated that human buccal epithelial cells fail to 
form a functional barrier, as measured by the TER, following use of the ABS/Ca2+ 
protocol (Figure 3.19); the TER values remained below 200 Ω∙cm2 at all of the time 
point assessed. This remained true even following the individual overexpression of 
GATA3 and PPARγ1 (Figure 5.10 and Figure 5.20). These result demonstrated an 
important functional difference between buccal epithelial cells and urothelial cells. The 
work has key implications for reprogramming and transdifferentiation-type 
experiments, where of the many attempts to convert multipotent and pluripotent stem 
cells into urothelial cells, only two of the groups demonstrated the measurement of 
barrier function as an assessment of successful differentiation to urothelial cells 
(Bharadwaj et al., 2013; Kang et al., 2014b). In both cases, permeability assays were 
performed, and the results were shown as relative change, making it difficult to infer 
whether barrier function was actually attained. Results from this thesis have identified 
gain of barrier function as a unique and important feature of urothelial cell 
differentiation, suggesting that assessment of barrier function may be a key test for 
successfully demonstrating urothelial cell differentiation. 
 
The expression of key urothelium barrier-associated proteins, CLDN3, -4 and -5, has 
been previously shown to be regulated by PPARγ in human urothelial cells (Varley et 
al., 2006). Work shown in this thesis demonstrated a similar expression profile of 
claudins 1-10 in buccal epithelial cells treated with TZ/PD in comparison to urothelial 
cells (Figure 3.15). This work demonstrated that much of the same claudin genes are 
capable of being expressed in buccal epithelial cells and urothelial cells. Future work 
investigating the exact transcription factor regulatory networks governing claudin gene 
expression may be important for revealing key differences in barrier function. In 
particular, an assessment of whether PPARγ specifically plays a role in claudin gene 
expression in buccal epithelial cells is necessary. 
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Evaluation of the expression of CLDN4, -5 and -7 in the human buccal epithelial cell 
sheets revealed that while their expression was present at the intercellular borders, it 
was restricted to only the upper half of the cell layers (Figure 3.16). In contrast, 
expression of these same three claudin proteins in urothelial cell sheets was identified 
throughout all of the cell layers. This work identified that although each of the cell types 
express these claudin proteins, they have distinct localisations. This work demonstrated 
the importance of using immunohistochemical and/or immunofluorescence-based 
experiments for assessing protein localisation, as an additional tool to techniques like 
western blotting, which simply assess protein abundance. The work identified a 
potential reason for the lack of barrier function of the buccal epithelial cell sheets. 
Future work evaluating a wider panel of claudin proteins expressed may reveal even 
more striking differences by immunohistochemistry. 
 
CLDN3 in particular has been shown to be critical for the barrier function of urothelial 
cells, as knockdown of CLDN3 resulted in complete ablation of barrier function in 
NHU cells in vitro (Smith et al., 2015). The authors also showed that gain of the 
ZO-1α+ protein isoform in urothelial cells appeared to be associated with urothelial cell 
differentiation and barrier function. Assessment of CLDN3 in human buccal epithelial 
cells revealed weak protein expression by western blotting during use of the ABS/Ca2+ 
protocol. Both GATA3 overexpression and PPARγ1 overexpression in human buccal 
epithelial cells appeared to upregulate CLDN3 expression (Figure 5.8 and Figure 5.17), 
although in both cases, the transduced buccal epithelial cells failed to form a functional 
barrier epithelium. Assessment of ZO-1 expression in human buccal epithelial cells 
during use of the ABS/Ca2+ protocol revealed that both of the ZO-1 protein isoforms 
were expressed at all of the time points assessed. This work further identified that 
although key barrier forming tight junction proteins can be expressed in buccal 
epithelial cells, their expression alone fails to result in barrier formation. This work 
further suggested that it is likely differences in the localisation of the tight junction 
proteins that may be critical for barrier formation. 
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 Criteria for Demonstrating Successful Conversion of a 
Cell Type into Urothelial Cells 
Work presented in this thesis identified many key differences between human buccal 
epithelial cells and urothelial cells, which have important implications for urothelial-
type reprogramming and transdifferentiation experiments. The work made it clear that a 
more rigorous set of standards must be generated for assessing successful urothelial-
type differentiation. This should likely include a more exhaustive panel of markers, as 
well as a set of functional assays assessing both the transcellular and paracellular barrier 
function. 
 
Based on the work shown in this thesis, several key tests to consider for future 
urothelial-type reprogramming experiments have been identified: 
 
1. Demonstrating Considerable Expression of FOXA1, GATA3 and PPARγ 
ELF3, FOXA1, GATA3 and PPARγ expression was weak in buccal epithelial cells 
even upon use of the TZ/PD and/or ABS/Ca2+ protocols. The ability to demonstrate 
considerable expression of these four transcription factors is likely an important test for 
distinguishing squamous-type epithelial cells and urothelial cells. 
 
2. Demonstrating Loss of CK14 Protein Expression 
CK14 expression was always abundantly present in buccal epithelial cells, even 
following use of the ABS/Ca2+ protocol, where its expression is lost in urothelial cells. 
The ability to demonstrate absence of CK14 expression is clearly another important 
assessment for specifying urothelial cell differentiation. 
 
3. Demonstrating Gain of UPK3A Expression 
The ability to demonstrate considerable upregulation or de novo induction of expression 
of all five of the uroplakin genes should be a standard test used to evaluate conversion 
of a cell type into urothelial cells. Particular importance should be placed on 
demonstrating considerable UPK3A gene expression, as its expression was unable to be 
detected in buccal epithelial cells in any of the cell culture systems assessed. This work 
identified UPK3A as a key urothelium-specific marker. 
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4. Demonstrating Barrier Function 
The ability to demonstrate functionality of a cell type is probably the most important 
aspect of reprogramming-type experiments. Therefore, when reprogramming to 
urothelial cells, the ability to demonstrate successful acquisition of barrier function is a 
vital test. Buccal epithelial cells were unable to form a functional barrier epithelium 
using the ABS/Ca2+ protocol, and this revealed an important difference between buccal 
epithelial cells and urothelial cells. 
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 Conclusions and Future Work 
In conclusion, the work presented in this thesis demonstrated that human buccal 
epithelial cells and urothelial cells do share several similar qualities when grown in 
basal conditions (KSFMc): they are both highly proliferative, express CK14, and have 
low expression of ELF3, FOXA1, GATA3 and PPARγ1. Major differences in the two 
cell types arose when the TZ/PD and ABS/Ca2+ protocols were investigated. The most 
striking difference was the inability of human buccal epithelial cells to form a functional 
barrier epithelium, which is a critical feature of urothelial cells. Further to this, at the 
molecular level, the inability of buccal epithelial cells to significantly upregulate 
FOXA1, GATA3 and PPARγ1 expression during use of the TZ/PD protocol, indicated 
that PPARγ activation is likely not occurring in buccal epithelial cells. Through this 
work, GATA3 and PPARγ were identified as key upstream transcription factors which 
could be used for urothelial-type reprogramming of buccal epithelial cells. A surprising 
result came with the investigation of uroplakin gene expression in buccal epithelial 
cells, where it was shown that four of the five uroplakin genes (UPK1A, UPK1B, UPK2 
and UPK3B) were expressed, and further upregulated by using the TZ/PD protocol. 
This work identified UPK3A as a potentially key urothelium-specific marker, as it was 
the only uroplakin gene that was not expressed in buccal epithelial cells. 
 
Future work in this area would aim to investigate whether GATA3 and PPARγ1 protein 
expression is truly absent in human buccal epithelial cells in culture. It is possible that, 
in a similar way to PPARγ1 expression in urothelial cells, they are rapidly degraded by 
the proteasome. Experiments performed using the proteasome inhibiting drug, MG132, 
could be used to examine this. An additional area of interest was the significant 
upregulation of ELF3, UPK2, UPK3B and TGM1 transcript expression observed 
following use of the TZ/PD protocol in buccal epithelia cells. Determining whether the 
upregulation of these gene was specifically as a result of PPARγ activation, or simply as 
a result of off-target effects of the drugs would be useful for deciphering a role for 
PPARγ in NHB cells. To investigate this, use of the PPARγ antagonist, T0070907, or 
PPARγ-specific siRNA could be employed. 
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Work in urothelial cells identified PPARγ1 as the primary PPARγ isoform involved in 
urothelial cell differentiation. Further to this, it was shown that PPARγ1 is only weakly 
expressed when human urothelial cells are grown in proliferative conditions (KSFMc). 
Only upon activation to differentiate, does PPARγ1 expression rapidly increase, but the 
expression appears to be largely labile; much of the PPARγ1 protein produced was 
rapidly degraded by the proteasome. PPARγ is clearly important for many aspects of 
urothelial cell identity and differentiation. Further research investigating the transient 
nature of PPARγ1 in normal human urothelial cells would be useful, as would 
identifying whether any novel variants or post-translationally modified versions of 
PPARγ are important in urothelial differentiation. 
 
This study also provided preliminary evidence identifying an important role for GATA3 
in the differentiation of normal human urothelial cells. In addition to this, the potential 
for GATA3 to have key roles in the regulation of urothelial differentiation-associated 
transcription factor expression was also identified. Further work to determine the exact 
role of GATA3 in normal urothelial differentiation is necessary, and has important 
implications for bladder cancer research, where GATA3 expression has already been 
identified as a key diagnostic and prognostic marker (Higgins et al., 2007; Miyamoto et 
al., 2012). Investigation into whether the GATA3 protein is primarily degraded by the 
proteasome in urothelial cells would also be of interest; similar to PPARγ1 protein 
expression, GATA3 protein expression was primarily weak, so it could be possible that 
it is also rapidly turned over in urothelial cells. 
 
In the final results chapter, GATA3 and PPARγ1 were individually overexpressed in 
human buccal epithelial cells using retroviral transduction. Although neither gene was 
able to cause complete transdifferentiation on their own, each was able to upregulate 
key genes associated with urothelial cell differentiation and barrier function. Future 
work attempting to completely transdifferentiate squamous epithelial cells into 
urothelial cells should attempt combined overexpression of GATA3 and PPARγ1. In 
both individual GATA3 overexpression and PPARγ1 overexpression experiments 
neither PPARγ1 nor GATA3, respectively, were able to be upregulated, indicating that 
key regulatory pathways were still not activated. 
 
 
  
253 
 
 
 
 
 
 
 
Chapter 7: 
Appendix 
 
Appendix 
254 
7 Appendix 
 Solution and Buffer Recipes 
Solution Recipe 
10% (v/v) Formalin 100 ml of 37% Formaldehyde  
900 ml of PBSc  
 
To make 1 L of PBSc:  
1 L of 1x PBS,  
0.5 ml of 1M MgCl2  
0.9 ml of 1M CaCl2 
2x SDS Buffer 
 
10 ml glycerol (20 % v/v), 1 g SDS (2 % w/v), 6.25 ml 
Tris-HCl (pH 6.8), 0.42 g NaF, 18.4 mg Na3VO4, 0.446 
Na4P2O7, 40 ml dH2O. 
Antifade (used for IF) 
 
Dissolved 100 mg p-PhenylendiaminoDihydrochloride 
in 10 ml PBS and then adjusted to pH8.0. 
Added 90 ml glycerol. 
Cell Freeze Mix KSFMc (for buccal epithelial and urothelial cells) or 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Gibco, 21969-035) (for cancer-derived cell lines) with 
10% Fetal Bovine Serum (FBS) (SeraLab, EU-000) 
(batch selected) and 10% DMSO (Sigma, D2650). 
Collagenase 
 
Dissolved 10,000 U collagenase (Sigma, C5138) in 100 
ml HBSS (with Ca2+ and Mg2+ ions) (Gibco, 24020-
091). Then added 10 mM Hepes (Gibco, 15630-056). 
Filter sterilised using a 0.2 μm low protein-binding 
syringe filters (VWR, 514-4105). 
DMEM10% Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Gibco®, 21969-035) with 10% Fetal Bovine Serum 
(FBS) (SeraLab, EU-000) (batch selected) and 1% L-
glutamine (LG) (Gibco®, 25030-024). 
dNTP Mix (10 mM) 
 
Combined 10 μl ATP (100 mM), 10 μl TTP (100 mM), 
10 μl CTP (100 mM), 10 μl GTP (100 mM) (Promega, 
U1240), and 60 μl dH2O. 
Dispase Solution (0.5 % or 
2 %) 
Dissolve dispase II powder (Sigma, D4693) in warm 1x 
DPBS (without Ca2+ and Mg2+ ions) (Gibco, 14185052) 
to 0.5 % or 2 %. Filter through Whatman 0 filter paper. 
Filter sterilise using a 0.2 μm low protein-binding 
syringe filters (VWR, 514-4105). 
Haematoxylin 
 
Solution 1: Dissolved 3 g haematoxylin in 20 ml 
ethanol. 
Solution 2: Dissolved 0.3 g sodium iodate, 1 g citric 
acid, 50 g chloral hydrate, and 50 g aluminium 
potassium sulphate in 850 ml dH2O. 
Combined solutions 1 and 2 and added 120 ml glycerol. 
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Solution Recipe 
KSFMc Keratinocyte Serum Free Medium (KSFM) (Gibco®, 
17005-034) containing 0.05 mg/ml bovine pituitary 
extract (Gibco®, 37000-015), 5 ng/ml epidermal growth 
factor (Gibco®, 37000-015) and 30 ng/ml cholera toxin. 
LB broth 
 
Dissolve 5 g Yeast extract (Oxoid, LP0021), 10 g 
tryptone (Oxoid, LP0042), and 10 g sodium chloride in 
1 L dH2O, at pH to 7.0. 
LB-Agar 
 
Dissolve 5 g Yeast extract (Oxoid, LP0021), 10 g 
tryptone (Oxoid, LP0042), and 10 g sodium chloride in 
1 L dH2O and pH to 7.0. Then add 15 g agar (Oxoid, 
LP0013). 
Phosphate Buffered Saline 
(PBS) 
Dissolved 5 PBS tablets (Sigma, P4417) to 1 L ELGA-
purified water and autoclaved. 
Stripper Medium 
(Southgate et al., 1994) 
 
444 ml of HBSS (without Ca2+ or Mg2+) (Gibco®, 
14170-088), 5 mL of 1 M Hepes (Gibco, 15630-056), 1 
ml of Aprotonin (500,000 KIU) (Nordic Pharma Ltd), 
and 50 ml 1% EDTA (final concentration 0.1%). 
Transfer Buffer (Western 
blotting) 
 
1.45 g Tris, 7.2 g Glycine, 200 ml Methanol, 800 ml 
dH2O. 
Transport Medium 
(Southgate et al., 1994) 
Hanks’ Balanced Salt Solution (HBSS) (containing 
Ca2+ and Mg2+) (Gibco®, 24020-091) with 10 mM 
HEPES (Gibco®, 15630-056), and 20 KIU/ml aprotonin 
(Nordic Pharma Ltd.). 
Tris Buffered Saline (TBS) 
(recipe used for western 
blotting) 
1.21 g Tris, 8.18 g NaCl, dH2O to 1 L, pH 7.6 
TBS-T 
(recipe used for western 
blotting) 
TBS with 0.1% Tween-20 (Sigma, P1379) 
Trypsin Inhibitor 
 
Dissolved 100 mg of trypsin inhibitor (Sigma, T6522) 
in 5 ml of 1x DPBS (without Ca2+ or Mg2+) (Gibco, 
14200-067). Filter sterilised using a 0.2 μm low protein-
binding syringe filters (VWR, 514-4105). 
 
Trypsin-Versene (TV) 
 
20 ml of 10x Trypsin (Sigma, T4549), 4 ml of 1% (w/v) 
EDTA and 176ml HBSS (without Ca2+ and Mg2+) 
(Gibco®, 14170-088).  
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 List of Companies 
Company Website 
Abcam Plc. http://www.abcam.com/ 
AbD Serotec® https://abdserotec.com/ 
Abnova Corp. http://www.abnova.com/ 
Agilent Technologies http://www.agilent.com/ 
Bio-Rad Laboratories Inc. http://www.bio-rad.com/ 
C A Hendley-Essex Ltd. http://www.hendley-essex.com/ 
Cell Signaling Technology Inc. http://www.cellsignal.com/ 
CellPath Ltd. http://www.cellpath.co.uk/ 
Clontech Laboratories inc. http://www.clontech.com/ 
Contained Air Solutions Ltd. http://www.containedairsolutions.co.uk/ 
Dako http://www.dako.com/ 
ELGA http://www.elgalabwater.com/ 
Envair Ltd. http://www.envair.co.uk/ 
Eurofins Genomics https://www.eurofinsgenomics.eu/ 
Fisher Scientific Ltd. http://www.fisher.co.uk/ 
Greiner Bio-One Ltd. http://www.greinerbioone.com/ 
Hawksley http://www.hawksley.co.uk/ 
Hettich Lab Technology http://www.hettichlab.com/ 
Leica Biosystems 
 Novocastra 
http://www.leicabiosystems.com/ 
Li-Cor Biosciences Ltd.  http://www.licor.com/ 
Life Technologies 
 Gibco® 
 Applied Biosystems® 
 Ambion® 
 Invitrogen™ 
 Zymed® 
http://www.lifetechnologies.com/ 
Media Cybernetics inc. http://www.mediacy.com/ 
Melford Laboratories Ltd. http://melford.co.uk/ 
New England BioLabs (NEB) https://www.neb.com/ 
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Company Website 
Olympus http://www.olympus.co.uk/ 
Priorclave ltd. http://www.priorclave.co.uk/ 
Promega https://www.promega.co.uk/ 
QIAGEN https://www.qiagen.com/ 
R&D Systems Inc. http://www.rndsystems.com/ 
Roche Products Ltd. http://www.roche.co.uk/ 
Santa Cruz Biotechnology Inc. http://www.scbt.com/ 
Sarstedt AG & Co. https://www.sarstedt.com/ 
Scientific Industries Inc. http://www.scientificindustries.com/ 
Scientific Laboratories Supplies Ltd. 
(SLS) 
http://www.scientificlabs.co.uk/ 
SCIE-PLAS http://www.scie-plas.com/ 
SciQuip Ltd. http://www.sciquip.co.uk/ 
Sera Laboratories International Ltd. 
(SeraLab) 
http://www.seralab.co.uk/ 
Sigma-Aldrich Co. LLC (Sigma) http://www.sigmaaldrich.com/ 
Source Bioscience http://www.sourcebioscience.com/ 
Syngene http://www.syngene.co.uk/ 
Taylor-Wharton International LLC http://www.taylorwharton.com/ 
The Binding Site Group Ltd. http://www.thebindingsite.com/ 
Thermo Fisher Scientific Inc. 
 RA Lamb 
http://www.thermoscientific.com/ 
Vector Laboratories Inc. https://www.vectorlabs.com/ 
VMR International 
 Jencons 
 BDH 
https://uk.vwr.com/ 
World Precision Instruments  http://www.wpiinc.com/ 
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 List of Acronyms 
Acronym Meaning 
ABS Adult Bovine Serum 
AUM Asymmetric Unit Membrane 
cDNA Complementary DNA 
CK Cytokeratin 
CLDN Claudin 
DMEM10% DMEM with 10% FBS and 1% LG 
DNA Deoxyribonucleic acid 
ELF3 E74-like Factor 3 
FBS Fetal Bovine Serum 
FOXA1 Forkhead Box Protein A1 
GATA3 GATA Binding Protein 3 
GRHL3 Grainyhead-like 3 
KLF5 Kruppel-like Factor 5 
KSFMc Keratinocyte Serum Free Medium – 
Complete 
LDS Lithium dodecyl sulphate 
LOR Loricrin 
NHB Normal human buccal epithelial 
NHU Normal human urothelial 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PCR Polymerase Chain Reaction 
PD PD153035 (EGFR-TK inhibitor) 
PPAR Peroxisome Proliferator-Activated 
Receptor 
RAR Retinoic Acid Receptor 
RNA Ribonucleic acid 
RT-qPCR Reverse Transcriptase Quantitative 
Polymerase Chain Reaction 
RXR Retinoid X Receptor 
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Acronym Meaning 
SDS Sodium dodecyl sulphate 
SPRR4 Small Proline Rich Protein 4 
TBS Tris Buffered Saline 
TBS-T TBS with 0.1% Tween-20 
TER Trans-epithelial Electrical Resistance 
TGM1 Transglutaminase 1 
TZ Troglitazone (PPARγ agonist) 
UPK Uroplakin 
ZO Zonula Occluden 
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 PPARγ Antibody Optimisation 
7.4.1 PPARγ Overexpression 
One of the most commonly published antibodies used for the detection of PPARγ 
expression by western blotting has been the E-8 antibody clone (monoclonal) produced 
by Santa Cruz Biotechnology, Inc. Its use for evaluating PPARγ expression in normal 
human urothelial cells has been difficult because it detects several different protein 
bands at the approximate heights corresponding to PPARγ1 and PPARγ2; using the E-8 
antibody, Georgopolous et al. described the detection of three PPARγ protein bands, but 
they did not identify which of the bands corresponded to which of the PPARγ protein 
isoforms. In order to evaluate the specificity of the E-8 and other PPARγ antibodies, it 
was decided to overexpress each of the PPARγ isoforms in an identified cell line with 
low PPARγ gene expression. 
 
PPARγ1 and PPARγ2 overexpression vectors were previously generated and transfected 
into PT67 retroviral packaging cells by Jennifer Hinley, a research technician at the Jack 
Birch Unit, University of York. The retroviral vector backbone used was pLXSN 
(Clontech Laboratories Inc.). PT67 cells were also transfected with the pLXSN vector 
only, to act as an empty vector control, for comparison. Ms. Hinley also confirmed 
successful transfection and selection of all three vectors into PT67 cells by PCR. 
 
To investigate the specificity of several PPARγ antibodies by western blotting and 
immunofluorescence, a cell line was identified with low PPARγ transcript abundance, 
in which to overexpress each of the two PPARγ isoforms. A search of the RNA-seq data 
generated for a range of commonly used cell lines on The Human Protein Atlas 
(proteinatlas.org) revealed that a number of cell lines had low PPARγ expression. 
MCF-7, a breast carcinoma-derived cell line, was chosen due to its relatively low 
abundance of PPARγ expression, and its availability as a cell line stock in the Jack 
Birch Unit. The MCF-7 cell stock had been previously genotyped upon arrival to the 
Jack Birch Unit MCF-7 cells were transduced with retroviruses generated from PT67 
cells transfected with either the empty pLXSN vector, or the pLXSN vector containing 
either the PPARγ1 or PPARγ2 coding sequence. Successfully transduced cells were 
maintained under antibiotic selection (0.1 mg/ml G418). For western blotting, cells 
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were grown to confluence and whole cell protein lysates were taken. For 
immunofluorescence experiments, PT67 packaging cells, which had been transfected 
with either the empty pLXSN vector or the PPARγ overexpression vectors, were first 
evaluated to determine the appropriate fixation method required for each antibody 
(either methanol:acetone or 10 % (v/v) formalin followed by 0.1 % Triton X-100). Cells 
were seeded onto 12-well glass slides and grown to near confluence. MCF-7 cells were 
then evaluated for PPARγ expression by immunofluorescence microscopy using the 
fixation method determined using the transfected PT67 cells. 
 
7.4.2 PPARγ Antibodies 
The list of PPARγ antibodies which were evaluated for their specificity for either 
western blotting (WB) or immunofluorescence (IF) can be found below in Table 7.1. 
Several antibodies were tested that could detect both PPARγ1 and PPARγ2, and a single 
antibody was evaluated which was specific for PPARγ2. The respective binding 
locations for each of the PPARγ antibodies to the PPARγ proteins are shown in Figure 
7.1. 
Table 7.1 List of PPARγ Antibodies 
Antibody 
Clone 
PPARγ 
Specificity 
Host 
(Production) 
Supplier Dilution* 
E-8 PPARγ1 and 
PPARγ2 
 
M (Monoclonal) Santa Cruz 1:500 (WB) 
1:200 (IF) 
81B8 PPARγ1 and 
PPARγ2 
 
Rb (Monoclonal) Cell Signaling 1:500 (WB) 
1:100 (IF) 
D69 PPARγ1 and 
PPARγ2 
 
Rb (Polyclonal) Cell Signaling 1:500 (WB) 
1:100 (IF) 
P&A53.25 PPARγ1 and 
PPARγ2 
 
M (Monoclonal) GSK (gift) - 
1:1200 (IF) 
N-19 PPARγ2 only 
 
Gt (Polyclonal) Santa Cruz 1:500 (WB) 
- 
M – Mouse, Rb – Rabbit, Gt - Goat 
* Dilutions were previously determined by titration. 
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Figure 7.1 PPARγ Antibody Binding Locations 
The 81B8, D69, E-8 and P&A53.25 antibodies all bind to both the human PPARγ1 and 
PPARγ2 proteins. The D69 and P&A53.25 antibodies bind to the more N-terminal 
portion of the proteins; the D69 antibody was raised against a peptide sequence 
surrounding the Asp69 residue of human PPARγ2.  The E-8 and 81B8 antibodies bind to 
the C-terminal portion of the proteins; the E-8 antibody was raised against a peptide 
mapping to residues 480-505 of the human PPARγ2 sequence, while the 81B8 antibody 
was raised against a peptide sequence surrounding the His494 residue of human PPARγ2. 
The N-19 antibody only binds to PPARγ2, and was raised against a peptide sequence in 
the first 28 amino acids of human PPARγ2, which is not part of the PPARγ1 protein. 
Information regarding binding location for each antibody was obtained from the 
corresponding product data sheet. The information pertaining to the P&A53.25 antibody 
was obtained from (Su et al., 1999). 
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7.4.3 Assessment of PPARγ Antibodies for Western Blotting 
The successful overexpression of PPARγ1 and PPARγ2 in MCF-7 cells was 
demonstrated by RT-PCR analysis (Figure 7.2 A). MCF-7 cells transfected with the 
empty vector only displayed weak total PPARγ expression and absent PPARγ2 gene 
expression. 
 
All of the total PPARγ antibodies (E-8, 81B8, and D69) evaluated demonstrated 
reactivity to PPARγ (Figure 7.2 B, C & D) by western blotting. The western blots 
showed bands in the PPARγ1 overexpressing cells at approximately 52 kDa, and in the 
PPARγ2 overexpressing cells at approximately 57 kDa. The E-8 antibody gave a variety 
of additional bands including one band directly below the PPARγ1 protein band. The 
81B8 and D69 antibodies also showed additional bands, but less than detected using the 
E-8 antibody. Based on these results, the D69 antibody was chosen to be the primary 
antibody used for detecting PPARγ expression by western blotting throughout this 
thesis; the antibody appeared to provided the most intense labelling, with the least 
amount of additional bands. 
 
The N-19 antibody appeared to be specific for detecting PPARγ2 expression by western 
blotting (Figure 7.2 E). It detected a PPARγ2-specific band in only the PPARγ2 
overexpressing cells at approximately 57 kDa. This band was equivalent to the one 
detected using the three PPARγ total antibodies. 
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Figure 7.2 PPARγ Antibodies Evaluated for Western Blotting Using Transduced 
MCF-7 Cells 
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Figure 7.2 PPARγ Antibodies Evaluated for Western Blotting Using Transduced 
MCF-7 Cells 
MCF-7 cells were transduced to either overexpress PPARγ1 or PPARγ2. Control cells 
were transduced with the antibiotic selection gene only, and are denoted in the figure as 
‘Empty’.  
A) Successful overexpression was shown by RT-PCR for total PPARγ expression and 
PPARγ2 expression (30 cycles). GAPDH expression was used as loading control (25 
cycles). H2O (no template) was used as a negative control. cDNA from adipocyte 
differentiated mesenchymal stem cells (generated by Ros Duke and Jenny Hinley) 
was used as the positive control for the PCR. 
Whole protein lysates were assessed by western blotting using total PPARγ antibodies 
B) E-8, C) 81B8, and D) D69 and a PPARγ2 specific antibody E) N-19. Histone 3 (H3) 
expression was used as a loading control. 20 μg of protein was loaded into each well. 
Note successful overexpression of PPARγ1 and PPARγ2 in MCF-7 cells. Also note 
detection of both PPARγ1 and PPARγ2 protein by the E-8, 81B8 and D69 antibodies. 
The PPARγ2-specific antibody, N-19, detected a unique band in the PPARγ2 
overexpressing MCF-7 cells. 
 
7.4.4 Assessment of PPARγ Antibodies for Immunofluorescence 
Using PT67 cells, which had been transfected with either the empty pLXSN vector, or 
the pLXSN vector containing either the PPARγ1 or PPARγ2 coding sequences, it was 
shown that fixation of the cells with formalin plus permeabilisation with Triton X-100 
was necessary to demonstrate specific PPARγ labelling. Fixation of the cells with 
Methanol:Acetone (50:50) resulted in only very weak nuclear expression in the cells, 
but no clear overexpression of PPARγ1 or PPARγ2 could be shown (Figure 7.3). Using 
formalin fixation, it was shown that the 81B8, D69 and E-8 antibodies demonstrated 
specificity to PPARγ, while the P&A53.25 antibody appeared non-specific to PPARγ 
(Figure 7.4). 
 
In MCF-7 cells, only the 81B8 and D69 antibodies demonstrated specificity to PPARγ 
(Figure 7.5). The 81B8 antibody showed weak cytoplasmic/background labelling in the 
control (empty) cells, while the PPARγ1 and PPARγ2 overexpressing cells displayed 
clear nuclear expression. The D69 antibody showed weak background expression, with 
some possible cell membrane specific labelling. In the PPARγ1 and PPARγ2 
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overexpressing cells, the expression was clearly nuclear in all of the cells. Both the 
81B8 and D69 antibody demonstrated clear overexpression of PPARγ in the PPARγ1 
and PPARγ2 overexpressing cells, in comparison to the control cells. 
 
The E-8 antibody appeared to be not specific at detecting PPARγ using the MCF-7 
cells; a similar cytoplasmic and nuclear expression was detected in the control and 
PPARγ overexpressing cells. The P&A53.25 antibody demonstrated similar results to 
those observed using the PT67 cells, and detected high levels of background in all of the 
cell types, again suggesting a lack of specificity. 
 
Based on the results described above, and consistent with western blotting, the D69 
antibody was chosen to be used for all subsequent experiments for the detection of 
PPARγ expression by immunofluorescence in this thesis. 
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Figure 7.3 PPARγ Antibodies Evaluated for Indirect Immunofluorescence Microscopy Using Transfected PT67 Cells Fixed by 
Methanol:Acetone – A) 81B8 and D69 
PT67 cells were transfected with either PPARγ1 or PPARγ2 overexpression vectors. Control cells were transfected with the empty vector only. 
Immunofluorescence labelling for the total PPARγ antibodies, (A) 81B8 and D69 and (B) E-8 and P&A53.25, was performed on methanol:acetone 
(50:50) fixed slides. UMUC9 cells were included as a positive control due to their known PPARγ expression. Inset images show the corresponding 
Hoechst 33258 staining to demonstrate cell density and nuclei location. Antibody labelled images were taken at the same exposure for each antibody. 
Hoechst 33258 images were taken at optimal exposures. Note the absence of PPARγ expression in all of the PT67 cells using either the 81B8 or D69 
antibodies, with methanol:acetone fixation of the cells. 
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Figure 7.3 PPARγ Antibodies Evaluated for Indirect Immunofluorescence Microscopy Using Transfected PT67 Cells Fixed by 
Methanol:Acetone – B) E-8 and P&A53.25 
See main caption on previous page. Note the absence of PPARγ expression in all of the PT67 cells using the E-8 antibody with methanol:acetone 
fixation. Use of the P&A53.25 antibody showed abundant PPARγ expression in all of the transfected PT67 cell types, suggesting that non-specific 
binding of the antibody may be occurring. 
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Figure 7.4 PPARγ Antibodies Evaluated for Indirect Immunofluorescence Microscopy Using Transfected PT67 Cells Fixed Using Formalin – 
A) 81B8 and D69 
PT67 cells were transfected with either PPARγ1 or PPARγ2 overexpression vectors. Control cells were transfected with the empty vector only. 
Immunofluorescence labelling for the total PPARγ antibodies, (A) 81B8 and D69, and (B) E-8 and P&A53.25, was performed on formalin fixed slides 
which had been permeabilised with Triton X-100. UMUC9 cells were included as a positive control for PPARγ expression. Inset images show the 
corresponding Hoechst 33258 staining to demonstrate cell density and nuclei location. Antibody labelled images were taken at the same exposure. 
Hoechst 33258 images were taken at optimal exposures. Note clear nuclear expression of PPARγ in the PPARγ1 and PPARγ2 overexpressing PT67 
cells using both the 81B8 and D69 antibodies. PPARγ expression was absent in the control (Empty) PT67 cells. 
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Figure 7.4 PPARγ Antibodies Evaluated for Indirect Immunofluorescence Microscopy Using Transfected PT67 Cells Fixed Using Formalin – 
B) E-8 and P&A53.25 
See main caption on previous page. Note clear nuclear expression of PPARγ in the PPARγ1 and PPARγ2 overexpressing PT67 cells using the E-8 
antibody and negative PPARγ expression in the control (Empty) PT67 cells. Use of the P&A53.25 antibody showed similar abundant PPARγ 
expression in all of the transfected PT67 cell types, again indicating that non-specific binding of the antibody may be occurring. 
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Figure 7.5 PPARγ Antibodies Evaluated for Immunofluorescence Using Transduced 
MCF-7 Cells Fixed using Formalin 
MCF-7 cells were transduced to either overexpress PPARγ1 or PPARγ2. Control cells 
were transduced with the antibiotic selection gene only, and are denoted in the figure as 
‘Empty’. Immunofluorescence labelling for the total PPARγ antibodies E-8, 81B8, D69, 
P&A53.25 was performed on formalin fixed slides which had been permeabilised with 
Triton X-100. Inset images represent the corresponding Hoechst 33258 staining to 
demonstrate cell density and nuclei location. Antibody labelled images were taken at the 
same exposure for each antibody to allow for comparison with the control and PPARγ 
overexpressing cells. Hoechst 33258 images were taken at optimal exposures. Note clear 
nuclear PPARγ expression in the PPARγ1 and PPARγ2 overexpressing MCF-7 cells 
using the 81B8 and D69 antibodies. Use of the E-8 and P&A53.25 antibodies showed 
similar PPARγ expression in both the control (Empty) and PPARγ overexpressing 
MFC-7 cells. 
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 In Vitro Characterisation of Buccal Epithelial Cells with 
Reference to Urothelial Cells 
7.5.1 Buccal Epithelial Cell Isolation and Culture 
Due to difficulty obtaining human buccal mucosa tissue samples, no direct experiments 
were performed to characterise their isolation or subsequent growth, in order to 
conserve the cells for other experiments. As a result, a description of the general 
observations pertaining to the isolation and culture of NHB cells can be found below. 
 
Isolation of NHB cells was achieved as described in methods section 2.4.3.1. As a 
general observation, the isolation method yielded less than 10 % of the seeded cells 
adhering to the plastic ware following 24 hours of incubation at 37 oC with 5% CO2 in 
air. The accumulation of dead cells was removed from the cultures following 24 hours 
and the cells were allowed to populate the dish, which typically took longer than one 
week due to the low initial plating density. NHU cells, by contrast, which were isolated 
using a different method (see method section 2.4.3.2), had an almost 100% adherence 
rate. 
 
For general maintenance and culture, NHB cells were expanded using a method 
previously optimised for urothelial cells, which relied on the use of a serum-free, low 
calcium (0.09 mM) medium (KSFMc) (Figure 7.6). Cells were subcultured upon 
reaching confluence. Buccal epithelial cells proliferated comparably in this culture 
system to urothelial cells, although senesced much earlier (typically by passage 5). 
NHU cells, in contrast, could be passaged on average up to 10 times before reaching 
senescence. 
 
In culture, buccal epithelial cells appeared more rounded in shape, while urothelial cells 
had a more elongated appearance (Figure 7.6). When buccal epithelial cells were treated 
with the TZ/PD (Figure 7.7), atRA/PD (Figure 7.8) or ABS/Ca2+ protocols (Figure 7.9), 
the cell appearance changed depending on the conditions. Using the TZ/PD and 
atRA/PD protocol, cultures grew to confluent monolayers. Use of the ABS/Ca2+ 
protocol on snapwell membranes produced multi-layered epithelia, of approximately 
3-4 cell layers thick, similar to that which could be achieved with NHU cells. 
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Figure 7.6 Phase Contrast Images of NHB Cells and NHU Cells Grown in a Serum-
Free, Low Calcium Medium (KSFMc) 
Buccal epithelial cells A) AS005b, and urothelial cells B) Y1334 grown in KSFMc. Scale 
bar = 200 μm. Note the rounded appearance of the NHB cells and the more elongated 
morphology of NHU cells. 
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Figure 7.7 Phase Contrast Images of NHB Cells and NHU Cells Following use of the 
TZ/PD Protocol for 24, 72 and 144 hours 
Buccal epithelial cells A) AS005b, and urothelial cells B) Y1453, which were treated 
with either 0.1% DMSO (vehicle control) or TZ/PD for 24, 72, or 144 hr. Scale bar = 200 
μm. Note both cell types reaching extreme confluence by the 144 hour time point. 
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Figure 7.8 Phase Contrast Images of Buccal Epithelial Cells Treated with PD, atRA/PD, TZ/PD, or atRA/TZ/PD 
Buccal epithelial cells (AS006b) were treated with either 1 μM PD (control) or 1 μM PD with 10 nM, 100 nM or 1 μM atRA. Additional cells 
were exposed to 1 μM PD and 1 μM TZ with and without 100 nM atRA. All protocols lasted for a total of 72 hours. Medium was changed 
following 24 hours; all treatments remained the same except the ones containing TZ, where the medium was changed to remove the TZ, following 
the standard TZ/PD protocol. Scale bar = 200 μm. Note the change in NHB cell appearance with increasing concentrations of atRA. 
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Figure 7.9 Haematoxylin and Eosin (H&E) Stained NHU and NHB Cell Sheets Generated using the ABS/Ca2+ Protocol 
Following 8 days of the ABS/Ca2+ protocol on Snapwell inserts, cell sheets were harvested from the substrate using dispase, and fixed in 10 % 
(v/v) formalin. The cell sheets were then processed into paraffin wax, sectioned, and H&E stained. Images were generated using brightfield 
microscopy for a single urothelial cell line (Y1334) and three independent buccal epithelial cell lines (AS001b, AS003b, and AS005b). Note the 
similar appearance and number of cell layers between the NHB and NHU cell sheets. 
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7.5.2 Positive Control for CK20 Expression – Immunofluorescence 
Microscopy 
 
 
Figure 7.10 Positive Control for CK20 Expression for Immunofluorescence 
Microscopy 
NHU cells (NHU4) were treated with the TZ/PD protocol for 6 days. CK20 expression 
was assessed by immunofluorescence microscopy. Inset image shows the corresponding 
Hoechst 33258 staining to demonstrate cell density and nuclei location 
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7.5.3 Additional Cell Line Results for Transcription Factor Gene 
Expression by RT-PCR in NHB Cells Treated with TZ/PD – 
(NHB5) 
 
Figure 7.11 Expression of Urothelial Differentiation-Associated Transcription 
Factors in NHB Cells by RT-PCR Following TZ/PD Treatment – Additional Cell 
Line (NHB5) 
Buccal epithelial cells (NHB5) were treated with TZ/PD for 24, 48 and 72 hours. The 
expression of ELF3, FOXA1, GATA3, GRHL3, IRF1, KLF5 and PPARγ (forward and 
reverse primers designed to sequences in exon 6) was assessed by RT-PCR. PCR was 
performed using 30 cycles. GAPDH was used as a loading control (25 cycles). H2O (no 
template) was used as a negative control (-). Genomic DNA was used as the positive 
control for the PCR (+). Note weak/absent expression of FOXA1, GATA3 and PPARγ in 
NHB cells. Also note the apparent upregulation of ELF3 expression in NHB cells as a 
result of TZ/PD. 
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7.5.4 Full Length Western Blot Showing PPARγ Expression in NHB 
Cells Following Treatment with DMSO, PD or TZ/PD for 72 
hours 
 
Figure 7.12 Full Length Western Blot Showing PPARγ Expression in NHB Cells 
(NHB7) Following Treatment with 0.1 % DMSO, PD and TZ/PD 
Example full length western blot showing PPARγ expression in NHB cells (NHB7). 
NHB cells were treated with either 0.1% DMSO (vehicle control), 1 μM PD or TZ/PD for 
72 hours. A single NHU cell line (NHU8) which had been treated with TZ/PD for 72 
hours was included on all blots to act as a positive control/for comparison. Note PPARγ1 
is not expressed in NHB cells. Additional possible non-specific bands were observed on 
the western blot. 
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7.5.5 Additional Cell Line Results for Evaluation of Transcription 
Factor Protein Expression by Immunofluorescence Microscopy 
in NHB Cells Treated with TZ/PD (NHB6) 
 
Figure 7.13 Evaluation of Transcription Factor Protein Expression by 
Immunofluorescence Microscopy in NHB Cells (NHB6) Treated with TZ/PD for 24, 
72 and 144 hours – A) ELF3 
NHB cells (NHB6) were treated with either 0.1% DMSO (vehicle control) or TZ/PD for 
24, 72 and 144 hours. A single NHU cell line (NHU7) which had been treated with either 
0.1 % DMSO or TZ/PD for 72 hours was used as a positive control for comparison. 
A) ELF3, B) FOXA1/2 (Santa Cruz, C-20), C) GATA3, and D) PPARγ (Cell Signaling, 
D69) expression was assessed by immunofluorescence on formalin-fixed slides which 
had been permeabilised using Triton X-100. Inset images show the corresponding 
Hoechst 33258 staining to demonstrate cell density and nuclei location. All antibody-
labelled images were taken at the same exposure for both NHB cells and NHU cells. 
Hoechst 33258 images were taken at optimal exposures. Note weak expression of ELF3 
in NHB cells at all time points. 
 
 
Appendix 
 
281 
 
Figure 7.13 Evaluation of Transcription Factor Protein Expression by 
Immunofluorescence Microscopy in NHB Cells (NHB6) Treated with TZ/PD for 24, 
72 and 144 hours - B) FOXA1/2 
See main caption on page 280. Note weak/absent expression of FOXA1/2 in NHB cells 
even following use of the TZ/PD protocol for up to 144 hours. 
 
 
Figure 7.13 Evaluation of Transcription Factor Protein Expression by 
Immunofluorescence Microscopy in NHB Cells (NHB6) Treated with TZ/PD for 24, 
72 and 144 hours - C) GATA3 
See main caption on page 280. Note weak/absent expression of GATA3 in NHB cells 
even following use of the TZ/PD protocol for up to 144 hours. 
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Figure 7.13 Evaluation of  Transcription Factor Protein Expression by 
Immunofluorescence Microscopy in NHB Cells (NHB6) Treated with TZ/PD for 24, 
72 and 144 hours - D) PPARγ 
See main caption on page 280. Note weak/absent expression of PPARγ in NHB cells 
even following use of the TZ/PD protocol for up to 144 hours. 
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7.5.6 Additional Cell Line Results for Evaluation of Transcription 
Factor Expression by Immunofluorescence Microscopy in NHB 
Cells Treated with TZ/PD - (NHB8) 
 
Figure 7.14 Evaluation of Transcription Factor Protein Expression by 
Immunofluorescence Microscopy in NHB Cells (NHB8) Treated with TZ/PD for 24, 
72 and 144 hours – A) ELF3 
NHB cells (NHB8) were treated with either 0.1 % DMSO (vehicle control) or TZ/PD for 
24, 72 and 144 hours. A single NHU cell line (NHU6) which had been treated with either 
0.1 % DMSO or TZ/PD for 72 hours was used as a positive control for comparison. 
A) ELF3, B) FOXA1/2 (Santa Cruz, C-20), and C) GATA3 expression was assessed by 
immunofluorescence on formalin-fixed slides which had been permeabilised using Triton 
X-100. Inset images show the corresponding Hoechst 33258 staining to demonstrate cell 
density and nuclei location. All antibody-labelled images were taken at the same exposure 
for both NHB cells and NHU cells. Hoechst 33258 images were taken at optimal 
exposures. Note weak nuclear expression of ELF3 in NHB cells at all time points, with 
some increased expression at the 144 hr TZ/PD time point. 
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Figure 7.14 Evaluation of Transcription Factor Protein Expression by 
Immunofluorescence Microscopy in NHB Cells (NHB8) Treated with TZ/PD for 24, 
72 and 144 hours – B) FOXA1/2 
See main caption on page 283. Note weak/absent expression of FOXA1/2 in NHB cells 
even following use of the TZ/PD protocol for up to 144 hours. 
 
 
Figure 7.14 Evaluation of Transcription Factor Protein Expression by 
Immunofluorescence Microscopy in NHB Cells (NHB8) Treated with TZ/PD for 24, 
72 and 144 hours – C) GATA3 
See main caption on page 283. Note weak/absent expression of GATA3 in NHB cells 
even following use of the TZ/PD protocol for up to 144 hours. 
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7.5.7 Additional Cell Line Results for Evaluation of Uroplakin Gene 
Expression by RT-PCR in NHB Cells Treated with TZ/PD 
 
Figure 7.15 Evaluation of Uroplakin Gene Expression by RT-PCR in NHB Cells 
(NHB4) Following TZ/PD Treatment 
Buccal epithelial cells (NHB4) were treated with either 0.1 % DMSO (vehicle control) or 
TZ/PD for 0.5, 3 or 6 days. The gene expression of the five uroplakin genes (UPK1A, 
UPK1B, UPK2, UPK3A, UPK3B) is shown by RT-PCR. PCR was performed using 30 
cycles. GAPDH was used as a loading control (25 cycles). H2O (no template) was used as 
a negative control (-). Genomic DNA was used as the positive control for the PCR (+). 
Note expression of UPK1A, UPK1B, UPK2 and UPK3B in NHB cells. UPK3A 
expression was absent. 
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7.5.8 Additional Cell Line Results for Assessment of Claudin Gene 
Expression by RT-PCR in NHB Cells Treated with TZ/PD 
 
Figure 7.16 Evaluation of Claudin Gene Expression by RT-PCR in NHB Cells 
(NHB4) Following TZ/PD Treatment 
NHB cells (NHB4) were treated with either 0.1 % DMSO (vehicle control) or TZ/PD for 
0.5, 3 or 6 days. The gene expression of claudins (CLDNs) 1-10 is shown by RT-PCR. 
PCR was performed using either 30 or 35 cycles for a given gene. GAPDH was used as a 
loading control (25 cycles). H2O (no template) was used as a negative control (-). 
Genomic DNA was used as the positive control for the PCR (+). Note expression of 
CLDN1, CLDN2, CLDN4, CLDN5 and CLDN7 in NHB cells. 
 
 
Appendix 
 
287 
7.5.9 Additional Cell Line Results for Evaluation of Stratified 
Squamous Differentiation-Associated Gene Expression by RT-
PCR in NHB Cells Treated with TZ/PD 
 
Figure 7.17 Assessment of Stratified Squamous Differentiation-Associated Gene 
Expression by RT-PCR in NHB Cells (NHB4) Following TZ/PD Treatment 
Buccal epithelial cells (NHB4) were treated with either 0.1 % DMSO (vehicle control) or 
TZ/PD for 0.5, 3 or 6 days. The transcript expression of several stratified sqaumous 
differentiation-associated genes (LOR, SPRR4 and TGM1) is shown by RT-PCR. PCR 
was performed using either 25 or 30 cycles for a given gene. GAPDH was used as a 
loading control (25 cycles). H2O was used as a negative control (-). Genomic DNA was 
used as the positive control for the PCR (+). Note expression of LOR, SPRR4 and TGM1 
in NHB cells. 
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7.5.10 Positive Control Images and Example Negative Control Images 
for Immunohistochemistry 
 
 
 
 
 
 
 
Figure 7.18 Positive Control Images and Example Negative Control Images For 
Immunohistochemistry 
The urothelium of human bladder or ureter was used as positive controls for of the 
proteins examined, except CK14, where human buccal mucosa was used. An example 
negative control (no primary antibody) cell sheet is shown, as are example negative 
controls for urothelium and buccal epithelium. 
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 Expression of PPARγ and GATA3 in Urothelial Cell 
Differentiation 
7.6.1 Additional Cell Line Results for Evaluation of Transcription 
Factor Protein Expression by Western Blotting in NHU Cells 
Following PPARγ Activation 
 
Figure 7.19 Evaluation of Transcription Factors, and Other Urothelial 
Cell-Associated Proteins in NHU Cells (Y1642) Following PPARγ Activation 
NHU cells (Y1642) were treated with either 0.1 % DMSO (vehicle control) or TZ/PD for 
24, 48, 72 or 144 hours. ELF3, FOXA1 (Santa Cruz, Q-6), GATA3, PPARγ (Cell 
Signaling, D69), and RXRα protein expression was assessed by western blotting. For 
PPARγ expression, the band corresponding to PPARγ1 (approximately 52 kDa) is shown. 
25 μg of protein was loaded into each well and β-actin was used as a loading control.  
CK13 expression was evaluated to demonstrate induction of transitional-type 
differentiation. Note the clear upregulation of ELF3, FOXA1, GATA3 and PPARγ 
expression following PPARγ activation using the TZ/PD protocol. 
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7.6.2 Additional Cell Line Results for Evaluation of Transcription 
Factor Protein Expression by Immunofluorescence Microscopy 
in NHU Cells Following PPARγ – Y1642 
 
Figure 7.20 Evaluation of Transcription Factor Protein Expression by 
Immunofluorescence Microscopy in NHU Cells (Y1642) Following PPARγ Activation 
using the TZ/PD Protocol for 12, 24, 48, 72 and 144 hours – ELF3 
NHU cells (Y1642) were treated with either 0.1 % DMSO (vehicle control) or TZ/PD for 
12, 24, 48, 72 and 144 hours. Immunofluorescence labelling for (A) ELF3, (B) FOXA1/2 
(Santa Cruz, C-20), and (C) GATA3 was performed on formalin-fixed slides which had 
been permeabilised with Triton X-100. Inset images represent the corresponding Hoechst 
33258 staining to demonstrate cell density and nuclei location. All antibody labelled 
images were taken at the same exposure to enable for comparison of expression between 
the untreated and treated cells, and between the different time points. Hoechst 33258 
images were taken at optimal exposures. Note the clear upregulation of expression and 
nuclear localisation of ELF3 as a result of PPARγ activation. 
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Figure 7.20 Evaluation of Transcription Factor Protein Expression by 
immunofluorescence Microscopy in NHU Cells (Y1642) Following PPARγ Activation 
using the TZ/PD Protocol for 12, 24, 48, 72 and 144 hours – FOXA1/2 
See main caption on page 290. Note nuclear expression of FOXA1/2 in NHU cells, with 
upregulated expression associated with PPARγ activation. 
 
 
Figure 7.20 Evaluation of Transcription Factor Protein Expression by 
immunofluorescence Microscopy in NHU Cells (Y1642) Following PPARγ Activation 
using the TZ/PD Protocol for 12, 24, 48, 72 and 144 hours – GATA3 
See main caption on page 290. Note nuclear expression of GATA3 in NHU cells, with 
upregulated expression associated with PPARγ activation as well as with increased 
confluence. 
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7.6.3 Additional Cell Line Results for Evaluation of Transcription 
Factor Protein Expression by Immunofluorescence Microscopy 
in NHU Cells Following PPARγ – Y1541 
 
Figure 7.21 Evaluation of Transcription Factor Protein Expression by 
immunofluorescence Microscopy in NHU Cells (Y1541) Following PPARγ Activation 
using the TZ/PD Protocol for 12, 24, 48, 72 and 144 hours – ELF3 
NHU cells (Y1541) were treated with either 0.1 % DMSO (vehicle control) or TZ/PD for 
12, 24, 48, 72 and 144 hours. Immunofluorescence labelling for (A) ELF3, (B) FOXA1/2 
(Santa Cruz, C-20), (C) GATA3 and (D) PPARγ (Cell, Signaling, D69) was performed 
on formalin-fixed slides which had been permeabilised with Triton X-100. Inset images 
represent the corresponding Hoechst 33258 staining to demonstrate cell density and 
nuclei location. All antibody labelled images were taken at the same exposure to enable 
for comparison of expression between the untreated and treated cells, and between the 
different time points. Hoechst 33258 images were taken at optimal exposures. Note the 
clear upregulation of expression and nuclear localisation of ELF3 as a result of PPARγ 
activation. 
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Figure 7.21 Evaluation of Transcription Factor Protein Expression by 
immunofluorescence Microscopy in NHU Cells (Y1541) Following PPARγ Activation 
using the TZ/PD Protocol for 12, 24, 48, 72 and 144 hours – FOXA1/2 
See main caption on page 292. Note nuclear expression of FOXA1/2 in NHU cells, with 
upregulated expression associated with PPARγ activation. 
 
 
Figure 7.21 Evaluation of Transcription Factor Protein Expression by 
immunofluorescence Microscopy in NHU Cells (Y1541) Following PPARγ Activation 
using the TZ/PD Protocol for 12, 24, 48, 72 and 144 hours – GATA3 
See main caption on page 292. Note nuclear expression of GATA3 in NHU cells, with 
upregulated expression associated with PPARγ activation and increased confluence. 
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Figure 7.21 Evaluation of Transcription Factor Protein Expression by 
immunofluorescence Microscopy in NHU Cells (Y1541) Following PPARγ Activation 
using the TZ/PD Protocol for 12, 24, 48, 72 and 144 hours – PPARγ 
See main caption on page 292. Note weak nuclear expression of PPARγ in NHU cells, 
with clear upregulated expression associated with PPARγ activation and 72 hours. 
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7.6.4 Example Positive Control (CK20 Expression) to Demonstrate 
Successful Differentiation of NHU Cells using TZ/PD 
 
Figure 7.22 Example of CK20 Expression by immunofluorescence Microscopy in 
NHU Cells (Y1642) Treated with TZ/PD for 144 hours 
CK20 expression was assessed in NHU cells (Y1642) to demonstrate successful 
differentiation of the cells using the TZ/PD protocol at the 144 hour time point. 
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7.6.5 Additional Cell Line Results for PPARγ Expression in MG132 
Treated NHU Cells (Y1691) 
 
Figure 7.23 Evaluation of PPARγ Protein Expression by Western Blotting in NHU 
Cells (Y1691) Following Proteasome Inhibition 
A) Western blot showing PPARγ protein expression (Cell Signaling, D69) in NHU cells 
(Y1691) treated with the proteasome inhibitor, MG132 (MG). NHU cells were first 
treated with either 0.1% DMSO (vehicle control) or TZ/PD for 72 hours. The 
medium was then changed, and the cells were either treated with 0.1 % DMSO 
(vehicle control) or 12.5 μM MG132 for 6 hours. β-actin was used as a loading 
control. 20 μg of protein was loaded into each well. 
B) The graph showing densitometry analysis for PPARγ1 protein expression. Data is 
shown relative to the DMSO treated cells. All values were first normalised to β-actin. 
Note clear upregulation of PPARγ1 protein expression in NHU cells following treatment 
with MG132. PPARγ2 expression was absent and not affected by proteasome inhibition 
in NHU cells. 
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7.6.6 Densitometry Analysis of Western Blots for MG132 Treated 
NHU Cells and UMUC9 Cells 
 
Figure 7.24 Densitometry Analysis for PPARγ1 and β-actin Expression in Two 
Independent NHU Cell Lines and UMUC9 Cells Treated with MG132 
Western blots for PPARγ (Cell Signaling, D69) and β-actin expression are shown for the 
cells lines indicated. Densitometry is shown for the PPARγ1-specific band at 
approximately 52 kDa. 
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7.6.7 Densitometry Analysis of Western Blots for GATA3 
Knockdown Experiments 
 
Figure 7.25. Densitometry Analysis for Western Blots for GATA3 and β-actin in 
NHU cells (Y1752) Transfected with Control and GATA3 siRNA – siRNA 
Titration  
Densitometry analysis of western blots for GATA3 and β-actin expression are shown 
for the titration of GATA3 siRNA in NHU cells (Y1752). 
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Figure 7.26. Densitometry Analysis for GATA3 and β-actin Expression in Three 
NHU Cell Lines Transfected with Control and GATA3 siRNA 
Western blots for GATA3 and β-actin are shown for the three independent cell lines 
(Y1356, Y938 and Y1815), which were transfected with control and GATA3 siRNA. 
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Figure 7.27. Densitometry Analysis for FOXA1 and β-actin Expression in Three 
NHU Cell Lines Transfected with Control and GATA3 siRNA 
Western blots for FOXA1 (Santa Cruz, Q6) and β-actin are shown for the three 
independent cell lines (Y1356, Y938 and Y1815), which were transfected with control 
and GATA3 siRNA. 
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Figure 7.28. Densitometry Analysis for CK13 and β-actin Expression in Three 
NHU Cell Lines Transfected with Control and GATA3 siRNA 
Western blots for CK13 and β-actin are shown for the three independent cell lines 
(Y1356, Y938 and Y1815), which were transfected with control and GATA3 siRNA. 
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 Overexpression of GATA3 in Buccal Epithelial Cells 
7.7.1 Additional Cell Line Result for Evaluation of Transcription 
Factor Expression by Immunofluorescence Microscopy in 
Control and GATA3 Overexpressing NHB Cells Following Use 
of the TZ/PD Protocol (Y1590) 
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Figure 7.29 Evaluation of ELF3, FOXA1, FOXA1 GATA3, and PPARγ Expression by Immunofluorescence Microscopy in Control and 
GATA3 Overexpressing NHB Cells (Y1590) Treated with 0.1 % DMSO or TZ/PD for 72 Hours 
Control (Empty) and GATA3 overexpressing NHB cells (Y1590) were treated with either 0.1 % DMSO (vehicle control) or TZ/PD for 72 hours. 
Immunofluorescence labelling for ELF3, FOXA1/2 (Santa Cruz, C-20), GATA3 and PPARγ (Cell Signaling, D69) was performed on formalin-fixed 
slides which had been permeabilised with Triton X-100. Inset images represent the corresponding Hoechst 33258 staining to demonstrate cell density 
and nuclei location. Antibody labelled images were taken at the same exposure for each antibody. Hoechst 33258 images were taken at optimal 
exposures. NHU cells (Y1642) which had been treated with TZ/PD for 72 hours were used as positive controls. 
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7.7.2 Additional Cell Line Results for Evaluation of Tight Junction 
Protein Expression by Western Blotting in Control and 
GATA3 Overexpressing NHB Cells During use of the ABS/Ca2+ 
Protocol (AS011b) 
 
Figure 7.30 Evaluation of Tight Junction-Associated Protein Expression by Western 
Blotting in Control and GATA3 Overexpressing NHB Cells (AS011b) During use of 
the ABS/Ca2+ Protocol 
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Figure 7.30 Evaluation of Tight Junction-Associated Protein Expression by Western 
Blotting in Control and GATA3 Overexpressing NHB Cells (AS011b) During use of 
the ABS/Ca2+ Protocol 
Control (Empty) and GATA3 overexpressing NHB cells (AS011b) were subjected to the 
ABS/Ca2+protocol for up to 7 days. Whole protein lysates were generated on the days 
indicated. 
C) CLDN3, CLDN4, CLDN5, CLDN7, and ZO-1 protein expression was assessed by 
western blotting. Evaluation of GATA3 expression demonstrated successful GATA3 
overexpression at all of the time points. 25 μg of protein was loaded into each well 
and β-actin was used as a loading control. Protein extracted from NHU cells (Y1336), 
which had been differentiated with ABS/Ca2+ for 5 days, was included on the same 
western blots, and used as a positive control.  
D) Densitometry analysis of CLDN3 protein expression at each of the time points during 
use of the ABS/Ca2+ protocol. Data is shown for the western blot above, 
corresponding to AS011b. All values were normalised to β-actin expression. 
Note the clear upregulation of CLDN3 expression as a result of GATA3 overexpression 
in NHB cells at all time points during use of the ABS/Ca2+ protocol. The other tight 
junction-associated proteins examined were not obviously affected by GATA3 
overexpression. 
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7.7.3 Densitometry Analysis of Western Blots for CLDN3 Expression 
in Control and GATA3 Overexpressing NHB Cells During use 
of the ABS/Ca2+ Protocol 
 
Figure 7.31 Densitometry Analysis of CLDN3 and β-actin Expression in Control and 
GATA3 Overexpressing NHB Cells (Y1595) During use of the ABS/Ca2+ Protocol 
Western blots for CLDN3 and β-actin are shown for the transduced NHB cell line, 
Y1595. 
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Figure 7.32 Densitometry Analysis of CLDN3 and β-actin Expression in Control and 
GATA3 Overexpressing NHB Cells (AS011b) During use of the ABS/Ca2+ Protocol 
Western blots for CLDN3 and β-actin are shown for the transduced NHB cell line, 
AS011b. 
 
  
Appendix 
 
308 
 Overexpression of PPARγ1 in Buccal Epithelial Cells 
7.8.1 Additional Cell Line Results for Evaluation of Transcription 
Factor Expression by RT-qPCR in Control and PPARγ1 
Overexpressing NHB Cells Following use of the TZ/PD 
Protocol (Y1721) 
 
Figure 7.33 RT-qPCR Analysis of PPARG, ELF3, FOXA1 and GATA3 Expression in 
Control and PPARγ1 Overexpressing NHB Cells (Y1721) Treated with TZ/PD for 72 
Hours 
Control (Empty) and PPARγ1 overexpressing NHB cells (Y1721) were treated with 
TZ/PD for 72 hr. RNA was extracted and cDNA produced. qPCR data was generated to 
evaluate A) PPARγ, B) ELF3, C) FOXA1 and D) GATA3 expression. Values are shown 
relative to the control (Empty) cells. Gene expression was first normalised to GAPDH 
expression. Error bars represent the standard deviation of three technical replicates. Note 
clear upregulation of ELF3, FOXA1 and GATA3 transcript expression in PPARγ1 
overexpressing cells. 
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7.8.2 Additional Cell Line Results for Evaluation of Transcription 
Factor Expression by RT-qPCR in Control and PPARγ1 
Overexpressing NHB Cells Following use of the TZ/PD 
Protocol (AS011b) 
 
 
Figure 7.34 RT-qPCR Analysis of PPARG, ELF3, FOXA1 and GATA3 Expression in 
Control and PPARγ1 Overexpressing NHB Cells (AS011b) Treated with TZ/PD for 
72 Hours 
Control (Empty) and PPARγ1 overexpressing NHB cells (AS011b) were treated with 
TZ/PD for 48 hr. RNA was extracted and cDNA produced. qPCR data was generated to 
evaluate A) PPARγ, B) FOXA1 and C) GATA3 expression. Values are shown relative to 
the control (Empty) cells. Gene expression was first normalised to GAPDH expression. 
Error bars represent the standard deviation of three technical replicates. Note clear 
upregulation of FOXA1 and GATA3 transcript expression in PPARγ1 overexpressing 
cells. 
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7.8.3 Densitometry Analysis for Western Blots of FOXA1 Expression 
in Control and PPARγ1 Overexpressing NHB Cells Treated 
with 0.1 % DMSO or TZ/PD for 72 Hours 
 
 
 
 
 
Figure 7.35 Densitometry Analysis of FOXA1 and β-actin Expression in Control and 
PPARγ1 Overexpressing NHB Cells (Y1600, AS027b, AS021b, and AS011b) Treated 
with TZ/PD for 72 hours 
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Figure 7.35 Continued. 
Western blots for FOXA1 and β-actin are shown for the transduced NHB cell lines, 
Y1600, AS027b, AS021b and AS011b. 
 
7.8.4 Additional Cell Line Results for Evaluation of ELF3, FOXA1, 
GATA3 and PPARγ Protein Expression by 
Immunofluorescence Microscopy in Control and PPARγ1 
Overexpressing NHB Cells Treated with 0.1 % DMSO or 
TZ/PD for 72 hours (Y1600 and Y1656) 
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Figure 7.36 ELF3, FOXA1, GATA3 and PPARγ Protein Expression by Immunofluorescence Microscopy in Control and PPARγ1 
Overexpressing NHB Cells (Y1600) Treated with TZ/PD for 72 hours 
Control (Empty) and PPARγ1 overexpressing NHB cells (Y1600 and Y1656) were treated with either 0.1% DMSO (vehicle control) or TZ/PD for 72 
hours. Immunofluorescence labelling for ELF3, FOXA1/2 (Santa Cruz, Q-6 or C-20), GATA3 and PPARγ (Cell Signaling, D69) was performed on 
formalin-fixed slides which had been permeabilised with Triton X-100. Inset images represent the corresponding Hoechst 33258 staining to 
demonstrate cell density and nuclei location. Antibody labelled images were taken at the same exposure for each antibody. Hoechst 33258 images 
were taken at optimal exposures. NHU cells (Y1642) which had been treated with TZ/PD for 72 hours were used as positive controls. 
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Figure 7.36 ELF3, FOXA1, GATA3 and PPARγ Protein Expression by Immunofluorescence Microscopy in Control and PPARγ1 
Overexpressing NHB Cells (Y1656) Treated with TZ/PD for 72 hours 
See main caption on previous page. Note increased nuclear localisation of ELF3and FOXA1/2 in the TZ/PD treated PPARγ1 overexpressing NHB 
cells. 
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7.8.5 Additional Cell Line Results for Evaluation of Tight Junction-
Associated Protein Expression by Western Blotting in Control 
and PPARγ1 Overexpressing NHB Cells During use of the 
ABS/Ca2+ Protocol (Y1721 and Y1600) 
 
Figure 7.37 Evaluation of Tight Junction-Associated Protein Expression by Western 
Blotting in Control and PPARγ1 Overexpressing NHB Cells During use of the 
ABS/Ca2+ Protocol (Y1721 and Y1600) 
Control (Empty) and PPARγ1 overexpressing NHB cells (Y1721 and Y1600) were 
subjected to the ABS/Ca2+ protocol for up to eight days. Whole protein lysates were 
generated on the days indicated. CLDN3, CLDN4, CLDN5, CLDN7, ZO-1 and ZO-3 
expression was assessed by western blotting. β-actin was used as a loading control. 
Protein extracted from NHU cells (Y1336), which had been differentiated with ABS/Ca2+ 
for 5 days, was included on all of the western blots to act as a positive control/for 
comparison. 25 μg of protein was loaded into each well. Western blots for transduced 
NHB cell line, Y1721, are shown above. Note upregulation of CLDN3 protein expression 
at Day 4 and 7 in PPARγ1 overexpressing cells. 
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Figure 7.37 Evaluation of Tight Junction-Associated Protein Expression by Western 
Blotting in Control and PPARγ1 Overexpressing NHB Cells During use of the 
ABS/Ca2+ Protocol (Y1721 and Y1600) 
See main caption on previous page. The western blots above correspond to transduced 
NHB cell line, Y1600. Note upregulation of CLDN3 protein expression at Day 4 and 7 in 
PPARγ1 overexpressing cells. 
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7.8.6 Densitometry Analysis of CLDN3 and FOXA1 Expression in 
Control and PPARγ1 Overexpressing NHB Cells Differentiated 
with ABS/Ca2+ 
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Figure 7.38 Densitometry Analysis of FOXA1, CLDN3 and β-actin Expression in 
Control and PPARγ1 Overexpressing NHB Cell Lines (AS027b, Y1721, and Y1600) 
Western blots for FOXA1, CLDN3 and β-actin are shown for the transduced NHB cell 
lines, AS027b, Y1721 and Y1600. 
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